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Abstract
Polycyclic polyether natural products have received much attention due to their diverse
biological activities, ranging from extreme toxicity to therapeutic properties, including
antimicrobial, antifungal, and anticancer activities. They are featured by multiple cyclic ether
groups that vary in the number, size, and arrangement. Ionophore polyethers contain multiple
tetrahydrofuran and tetrahydropyran rings connected by either spiroketal systems or carbon-carbon
single bonds. Over the past 40 years, significant progress has been made in deciphering polyether
biosynthesis pathways. Remarkably, all members of the polycyclic polyether family are thought
to be generated via a common biosynthetic scheme. In 1983, Cane, Celmer, and Westly proposed
a biosynthetic model for producing the stereospecific ether rings of polycyclic polyethers. It
postulates that linear polyene intermediates undergo a cascade of enzyme-catalyzed reactions to
form the polyether rings, including stereospecific epoxidation and epoxide ring opening reactions.
In 2001, the biosynthetic gene cluster for polyether monensin was isolated from
Streptomyces cinnamonensis. It contains the genes of a flavin-dependent epoxidase MonCI and
two epoxide hydrolases MonBI and MonBII. Gene deletion and feeding experiments showed that
MonCI catalyzes all three stereoselective epoxidations for the intermediate premonensin, while
MonBI and MonBII are responsible for the following epoxide ring opening reactions. In 2008, the
gene cluster responsible for the biosynthesis of lasalocid was identified from Streptomyces
lasaliesis. It also includes the genes of a flavin-dependent epoxidase Lsd18, and an epoxide
hydrolase Lsd19. Similar to MonCI, Lsd18 transforms two olefins in the intermediate prelasalocid
into two epoxides in a stereoselective manner. Also similar to MonBI/MonBII, Lsd19 catalyzes
epoxide ring opening reactions, generating the final product lasalocid with a THF-THP
construction. So far, the mechanism of epoxide ring opening reactions has been extensively studied
well. The Lsd19-substrate/product complex crystal structures revealed how energetically favored
5-exo cyclization and energetically unfavored 6-endo cyclization are catalyzed. Also, gene
mutagenesis and the crystal structure determination of MonBI/MonBII further explained the
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synergistic effects and allosteric regulation between the epoxide hydrolases. In contrast, as the first
step of the polyether ring construction, the mechanism of stereoselective epoxidation is poorly
understood due to the lack of epoxidases’ molecular structures.
My research project is focused on determining the molecular mechanism of stereospecific
epoxidation catalyzed by MonCI and Lsd18. Recombinant MonCI and Lsd18 was successfully
expressed in E. coli BL21(DE3) and purified using standard chromatography techniques. These
proteins were shown to be active by in vitro enzyme assays that included the extracted proteins
MonCI/Lsd18, substrates, FAD, and reducing agent nicotinamide adenine dinucleotide (NADH)
or nicotinamide adenine dinucleotide phosphate (NADPH). The epoxide products were detected
by either GC-MS or LC-MS. We solved the MonCI crystal structure at 1.90 Å resolution and the
Lsd18 ligand-free and ligand-bound complex crystal structures at 1.54 and 1.85 Å, respectively by
X-ray crystallography. MonCI and Lsd18 share high similarity in both sequence (identity = 47.8%)
and three-dimensional structure (RMSD = 1.63). Both MonCI and Lsd18 structures contain a fused
FAD- and substrate-binding pocket with three openings. Presumably, one for substrate, one for
solvent, and one for FAD reduction/NAD(P)H binding. Since they share high structural similarity
to the p-hydroxybenzoate hydroxylase, especially the FAD-binding domain, the mechanism of
FAD reduction and oxidation process is expected to be similar. The catalytic cycle consists of five
steps. First step is FAD reduction. When the isoalloxazine ring of oxidized FAD moves out from
the pocket (“out” conformation), it is exposed to the solvent and accepts electrons from NAD(P)H.
After reduction, FAD moves back to the pocket (“in” conformation) and transforms into the
intermediate C4a-(hydro)peroxyflavin by reacting with molecular oxygen. Then C4a(hydro)peroxyflavin donates one hydroperoxyl oxygen atom to the substrate (oxidation). The final
step is accomplished at the end by FAD eliminating one water molecule and turning back to the
oxidized status. To investigate how epoxidases that are involved in the polyether biosynthesis
achieve stereoselectivity, we conducted the docking and modeling work on MonCI and Lsd18. A
molecular dynamic simulation was also performed on MonCI with its native substrate
premonensin. Our findings suggest that the stereoselectivity of epoxidation is determined by the
vii

unique preorganization of the substrate-binding pocket which permits only one face of the alkene
to approach the reactive C4a-(hydro)peroxyflavin. Several key residues at the active site that play
an important role in stereoselectivity have been identified and mutated to further test our
hypothesis.
Overall, our crystallographic and computational studies have provided important molecular
insights into how the stereoselective epoxidation is achieved by the flavin-dependent
monooxygenases MonCI and Lsd18. Due to the high sequence similarity, all epoxidases that are
involved the biosynthesis of polyether natural products could are likely to employ the same
catalytic mechanism. Our results are expected to help bioengineering efforts for bioproduction of
polyether natural product analogs for drug research.
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Chapter 1: Background and Introduction
1.1 NATURAL PRODUCTS IN LIFE SCIENCES
Natural products are the organic compounds produced by living organisms.(1) They can
also be prepared by chemical synthesis. In fact, the fields of chemical synthesis including semisynthesis and total synthesis, often target natural products and their derivatives.
Natural products are often divided into two major classes: primary and secondary
metabolites. Primary metabolites are molecules which participate in metabolic pathways that are
essential for survival of the organism, such as energy production, nutrient assimilation, and growth.
Examples of primary metabolites include nucleic acids, amino acids, lipids, and carbohydrates.
Secondary metabolites are molecules that are not essential for organism to survive but provide
competitive advantages. Secondary metabolites act as social signaling, communication molecules,
agents that solubilize and transport nutrients, and competitive weapons like repellants, venoms,
and toxins. Some common examples of the secondary metabolites are antibiotics, growth factors,
peptides, and nucleosides.(2) Secondary metabolites can be divided into alkaloids,
phenypropanoids, polyketides, and terpenoids. Alkaloids contain basic nitrogen atoms.
Phenylpropanoids are synthesized from phenylalanine and tyrosine. Polyketides are assembled
from acetate and malonate. Terpenoids are constructed from the five-carbon monomer building
blocks called isoprene.
Natural products exist almost everywhere in the life kingdoms including bacteria, archaea,
fungi, plants, and animals. They can be extracted from cells, tissues, and secretions.(3) Diversity
of their chemical structures contributes to the diversity of their biological activities. Many natural
products have been extracted, identified, and processed for medical use. For example, many antibacterial and anti-fungal agents were found in bacteria, including tetracycline (from Streptomyces
spp.)(4), rifamycines (from Amycolatopsis rifamycinica)(5), and polymyxins (from Paenibacillus
polymyxa)(6). The glycopeptide bleomycin for cancer treatment originates from Streptomyces
verticillus.(7) The neutrotoxin botulinum responsible for botulism is produced by Clostridium
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botulinum.(8) Natural products not only come from bacteria but also come from fungi, plants, and
animals. The first antibiotic penicillin is derived from the Pencillium fungus.(9) The
antihypertensive drug teprotide was discovered in the venom of the Brazilian arrowhead viper
Bothrops jaraca.(10) The antineoplastic drug trabectedin is from the sea squirt Ecteinascidia
turbinate.(11) There are also natural products from the plants, such as the antimalarial drug
artemisinin (12) and the antineoplastic drug taxol (13).
1.2 POLYKETIDE NATURAL PRODUCTS
Polyketides are one of the major natural product classes. They are assembled from acetate
and malonate building blocks into complex structures, and they exhibit a wide range of structural
and functional diversity. They display a variety of therapeutically important activities such as
antibiotic, anticancer, antimalaria, and immunosuppressive properties.(14, 15) At the same time,
many polyketides are also infamous as food-spoiling toxins or virulence factors.(16) Questions
like how polyketides possess highly diverse structures and functions from very simple building
blocks have triggered many researchers to investigate their biosynthetic mechanisms by chemical,
genetic, and biochemical experiments.
1.2.1 Macrolides
The macrolides are a class of polyketide natural products that contain a large 14-, 15-, or
16-membered macrocyclic lactone ring to which deoxy sugars such as cladinose and desoamine
are attached. Some macrolides possess antibiotic or antifungal activities and have been developed
into successful pharmaceuticals. Pikromycin, the first antibiotic macrolide, was isolated in
1951.(17) Other macrolide antibiotics include erythromycin A, clarithromycin, and azithromycin.
Macrolides avermectin and ivermectin are used as antihelminthics and spinosad is used as an
insecticide.
1.2.2 Ansamycins
Ansamycins are macrolides with antimicrobial activities again many Gram-positive and
Gram-negative bacteria. It was first discovered in 1959 from an actinomycete bacterial strain
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Amycolatopsis mediterranei.(18) They are constructed uniquely with an aromatic moiety
connected by an aliphatic chain. The variation among ansamycins are the aromatic moiety which
can be a naphthalene ring or a napthoquinone ring as in rifamycin and the napthomycin.(19)
The benzene or benzoquinone ring system can also be a variation in geldanamycin or
ansamitocin. Examples of ansamycins are rifamycins that have high potency against mycobacteria,
which have been widely used in treating tuberculosis, leprosy, and mycobacterial infections.(20)
1.2.3 Acetogenins
Acetogenins are a class of polyketide natural products found in the Annonaceae family of
plants. They are characterized by linear 32- and 34-carbon chains containing oxygenated
functional groups including hydroxyls, ketones, epoxides, tetrahydrofurans, and tetrahydropyrans.
They are often terminated with lactone or butanolide. Over 400 members of this family of
compounds have been isolated from 51 different species of plants. Many acetogenins are
characterized by neurotoxicity.
1.2.4 Polycyclic polyethers
The polycyclic polyethers from plants, microorganisms and marine organisms are
identified by their regular occurrence of multiple C-O-C motifs. They have gathered much interest
due to their fascinating structural diversity and diverse biological activities, including antibiotic,
anticancer, and antimalaria to extreme toxicity.(21, 22) Based on their structural features and
origin, the natural polycyclic polyethers can be divided into two groups. First group includes
molecules with multiple fused cyclic ethers, which are constructed by all-endo cascade of epoxide
openings. The second group consists of molecules characterized by their multiple rings
interconnected by carbon-carbon bonds. They are produced through an all-exo biosynthetic
cascade of epoxide openings.
1.2.4.1 Polyether ionophores
The polyether ionophores are lipophilic carboxylic acids with multiple five- and sixmembered cyclic ethers as either spiroketal systems or linked bicyclic ethers (Figure 1.1). Since
3

the first ionophores nigericin and lasalocid were isolated in 1951, over 120 naturally occurring
ionophores have been reported.(23) Most of the ionophore natural products are from the
Streptomyces genus. These ionophores are used to control coccidiosis and as growth promoters in
ruminant animals, which can specifically target the ruminal bacterial population. Commercially
available ionophores include monensin 1, 2 (Coban, Rumensin, and Coxidin), lasalocid 3 (Avatec,
Bovatec), maduramicin 4 (Cygro), narasin 5 (Monteban, Maxiban), and salinomycin 7 (Bio-cox,
Sacox).(24)
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Figure 1.1: Structures of representative polyether ionophores
Biological activities of ionophore polyethers are closely related with their ability to bind
metals and transport them across the bacterial cell membrane.(25) The physiological pH in
ruminants is slightly acidic while the intercellular pH of most of the ruminal bacteria is near
neutral. This makes an inwardly directed proton gradient. The ruminal bacteria also maintain ionic
gradients across the membrane to take in nutrients efficiently. For example, it maintains a high
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intracellular potassium concentration and a low sodium concentration compared with the ruminal
environment. Due to their lipophilicity, polyether ionophores are able to insert into the bacterial
membrane easily. Once ionophores form a complex with the metal cations like potassium or
sodium, the ether oxygen of the ionophore loses its solvated water molecules and a neutral
zwitterionic metal-ionophore complex is formed.(26) Then transportation though the membrane
can take place. At the opposite side of membrane, the anionic ionophores are formed again after
releasing the metals. It needs to bind another cation, usually a proton, to return to the initial side
of the membrane.(27) The ionophores have different preferences to the metal cations. For example,
monensin A 1 can bind with potassium more stable than sodium, but its transport of sodium is
much faster than potassium.
1.2.4.2 Oxasqualenoids
Oxasqualenoid natural products exist in tropical plants, marine sponges and red algae.(28)
They are polycyclic polyethers derived from squalene and similar to polyether ionophore
structures, and contain regularly occurring tetrahydrofuran rings connected by carbon-carbon
bonds (Figure 1.2). Many triterpenic polyethers have been discovered with structural and
pharmacological diversities. For example, dehydrothyrsiferol 13 from the red seaweed Laurencia
viridis, is identified as a lead compound with moderate to potent cytotoxic activities.(29) Another
bromotriterpene polyether aurilol 15, is isolated from the Indian Ocean sea hare Dolabella
auricularia.(30) Relying on the similarity with polyether ionophores in structure and the
discoveries of the steroid biosynthesis from squalene epoxide, the biogenesis of the oxasqualenoids
was also proposed.(31, 32)
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Figure 1.2: Structures of representative oxasqualenoids
1.2.4.3 Ladder polyethers
Ladder polyethers feature 4 to 32 five- to nine-membered membered cyclic ethers fused
which are in a trans-syn-trans arrangement, thus result in a repeating C-C-O sequence that
stretches throughout their polycyclic core (Figure 1.3). The first ladder polyether, brevetoxin B,
was isolated in 1981 by Nakanishi and Clardy.(33) A large number of other ladder polyethers were
also discovered including the smallest member, hemibrevetoxin B 19 with only four rings and the
largest member, maitotoxin 16 with four polyether ladders and unequaled thirty-two rings.(34-37)
The ladder polyethers are best known for their association with harmful algal blooms,
commonly referred to as red tides, which involve a rapid increase of algae concentration in coastal
areas.(38) For example, Karenia brevis, the causative agent of algal blooms, produces the ladder
polyethers that are cytotoxic and cause devastating death of fish and marine mammals. The marine
species unaffected by red tide toxins can accumulate toxins, moving them upward in the food chain
and causing poisoning in humans.(39, 40) Despite the effects in red tides, ladder polyethers also
exhibit a variety of biological activities. Many members of this group show high binding affinity
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to sodium, potassium, and calcium ion channels, which would disrupt these channel functions.(41)
Some of the ladder polyethers also possess anticancer (42) and antifungal (43) properties.
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Figure 1.3: Structures of representative ladder polyethers
Based on the structure of brevetoxin B 18 and comparison to the well-studied polyether
ionophores like monensin 1, 2, lasalocid 3, and nigericin 9, Nakanishi (44) and Shimizu (45) both
proposed a hypothesis that the structural and stereochemical uniformity of ladder polyethers arise
from epoxidation and an epoxide-opening cascade that transforms the polyepoxide into a ladder
polyether.(46) The C-C-O backbone of ladder polyethers, which is shown in the figure 1.3, comes
from the oxygen and carbon atoms in the epoxide rings. All ring openings take place with inversion
of configuration at each epoxide that is derived from an E alkene. This explains how the transsyn-trans topography is generated. Since all alkenes of the precursor polyene needs identical
enantiofacial selectivity of epoxidation to produce either all-(S,S) or all-(R,R) polyepoxide, a single
promiscuous oxidase should be sufficient for this function.(37) Feeding experiments using
oxygen-18 in either molecular oxygen or acetate suggested that the ether oxygens of ladder
polyethers come from molecular oxygen while the hydroxyl oxygen is derived from acetate, which
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supports Nakanishi and Shimizu’s hypothesis that the precursor polyene is oxidized from head to
tail (or right to left) by a monooxygenase after acetate condensation.(47-49)
1.2.5 Polyketide biosynthesis
Polycyclic polyethers belong to a large family of polyketide natural products. Even though
they exhibit extremely high diversity in structure and biological activity, all polyketides are
constructed by successive rounds of decarboxylative Claisen condensations between a
thioesterified malonate derivative and an acyl thioester. The enzymes responsible for these
condensations are called polyketide synthases (PKSs) which are classified into three types I, II and
III.(15, 50-53)
Type I PKSs consist of two groups: modular and iterative PKSs. The modular system
contains a set of catalytic domains that are covalently linked as modules responsible, each module
being responsible for the incorporation of one precursor molecule into the polyketide backbone.
The typical example of PKSs is 6-deoxyerythronolide B synthase which assembles the 6dexyerythronolide B moiety of erythromycin A.(54) A PKS module has at least three core
domains: an acyl carrier protein (ACP), an acyltransferase (AT), and a ketosynthase (KS) for
extending the polyketide chain by two carbon atoms. The ACP domain utilizes a
phosphopantetheine arm and thioester bond to bind the growing polyketide chain and the extender
unit and transfer them to other domains. The AT domain recognizes a specific extender unit and
tethers it to the sulfhydryl group of the ACP prosthetic arm. The KS domain catalyzes carboncarbon formation between the ACP-linked malonate derivative and the other ACP-linked acyl
thioester through the decarboxylative Claisen condensation reaction. In addition to the KSinvolved condensation, a PKS module may also contain other catalytic domains to perform
different kinds of !-keto group modification. Examples of such domains include ketoreductase
(KR), dehydratase (DH), and enoylreductase (ER). Once the polyketide intermediate is fully
processed, the ACP domain transfers the elongated polyketide chain to the KS of the subsequent
module for another round of elongation or to the thioesterase (TE) domain for release of the final
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product through hydrolysis or cyclization. Iterative type I PKSs are similar to the modular PKSs
in that they use the same set of catalytic domains for transferring, extending, and modifying
polyketide chain. The main difference between the two PKS types is that in iterative type I PKSs,
a single module acts on the substrate repetitively.(55) The biosynthetic pathway of the polyketide
lovastatin is a typical iterative PKS, all 35 reactions are conducted by a single iterative
dihydromonacolin L synthase.(56, 57)
Type II PKSs contain the same KS, AT, KR and DH domains like type I PKSs, but typically
contains two KS domains: KSa domain same with one in type I PKSs, and KSb domain controlling
polyketide length. Additionally, reduction of the !-keto group takes place only after the polyketide
backbone is completely synthesized.(58) The anticancer drugs daunorubicin and doxorubicin are
synthesized by type II PKS proteins.(59, 60)
Type III PKSs, which are distinct from type I and II PKSs, contain iterative domains as
homodimers, and they are ACP independent. They act directly on acyl-Coenzyme A (CoA)
thioesters and transfer the acyl group between CoA and an active site cysteine. The most wellstudied type III PKS is the plant chalcone synthase, which condenses three acetate units to a 4coumaroyl-CoA starter molecule which is cyclized to form the aromatic tetraketide product
naringenin chalcone.(53)
1.3 SYNTHESIS OF POLYETHER IONOPHORES
1.3.1 Total synthesis
Over the past decades, much effort has been made to synthesize polyether ionophore
antibiotics. So far, about 16 polyether ionophore natural products have been successfully prepared
by total synthesis.(61, 62) The tricky part is to synthesize the polyether rings (tetrahydrofurans and
tetrahydropyrans) and the spiroketal systems. The landmark total synthesis of the polyether
lasalocid A was first reported by Kishi’s group.(63, 64)
To synthesize polypropionates, several acyclic methods have been developed. For
example, allylic 1,3 strain (A-1,3) was used to synthesize propionates and form tetrahydrofuran
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through hydroboration, haloetherification, and epoxidation reactions.(65) Sharpless asymmetric
epoxidation was used to produce enantiometrically pure propionate fragments.(66, 67) The Cramand Cram-chelate-controlled addition of nucleophiles to carbonyls were also introduced by Kishi
and Still to build the propionate fragments.(68) Later on, a more versatile and efficient method,
chiral enolate bond construction was developed by Evans.(69) Besides, there were also several
strategies developed for fragment coupling. The most popular and important reaction for fragment
coupling is the aldol reaction. However, there were other reactions that have been used for the
fragment couplings and the formation di- and trisubstituted carbon double bonds, including Julia
olefination, Witting, and Diels-Alder reactions.
Total synthesis of lasalocid A and its isomer isolasalocid A, first polyether ionophores that
were prepared by total synthesis, was achieved in 1978.(63) Lasalocid A and isolasalocid A both
contain a central tetrahydrofuran B-ring and 10 chiral centers. But lasalocid A has a
tetrahydropyran C-ring while isolasalocid A has a tetrahydrofuran C-ring. The total synthesis of
lasalocid A involves separate synthesis of C1-C11 and C12-C24 fragments. The C1-C11 fragment was
prepared in two steps. The C12-C24 fragment was prepared by two complimentary approaches using
the highly regioselective and stereoselective addition of alcohols to epoxides.(70) In one approach,
A-1,3 interactions was used to prepare the tetrahydrofurans by epoxidation of bishomoallylic
alcohols and stereoselective reduction of ketones that is followed by epoxidation ring opening
reactions. In the other alternative approach, the C19 alcohol was prepared by the epoxidation of the
olefin followed by the reduction. The absolute stereochemistry of the intermediates was achieved
by resolution, chiral pool, equilibration, Cram- and Cram-chelate-controlled addition. These two
fragments were coupled together by aldol reaction.
The total synthesis of monensin A was also reported by both Kishi and Still in 1979.(7173) Similar to lasalocid A, total synthesis of monensin A involves separate preparation of the C1C7 and C8-C26 fragments. A new method using hydroboration reaction was developed by Kishi for
propionate synthesis. In the Kishi’s total synthesis method (71, 72), the preparation of the C1-C7
fragment is achieved in six steps in total, which includes furan ring ozonolysis, alcohol oxidation,
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and the hydroxyl protection. Synthesis of the C8-C25 fragment is achieved in 15 steps, using
epoxidation of bishomoallylic alcohols. The absolute stereochemistry was controlled by
resolution, A-1,3 and thermodynamic equilibration. In Still’s total synthesis method (74, 75), three
fragments C1-C7, C8-C15, and C16-C25 were prepared first. The Cram- and Cram-chelate
nucleophilic addition reactions were heavily used to generate the 7 stereogenic centers of monensin
A. The C1-C7 fragment was prepared in 10 steps through two sequential aldol reactions. The C8C15 fragment was prepared 16 steps by chelate-controlled addition, diol protection, desilylation,
and bromination reactions. The fragments were coupled together at the end by aldol reactions.
Total synthesis of several other polyether natural products have been reported, including
calcimycin (1979) (69), indanomycin (1981) (76), narasin and salinomycin (1981) (77), and
zincophorin (1987) (78). However, there still remains some problems in synthesizing the polyether
ionophores, including controlling the stereoselectivity, separating the isomers, and coupling
fragments. The total yield of the final products is still very low. More efficient and predictable
methods need to be developed in the future.
1.3.2 Biosynthesis
1.3.2.1 Unified model
Polyether ionophores belong to the polyketide family of natural products. Soil bacteria
such as Streptomyces strains produce various polyether ionophores for the purpose of killing off
their competitors and compositing for water, food, and other limited resources (79). So far, over
hundreds of polyether natural products have been discovered in bacteria. For example, monensin
A is produced by Streptomyces cinnamonensis, lasalocid A is produced by Streptomyces
lasaliensis, salinomycin is produced by Streptomyces albus, and nigericin is produced by
Streptomyces violaceusniger.
All polyether-producing bacteria contain a gene cluster for polyether ionophore
biosynthesis. The genes in this cluster code for various enzymes responsible for biosynthesis of
polyether ionophores. Biosynthesis of ionophore polyethers includes two reactions: synthesis of
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linear polyene and formation of ether rings. The synthesis of linear polyene is carried out
polyketide synthases. The formation of ether rings is carried out by epoxidases and hydrolyses.
A series of feeding experiments on ionophore-producing organisms revealed their
polyketide biosynthetic origin.(80-82) It also indicated that their oxygen atoms come not only from
the building blocks acetate, propionate, and butyrate but also from the molecular oxygen. In 1983,
based on all the previous experimental results, Cane, Celmer, and Westly proposed a biosynthetic
model (CCW model) that describes how polycyclic polyether skeletons with various stereocenters
is constructed.(83) It suggests that a chiral polyene first undergoes sequential enantioselective
epoxidation to install all the necessary stereochemistry, and then the resulting polyepoxide serves
as a substrate of epoxide opening cascades to give elaborated polyethers. The first class of
polyethers including monensin 1, 2, dianemycin, and lenoremycin, which has the identical
tetrahydropyranyl rings at the termini, are produced with the building blocks as acetate, propionate,
propionate, and acetate (APPA). The second class of polyethers, including lasalocid 3 and
isolasalocid 6, the building blocks vary as (PABA, BABA, and PAPA) and give either a
tetrahydrofuran linked to a tetrahydropyran, or two adjacent five-membered ether rings at the
termini. This was the first time that a unified stereochemical model was proposed to summarize
the biosynthesis of a large number of polyethers, and it leads to the consideration that each polyene
prototype is constructed by enzymes expressed by the gene cluster corresponding to the polyene
chain-building sequence.
In 2001, Leadlay and co-workers identified a gene cluster for monensin biosynthesis,
which consists of twelve polyketide synthase modules, MonAI to MonAX, responsible for
building the twelve acyl units of monensin, one epoxidase gene MonCI, and two epoxide hydrolase
genes MonBI and MonBII.(84) After a series of gene inactivation experiments in monensin
biosynthesis (85, 86), the CCW model was further improved and finally established. Later on, both
Oikawa’s and Leadlay’s group reported a gene cluster of lasalocid biosynthesis pathway
containing an epoxidase Lsd18 (also called LasC) and an epoxide hydrolase Lsd19 (also called
LasB), which also supports the CCW model.
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1.3.2.2 Biosynthesis of monensin
Monensin A and B are the polyether ionophores that are produced by Streptomyces
cinnamonensis. They can dissipate ionic gradient across cell membranes and are widely as food
additive in poultry to prevent coccidiosis.(87) Early feeding experiments indicate that monensin
A 1 is produced from five acetate, seven propionate, and one butyrate precursors, while monensin
B 2 requires an extra propionate replacing the butyrate.(88) Four out of their nine oxygen atoms
come from molecular oxygen while the other five are derived from the corresponding carboxylic
acids.
In 2001, the gene cluster for monensin biosynthesis was identified by Leadlay’s group
(Figure 1.4).(84) It contains a twelve-module polyketide synthase system responsible for
constructing the linear triene premonensin 20. The loading module has an N-terminal KSQ domain
that act as a malonyl-CoA decarboxylase to generate starter units in situ. The monensin PKSs don’t
have an integrated C-terminal thioesterase at the end of module 12 for the polyketide chain release.
The enzymes encoded by monCII, monAIX, and monAX genes have been shown to function as
thioesterases based on their gene sequence alignment and deletion experiments.(85, 89)
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Figure 1.4: The proposed biosynthesis pathway of monensin. X= OH, SCoA, or S-protein.
After released from the PKSs, epoxidation and epoxide-opening cascades of premonensin
take place. The monCI gene encodes a flavin-dependent monooxygenase, which is responsible for
the epoxidation of all three carbon double bonds in premonensin 20. Deletion of monCI gene
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resulted in complete loss of the final product monensin and the accumulation of the linear E, E, Etriene lactones (86), which supports the CCW biosynthetic model proposed by Cane et al. The
monBI and monBII genes, which are homologous to each other, encode the enzymes for epoxide
ring opening and the following polyether ring formation.(90) Deletion of these genes resulted in
no production of monensin. After a series of gene deletion and mutation experiments, and solving
the crystal structure of MonBI by Oikawa’s group, the role of MonBI and MonBII has been further
understood.(91, 92) It shows that MonBI and MonBII function with synergistic effect as epoxide
hydrolase and cyclase. More specifically, MonBII catalyzes two rounds of cyclization while
MonBI acts as an allosteric regulator for MonBII through protein-protein interaction. Only after
the conformational changes induced by MonBI, MonBII is able to catalyze multiple
cyclizations.(92)
1.3.2.3 Biosynthesis of lasalocid
Lasalocid is a carboxylic ionophore produced by Streptomyces lasalinesis. It has been used
as antibacterial and anti-coccidiosis agent, commercially available as the feed additives like
Bovatec and Avatec. It can bind with divalent and monovalent cations, altering ionic transportation
across lipid membranes of cells. The feeding experiments indicate that lasalocid A is produced
from the three butyrate, four propionate, and five acetate building units.(63, 93, 94) The five
oxygen atoms at C-1, C-3, C-11, C-13, and C-15 of lasalocid A are derived from their respective
building units, while three other oxygen atoms at C-19, C-22, and C-23 come from the molecular
oxygen.(95)
Around 2008, Leadlay’s (96) and Oikawa’s (97) group both reported a gene cluster of
lasalocid A biosynthesis (Figure 1.5). It contains a seven-domain type I PKS system, named as
lsd11-lsd17 (or lasAI-lasAVII) including a loading module and 11 extension modules to construct
the prelasalocid 21, a linear dodecaketide from five malonyl-CoA, three ethylmalonyl-CoA, and
four methylmalonyl-CoA precursors. The KSQ motif was also found in its loading module, which
agrees with the feeding experiment result. It indicates that the starter unit is from malonate instead
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of acetate.(98) The gene lsd4 shows a high homology to monAX gene (54% identity) of monensin
biosynthesis, which is a type II thioesterase for removing the aberrantly aattached acyl
intermediates from the PKS.(99, 100) Unlike monensin biosynthesis which has a discrete TE
domain, lasalocid biosynthesis has a fused TE domain at the Lsd17 C-terminal. This finding
suggests that the full-length polyketide can be cleaved from the ACP domain, even before the
complete formation of polyethers.
Guided by the CCW biosynthesis model, the genes of epoxidase and epoxide hydrolase
were also identified from the gene cluster, which are lsd18 (also named as lasC) and lsd19 (also
named as lasB), respectively. Lsd18 is a flavin-dependent monooxygenase with two flavin adenine
dinucleotide (FAD) binding motifs, GxGxxG and GD (101, 102), sharing 52% identity with
MonCI. Biotransformation of Lsd18 in an organic-solvent-resistant strain Rhodococcus
erythropolis showed that Lsd18 catalyzes epoxidation of both carbon double bonds in a
stereoselective manner. Time course analysis also showed that epoxidation starts from the terminal
olefin of prelasalocid 21.(103) According to the structural analysis and sequence alignment of its
homologs like p-hydroxybenzoate hydroxylase (PHBH) (104), TetX (105) and RebC (106), it
indicates that the isoalloxazine ring of FAD in Lsd18 might move from the “out” position to “in”
position during their catalysis for the FAD oxidation and reduction.(107-109) In 2014, Oikawa’s
group examined six differently substituted olefins to explore Lsd18 stereoselective
mechanism.(110) Based on the results, they proposed a substrate binding model for Lsd18.
According to their hypothesis, the substitution patterns on the substrate olefin would affect the its
transformation and enantiofacial selectivity because of the steric hindrance with the active site.
However, this hypothesis hasn’t been verified yet due to the lack of Lsd18 molecular structure.
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As a homolog of epoxide hydrolases MonBI/MonBII in monensin biosynthesis, Lsd19
catalyzes two rounds of epoxide opening reactions with high regioselectivity, including an
energetically favored 5-exo cyclization and an energetically unfavored 6-endo cyclization (Figure
1.5).(111, 112) The crystal structures of Lsd19 with the substrate and product analogs has been
solved. It showed that Lsd19 has two fused domains, Lsd19A and Lsd19B, with two separate
active sites. They are able to catalyze a single cyclization reaction independently. Structural
analysis of Lsd19B by computational calculations suggests that the preorganization of the active
site could be the key to initiate the second round, energetically disfavored 6-endo cyclization.
Further studies on the Lsd19 regioselective mechanism would shed light on its bioengineering to
produce various ladder polyethers.(113, 114)
1.4 FLAVIN-DEPENDENT MONOOXYGENASES
Flavin-dependent monooxygenases are the enzymes that use flavin as a cofactor and
catalyze the incorporation of one oxygen atom into the substrate. Oxygen activation in the flavindependent monooxygenases typically involves the formation of a transiently C4a(hydro)peroxyflavin intermediate.(115) These flavin-dependent monooxygenases are involved in
various biological processes, including the epoxidation during the formation of ether rings in the
biosynthesis of polyether ionophores. According to the standards of the nomenclature committee
of the International Union of Biochemistry and Molecular Biology, the flavin-dependent
monooxygenases are a part of the oxidoreductase subclasses 1.13 and 1.14. Based on their
functional and structural properties, all the flavin-dependent monooxygenases are divided into
eight groups A-H.(116)
Group A flavin-dependent monooxygenases are encoded by a single gene and use
NAD(P)H as the electron donor. They contain a typical glutathionite reductase (GR-2) type
Rossmann fold for cofactor flavin binding and a DG fingerprint for both flavin and NAD(P)H
binding. Group A flavin-dependent monooxygenases catalyze the degradation of polyaromatic
compounds and biosynthesis of some natural products. Most of the group A flavin
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monooxygenases are responsible for the ortho- or para-hydroxylation od the phenolic compounds.
The prototype includes PHBH that transforms 4-hydroxybenzoate into 3,4-dihydroxybenzoate.
Group B flavin-dependent monooxygenases are also encoded by a single gene. They
contain two "/! Rossmann like domains for flavin and NAD(P)H binding. Unlike group A
enzymes, the group B flavin monooxygenases remain bound to their pyridine nucleotide
coenzymes during catalysis. This group consists of four subgroups: Baeyer-Villiger
monooxygenases, N-hydroxylating monooxygenases, flavoprotein monooxygenases, and a more
recently discovered YUCCAs.
Group C flavin-dependent monooxygenases are two-component enzyme systems that rely
on a NAD(P)H-dependent flavin reductase for reducing their flavin cofactors. The prototype is
luciferase in bacteria, which is the first flavoprotein with the direct nuclear magnetic resonance
(NMR) proof for C4a-(hydro)peroxyflavin intermediate. The reactions that group C enzymes
catalyze include light emission, Baeyer-Villiger oxidation, epoxidation, desulfurization,
sulfoxidation, and hydroxylation.
Group D flavin-dependent monooxygenases are featured by an acyl-CoA dehydrogenase
fold. They are also a two-component enzyme system that receive the reduced flavin from a
NAD(P)H-dependent flavin reductase. They are involved in the reactions like aromatic
hydroxylation and N-hydroxylation. The prototype enzyme is 4-hydroxyphenylacetate 3hydroxylase.
Group E flavin-dependent monooxygenases are the epoxidases that are a two-component
enzyme system and contain a PHBH (GR-2) Rossmann fold. They use a NAD(P)H-dependent
flavin reductase to generate the reduced FAD. The prototype of group E enzyme is styrene
monooxygenases that transform styrene derivatives into the (S)-styrene oxides.
Group F flavin-dependent monooxygenases are a two-component enzyme system, also
generate the reduced flavin from a NAD(P)H-dependent flavin reductase. Structurally similar to
group A enzymes, group F enzymes also contain a glutathione reductase (GR-2) FAD-binding
fold. They catalyze halogenation reaction. The prototype is tryptophan 7-halogenase. Group G
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enzymes contain a monoamine oxidase Rossmann fold and use an amino acid substrate as the
electron donor. They are responsible for oxidative decarboxylation. The typical group G enzyme
is tryptophan 2-monooxygenase. Group H flavin-dependent monooxygenases contain a flavin
mononucleotide (FMN) as their cofactor. They are feature by a Tim-barrel (glycolate oxidase)
fold. They catalyze oxidative decarboxylation and oxidative denitration reactions. The prototype
of group H enzymes are lactate 2-monooxygenase and nitronate monooxygenase.
1.5 EPOXIDATION
1.5.1 Epoxidation in organic synthesis
An epoxide is a cyclic ether with a highly reactive three-atom ring. The basic structure
consists of an oxygen atom bound to two carbon atoms. Epoxidation reaction is one of the most
frequently used reactions in industry.
There are two main ways to prepare epoxides in organic synthesis. The most common
laboratory operation includes the direct oxidation of alkenes with peroxycarboxylic acids, which
can be represented by the Prilezhaev reaction (Illustration 1.1 A).(117-119) In this approach, metachloroperoxybenzoic acid (m-CPBA) is employed as the peroxyacid. Magnesium monoperpthalate and peracetic acid can also be used. This reaction proceeds through a “butterfly
mechanism” initially proposed by Bartlett in 1950, where the peroxy acid tends to adopt an
intramolecularly hydrogen-bonded conformation in solution at the transition state (Illustration 1.1
B).(120) The peroxide is an electrophile while the alkene is a nucleophile. This high degree of
peroxide polarization causes an electrophilic oxygen atom added to the alkenes. This type of
epoxidation is highly stereospecific in terms of the double bond stereochemistry, which means that
a trans-olefin only leads to a trans-2,3-substituted epoxide, while a cis-olefin would only produce
the cis-epoxide. Hyperoxides can also be applied in the enantioselective epoxidations, such as
Jacobsen epoxidation (121), Sharpless epoxidation (122), and Shi epoxidation (123, 124). All of
these reactions are very useful for the enantioselective synthesis of enantiopure epoxides.
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Illustration 1.1: Epoxidation reactions. (A) Prilezhaev reaction. (B) The proposed “butterfly
mechanism”.
The other way of synthesizing epoxides is through dehydrohalogenation, which involves
the cyclization of halohydrins with base. This is a variant of the Williamson ether synthesis (125).
Like the bimolecular SN2 substitution, this reaction takes place by backside substitution of the
nucleophile, the oxygen anion at the halide-bearing carbon. And this substitution requires an ‘anti’
relationship of the nucleophilic oxygen and the leaving halide at the transition state, which is
generally achieved by a simple internal rotation in the noncyclic halohydrins (92). The
representative example of this method can be found in the Johnson-Corey-Chaykovsky reaction.
1.5.2 Enzymatic epoxidation
The enzymatic epoxidation can be conducted directly by the oxygenases that incorporate
one oxygen atom of either water or molecular oxygen into the substrates. They play an important
role in the metabolic reactions, including the degradation of drugs, interconversion of amino acids,
lipids, and hormones, and also the biosynthesis of antibiotics. So far, only few of these enzymes
have been well-studied due to their flexibility and difficulty of protein purification. Among all the
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identified enzymes, there are two main types: cation-dependent monooxygenases and flavindependent monooxygenases.
1.5.2.1 Cation-dependent epoxidases
The cation-dependent monooxygenases typically contain heme as a cofactor. They have
been found in all types of living cells, including animals, insects, plants, fungi and bacteria. The
cytochrome P450 monooxygenases are the important members of this type.(126) They catalyze a
variety of the regio-, chemo-, and stereospecific oxidation by utilizing electrons derived from
NAD(P)H.(127) For catalytic activities, cytochrome P450s need to rely on a redox partner protein
to transfer the electrons from NAD(P)H to the heme center of the P450. Based on the nature of the
electron transfer protein, the P450 enzymes can be further divided into several subgroups.(128)
One subgroup needs both an iron-sulfur ferredoxin and a FAD-containing reductase.(129) Another
subgroup only needs a FAD- or FMN-containing reductase.(130, 131)
1.5.2.2 Flavin-dependent epoxidases
The flavin-dependent monooxygenases also participate in various chemo-, regio-, and
stereoselective oxygenation reactions, where one atom of the molecular oxygen is incorporated
into the substrate and the other is reduced into water.(116) In nature, the cofactor flavin exists in
three forms: riboflavin, flavin mononucleotide (FMN), and flavin adenine dinucleotide (FAD).
They have different-length functional groups on the ribityl side chain.(116) In general, the
mechanism of oxygenation by flavin-dependent monooxygenases is shown in the illustration 1.2.
At first, the reduced nicotinamide NAD(P)H transfers its hydride to the isoalloxazine group of the
flavin cofactor. The reduced flavin then can react with molecular oxygen, yielding a catalytically
active peroxide, C4a-(hydro)peroxyflavin, which is transiently stabilized by the enzymes.(115)
The oxygen-oxygen bond in peroxide is split once the peroxide reacts with the nucleophilic or
electrophilic substrates. One oxygen atom is incorporated to the substrate, and the other one is
reduced to water.(104, 132) Styrene monooxygenases (SMO) are one of the most-studied flavindependent monooxygenases, which transfer styrene into (S)-styrene oxide in the pathway of
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styrene degradation.(133, 134) It contains two individual components: a FAD-bound styrene
epoxidase (StyA) and a NADH-utilizing flavin reductase (StyB).(135, 136) During the epoxidation
of styrene, molecular oxygen first reacts with the reduced FAD in StyA to produce a transiently
stable flavin-C4a-peroxide adduct. Then the substrate styrene reacts with peroxide intermediate
and turns into an epoxide. The crystal structure of StyA from P. putida S12 has been solved.(136138) It shows that StyA has two distinct domains: one is the FAD binding site and the other is the
styrene binding site.(137, 138) The kinetic studies of StyB revealed the sequential binding of
NADH and flavin, and it also proved that the presence of StyA doesn’t affect the NADH oxidation
activity.(136)
R

H+

N

N

O

NH
N
H

( III )

R

O

-O

N

O

N

O

4a-peroxyflavin

O2

( II )

NH
N
H

N

O

HO

R
N-

O

4a-Hydroperoxyflavin

O

Substrate
NH

( IV )

N
H

Product-O

O

Reduced flavin
R

NAD(P)+

N

(I)

N

O

NH

R

NAD(P)H

N

N

O

(V)

N
H

OH
O

Hydroxyflavin

NH
N

H2O
O

Oxidized flavin

Illustration 1.2: Simplified catalytic cycle of flavin-dependent monooxygenase
1.6 EPOXIDATION INVOLVED IN POLYETHER BIOSYNTHESIS
Epoxidation is a key step to form ether rings during the biosynthesis of polyether
ionophores. So far, there have been several epoxidases identified in the gene clusters responsible
for polyether biosynthesis. The two most well-studied epoxidases involved in the polyether
biosynthesis are MonCI and Lsd18 that are responsible for the epoxidation in the biosynthesis of
monensin and lasalocid, respectively.
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Since the gene cluster for the polyether monensin biosynthesis was discovered by Leadlay
and his co-workers in 2001 (84), epoxidase MonCI has raised up researchers’ attention. MonCI
was identified as epoxidase due to the significant gene similarity to other authentic non-haem
epoxidases. It was considered as a candidate to catalyze the epoxidation on all three alkenes of
premonensin. For the Streptomyces mutant with the gene deletion of monCI, it only produced the
linear polyene premonensin precursor instead of producing the final product monensin. This
experiment indicated that MonCI plays an important role during the biosynthesis of monensin.
Oliynyk et al. also demonstrated that the heterologous overexpression of protein MonCI in another
strain Streptomyces coelicolor increased its ability to epoxide linalool, an unsaturated terpene, by
a 10-20 fold, thereby further establishing MonCI as the enzyme responsible for the epoxidation
step in monensin biosynthesis.(85) It has shown that MonCI is able to install (R, R)-epoxides on
the two internal olefin moiety and a (S,S)-epoxide on the terminal olefin moiety.
After the discovery of MonCI, Lsd18 was also identified as an epoxidase from the gene
cluster responsible for the biosynthesis of lasalocid in Streptomyces lasaliensis. It shares high
sequence identity to MonCI. Gene deletion experiment also showed its role as epoxidase in
biosynthesis of lasalocid. Recently, Oikawa’s group studied Lsd18 by both in-vivo and in-vitro
studies.(103) They used simple olefin and truncated diene of the Lsd18 native substrate as its
substrate analogs. It showed that Lsd18 is able to conduct enantioselective epoxidation on the
internal and terminal two olefin moieties one by one in a stereoselective and regioselective manner.
The epoxidation starts from the terminal olefin. Lsd18 transforms both internal and terminal olefin
moieties into (R,R)-epoxides. Besides, Oikawa’s group also explore the mechanism of the
stereoselectivity of Lsd18 by analyzing the products’ stereochemistry after reaction.(110) They
used different monoolefin substrate analogs with various substitution patterns such as hydrogen
and methyl groups. They observed that for the substrate analogs with different substitution
patterns, the enantiomeric ratio of the (R,R)-epoxide products is also different. Based on this result,
Oikawa’ group proposed a substrate binding model of Lsd18, which has a relatively large primary
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site and a space-limited secondary site for the substrate binding. However, this binding model has
be verified yet due to the lack of structural information.
Besides MonCI and Lsd18, there are also several other epoxidases identified from the gene
clusters of polyether biosynthesis. For example, SalC is the epoxidase involved in biosynthesis of
polyether salinomycin. It converts two carbon double bonds of the salinomycin precursor into two
(R, R)-epoxides.(139) TmnC is found to be the epoxidase involved in biosynthesis of polyether
tetronomycin. It transfers one terminal carbon double bond of the tetraonomycin precursor into a
(S, S)-epoxide.(140) Nano and NigCI are also epoxidases responsible for the epoxidation reactions
in the biosynthesis of nanchangmycin and nigericin, respectively.(141, 142) However, due to the
difficulty of obtaining stable enzyme samples in vitro and lack of structural information, the overall
study about the epoxidases is very limited. How these enzymes catalyze multiple epoxidation in a
regio- and stereoselective manner still remains unknown.
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Chapter 2: Materials and Methods
2.1 HETEROLOGOUS PROTEIN EXPRESSION AND PURIFICATION
2.1.1 Cloning
The genes lsd18 from Streptomyces lasalinesis and monCI from Streptomyces
cinnamonensis were separately cloned into the vector pCold I (Takara Bio) between the restriction
sites NdeI and EcoRI. For the best production of protein MonCI, the monCI-pCold I plasmid was
transformed into the BL21-AI Escherichia coli bacterial strain (ThermoFisher). For Lsd18, a
chaperone-encoding vector pG-KJE8 (Takara Bio) was transformed together with lsd18-pCold I
plasmid into the Escherichia coli BL21(DE3) bacterial strain (Sigma Aldrich). This pG-KJE8
vector encodes chaperones of dnaK, dnaJ, grpE, groES, and groEL, which can help with protein
folding and increase the recovery of expressed Lsd18 in the soluble fraction. Other genes including
lsd19, gdh, fre, and monACPX were all inserted the vector pET-28a(+). The genes lsd18, monCI,
lsd19, fre and monACPX were synthesized by GenScript. The gdh-pET-28b plasmid was provided
by courtesy of Professor Adrian Keating-Clay from University of Texas at Austin. For protein
expression, the lsd19-pCold plasmid was transformed into E.coli BL21(DE3) bacterial strain
together with the chaperon pG-KJE8 plasmid. The fre-pET28a(+) and gdh-pET28b plasmids were
also transformed into E.coli BL21(DE3) bacterial strain, respectively. For the protein expression
of MonACPX, the monACPX-pET28a(+) plasmid was transformed into the E.coli BAP1 bacterial
strain. All the detailed gene information is listed in the table 2.1.

Table 2.1: List of all the plasmids used. Amp: ampicillin; Kan: kanamycin; Cm:
chloramphenicol.

Gene

Plasmid

Expressed protein

Resistance

Origin

lsd18

pCold I

Lsd18

Amp

Streptomyces lasalinesis

monCI

pCold I

MonCI

Amp

Streptomyces cinnamonensis
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lsd19

pCold I

Lsd19

Amp

Streptomyces lasalinesis

gdh

pET-28a(+)

Glucose-1-dehydrogenase (GDH)

Kan

Bacillus subtilis (strain 168)

fre

pET-28a(+)

NAD(P)H-flavin reductase (Fre)

Kan

Escherichia coli (strain K12)

monACPX

pET-28a(+)

MonACPX

Kan

Streptomyces cinnamonensis

pG-KJE8

DnaK, DnaJ, GrpE, GroES, GroEL

Cm

Escherichia coli (strain K12)

dnaKdnaJgrpEgroESgroEL

2.1.2 Site-directed mutagenesis of lsd18 gene
The construct of Lsd18 mutants follows the protocol described before.(143) The
oligonucleotides shown in the table 2.2 were used to obtain Lsd18 mutants Y218F, Y218S, H71A,
H71A, H71S, I72A, I72G, Q66N, and Q66G. All the primers were synthesized by IDT company.
The components for polymerase chain reaction (PCR) system are listed in the table 2.3. Detailed
steps of PCR protocol are also shown in table 2.4. All the mutant constructs were verified by gene
sequencing at the Genomic Analysis Core Facility of the University of Texas at El Paso.

Table 2.2: Oligonucleotide primers for constructing Lsd18 mutants.

Primers

Sequence

Lsd18 Y218F Forward Primer

5’-GTATGGTCTTTGCTACCCGTCTGTTTCGTG-3’

Lsd18 Y218F Reverse Primer

5’-CGGGTAGCAAAGACCATACCGCTATCAAC-3’

Lsd18 Y218S Forward Primer

5’-GTATGGTCTCTGCTACCCGTCTGTTTCGTG-3’

Lsd18 Y218S Reverse Primer

5’-CGGGTAGCAGAGACCATACCGCTATCAAC-3’

Lsd18 H71A Forward Primer

5’-GTCATGCGGCCATTCTGTGGTCTGGCG-3’
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Lsd18 H71A Reverse Primer

5’-CACAGAATGGCCGCATGACGAGCTTGC-3’

Lsd18 H71S Forward Primer

5’-GTCATGCGTCCATTCTGTGGTCTGGCG-3’

Lsd18 H71S Reverse Primer

5’-CACAGAATGGACGCATGACGAGCTTGCG-3’

Lsd18 I72A Forward Primer

5’-CATGCGCACGCTCTGTGGTCTGGCGGTG-3’

Lsd18 I72A Reverse Primer

5’-GACCACAGAGCGTGCGCATGACGAGCTTGC-3’

Lsd18 I72G Forward Primer
Lsd18 I72G Reverse Primer
Lsd18 Q66N Forward Primer
Lsd18 Q66N Reverse Primer
Lsd18 Q66G Forward Primer
Lsd18 Q66G Reverse Primer

5’-CATGCGCACGGTCTGTGGTCTGGCGGTG-3’
5’-GACCACAGACCGTGCGCATGACGAGCTTGC-3’
5’-GTGTCCCGAATGCTCGTCATGCGCACATTC-3’
5’-TGACGAGCATTCGGGACACCTTTGCGCAG-3’
5’-GTGTCCCGGGAGCTCGTCATGCGCACATTC-3’
5’-ATGACGAGCCCTCGGGACACCTTTGCGCAG-3’

Table 2.3: PCR components for Lsd18 mutant construction. Phusion HF buffer purchased from
New England Biolabs creates the optimal reaction conditions for high fidelity amplification.
Phusion GC buffer purchased from New England Biolabs promotes excellent amplification of
GC-rich DNA.

Components

50 µl reaction

Final concentration

Nuclease-free water

to 50 µl

/

5x Phusion HF or GC buffer

10 µl

1x

10 mM dNTPs

1 µl

200 µM

10 µM Forward Primer

2.5 µl

0.5 µM

10 µM Reverse Primer

2.5 µl

0.5 µM

Template DNA (lsd18-pCold plasmid)

variable

120 ng

DMSO

1.5 µl

3%

Phusion DNA Polymerase

0.5 µl

1.0 units/50 µl PCR
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Table 2.4: Thermocycling conditions for Lsd18 mutant PCR.

Steps

Temperature

Time

Initial Denaturation

98 ℃

30 seconds

30 cycles

98 ℃

10 seconds

72 ℃

175 seconds

Final Extension

72 ℃

5 minutes

Hold

4℃

hold

2.1.3 Heterologous protein expression
For Lsd18 expression, the culture of BL21(DE3) strain carrying lsd18-pCold I and pGKJE8 plasmids was grown in Luria Broth medium (Molecular Dimensions) to OD600nm of 0.6.
Lsd18 was induced together with the chaperones by 100 µM isopropyl-b-D-galactoside (IPTG),
0.5 mg ml-1 L-arabinose and 5 ng ml-1 tetracycline. The culture was incubated for another 20 hours
at 15 ℃. After harvested by centrifugation, the cell pellets were used immediately for purification
or kept at -80 ℃ for future use. For MonCI expression, the culture of BL21-AI strain carrying
monCI-pCold I plasmid was also grown in the LB medium to OD600nm of 0.6. Then it was induced
by 100 µM IPTG and 2 mg ml-1 L-arabinose. The induction condition and cell harvesting method
are the same as MonCI. Expression of Lsd19 is the same as Lsd18 while the GDH, Fre and
MonACPX were expressed in BL21(DE3) E. coli strain with 100 µM IPTG for 20 hours at 18 ℃.
2.1.4 Recombinant protein purification
For epoxidase MonCI purification, the cell pellet from 4-liter cell culture was resuspended
in the cell lysis buffer containing 50 mM sodium phosphate pH 7.4, 300 mM sodium chloride, 40
mM imidazole, 10% (v/v) glycerol and lysed by sonication. After centrifuged at 18,000 g for 40
minutes, the MonCI protein sample was first purified by immobilized metal affinity
29

chromatography (IMAC). The clear supernatant was loaded onto a 5 ml HisTrap column (GE
Health Life Sciences) and washed with a wash buffer containing 50 mM sodium phosphate pH7.4,
300 mM sodium chloride, 70 mM imidazole, 10% (v/v) glycerol. N-terminal His-tagged MonCI
proteins were eluted out with a wash buffer supplemented with 200 mM imidazole. Fractions
containing MonCI were diluted by a buffer containing 20 mM Tris pH8.5, 10% (v/v) glycerol and
further purified by anion exchange chromatography (IEX) using a 5 ml HiTrapQ column (GE
Health Life Sciences). The MonCI was eluted out with an elution buffer 20 mM Tris pH8.5, 400
mM sodium chloride, and 10% Glycerol. After IEX, the protein samples were further purified by
gel filtration using a Superdex75 10/300 GL column or Superdex200 10/300 GL column (GE
Health Life Sciences) with a final protein buffer 20 mM Tris pH7.5, 150 mM sodium chloride,
10% (v/v) glycerol. The purity of purified MonCI was checked by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS PAGE). MonCI protein sample was finally concentrated
into 6.2 mg ml-1 for storage.
For epoxidase Lsd18 purification, the cell pellet from 2-liter cell culture was resuspended
in the cell lysis buffer 50 mM sodium phosphate pH 7.4, 300 mM sodium chloride, 40 mM
imidazole, 10% (v/v) glycerol and lysed by sonication. After centrifuged at 18,000 g for 40
minutes, the clear supernatant was loaded onto a 5 ml HisTrap column (GE Health Life Sciences)
and washed with a wash buffer containing 50 mM sodium phosphate pH7.4, 300 mM sodium
chloride, 80 mM imidazole, 10% (v/v) glycerol. N-terminal His-tagged Lsd18 proteins were eluted
out with a wash buffer supplemented with 200 mM imidazole. Fractions containing Lsd18 were
diluted by a buffer containing 20 mM Tris pH8.5, 10% (v/v) glycerol and further purified by IEX
method using a 5 ml HiTrapQ column (GE Health Life Sciences). After IEX, the protein samples
were further purified by gel filtration using a Superdex75 10/300 GL column or Superdex200
10/300 GL column (GE Health Life Sciences) with a final protein buffer 20 mM Tris pH8.5 and
100 mM sodium chloride. The purity of purified Lsd18 was checked by SDS PAGE. The protein
sample was concentrated to 5.5 mg ml-1 for storage. For Lsd18 mutant purification, the protocol
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was the same as the native Lsd18 purification except that more liters of cell culture were required
due to the lower yield of Lsd18 mutant expressed in the E.coli bacteria.
For epoxide hydrolase Lsd19 purification, the first step, IMAC purification is the same as
Lsd18. After sample loading, the column was first washed at 50 mM sodium phosphate pH7.4,
300 mM sodium chloride, 10 mM imidazole, 10% (v/v) glycerol, then Lsd19 was eluted by
gradient elution. After IMAC, Lsd19 was further purified by IEX with elution buffer 20 mM Tris,
pH8.5, 200 mM sodium chloride, 10% Glycerol by gradient elution. The eluted Lsd19 protein
sample was concentrated to 15 mg ml--1 for storage. The final Lsd19 protein sample was also
analyzed by SDS PAGE.
For glutamate dehydrogenase GDH purification, the cell pellet from 1-liter cell culture was
first lysed by sonication with the lysis buffer 50 mM sodium phosphate pH7.4, 300 mM sodium
chloride, 40 mM imidazole, 10% glycerol, and 500 µM protease inhibitor, phenylmethylsulfonyl
fluoride (PMSF). After sonication, the cell lysis was centrifuged at the speed of 18,000 g for 1
hour. The supernatant was loaded onto a 5 ml Histrap column (GE Health Life Sciences). The
column was washed by the buffer of 50 mM sodium phosphate pH7.4, 300 mM sodium chloride,
70 mM imidazole, and 10% (v/v) glycerol until the UV absorption at 280 nm stabilized. Then the
GDH protein was eluted out by the elution buffer consisting of 50 mM sodium phosphate pH7.4,
300 mM sodium chloride, 200 mM imidazole, and 10% (v/v) glycerol. The IMAC elute was
concentrated and injected onto a Superdex 75 10/300 GL column (GE Health Life Sciences) for
size exclusion chromatography (SEC). After that, GDH protein was concentrated to 6.5 mg ml-1.
The final protein buffer was 20 mM Tris pH7.5, 150 mM sodium chloride, and 10% glycerol. The
final MonCI protein sample was also analyzed by SDS PAGE.
For FAD reductase Fre purification, the protein samples were first purified by IMAC using
a 5 ml HisTrap column (GE Health Life Sciences). The protein samples were washed out by
gradient elution. The eluted fractions were diluted by a buffer containing 20 mM Tris pH8.5 and
10% glycerol. Then the sample was loaded onto a 5 ml HiTrapQ column (GE Health Life Sciences)
and washed out by gradient elution. After IEX, the protein samples of Fre were purified by gel
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filtration. The final protein buffer for Fre was 20 mM Tris pH7.5, 10% Glycerol. The final Fre
protein samples were also analyzed by SDS PAGE.
For the MonACPX protein purification, the cell pellet of 2-liter cell culture was dissolved
in the buffer containing 50 mM Tris pH8.0, 0.2 M sodium chloride, and 10% glycerol. After the
cell pellet got lysed by sonication and span down at 18,000 g for 1 hour, the supernatant was loaded
onto the 5 ml Histrap column (GE Health Life Sciences). The IMAC wash buffer was 50 mM Tris
pH8.0, 0.2 M sodium chloride, and 25 mM imidazole. The MonACPX protein was eluted out by
the buffer containing of 50 mM Tris pH8.0, 0.2 M sodium chloride, and 250 mM imidazole. The
IMAC elute of MonACPX was about 0.21 mg ml-1 in 28 ml volume. It was incubated with 94 µl
1KU ml-1 thrombin and 3 ml 10x cleavage buffer containing 200 mM Tris pH8.5, 1.5 M sodium
chloride, and 25 mM calcium chloride. The mixture was incubated at room temperature for 20
hours for his tag cleavage. After that, the mixture was injected into the gel filtration column for
final purification and the separation of the cleaved his tag. The final protein buffer for MonACPX
was 20 mM Tris pH7.5, 150 mM sodium chloride, and 10% Glycerol. The final MonACPX protein
samples were also analyzed by SDS PAGE.
The concentration of all the protein samples including MonCI, Lsd18, Lsd19, Fre, and
GDH were measure by the UV absorption. Due to the lack of aromatic amino acids in its protein
sequence, the concentration of MonACPX was measured by the colorimetric dye-based method,
the Bradford (Coomassie) protein assay. The first step of the Bradford (Coomassie) protein assay
is the preparation of the diluted albumin (BSA) standards. The original BSA concentration is 2 mg
ml-1. Then it was diluted to 0.05 mg ml-1, 0.033 mg ml-1, 0.025 mg ml-1, 0.02 mg ml-1, 0.017 mg
ml-1, 0.0125 mg ml-1, 0.010 mg ml-1, and 0.0083 mg ml-1. Then the Coomassie reagent was mixed
with the diluted standards and the MonACPX protein sample. After incubation at the room
temperature for 5 minutes, the absorption of the mixture was measured at UV 595 nm. Since there
is a correlation between the protein concentration and their absorption at 595 nm after mixing with
the Coomassie dye, a linear line and equation was generated by using the known protein
concentrations of a series of diluted BSA standards as the x-axis, and their absorption at 595 nm
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as the y-axis. The R2 value was used to evaluate how accurate the assay was. Based on this
correlationship and its absorption at 595 nm, the protein concentration of the MonACPX purified
sample could also calculated. Every method to measure protein concentration has their advantages
and disadvantages. For the direct measurement at UV 280nm, it is very simple and does not require
the use of any assay reagents, but it is prone to have high errors with the protein mixtures or
complex samples such as cell lysates. For the Bradford (Coomassie) protein assay, it is fast and
easy. It can be performed at the room temperature and compatible with most solvents, salts,
buffers, reducing substances, and metal-chelating agents. However, this method is not compatible
with any detergents. Also, there is high protein-protein variation compared with the copper-based
assays.
2.1.5 Protein molecular weight determination
After protein purification, the protein molecular weight of Lsd18 and MonCI was
determined by column calibration. Size-exclusion chromatography was performed using a
Superdex 10/300 GL column (GE Healthcare) and a flow rate of 0.5 ml min-1. Protein standards
carbonic anhydrase (29 kDa), and conalbumin (75 kDa) were purchased from GE Healthcare. The
human intestinal trefoil factor monomer (6.86 kDa) and dimer (13.7 kDa) were provided by Dr.
Chen Xi form the Northwest University in China. The void volume was determined by using the
Blue Dextran 2,000 (GE Healthcare). The use of size-exclusion chromatography to determine
protein molecular weight has been well documented. This method relies on the well-established
ability of size-exclusion media to separate molecules based on their different size. The
determination of the protein molecular weight was carried out by comparing the elution volume
parameter Kav of the Lsd18 and MonCI to the Kav of the several protein standards carbonic
anhydrase, conalbumin, and the human intestinal trefoil factor monomer and dimer. The elution
volume parameter Kav of the proteins is found to have a sigmoid relationship with the logarithm
values of their molecular weights. To achieve a successful molecular weight determination, all the
protein standards were dissolved in the same buffer that contains 0.1 M sodium phosphate pH7.2
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and 1 mM DTT. For protein stabilization, MonCI protein sample was dissolved in the buffer
containing 20 mM Tris pH8.5 and 100 mM sodium chloride, while Lsd18 protein sample was
dissolved in the buffer containing 20 mM Tris pH7.44, 150 mM sodium chloride, and 10%
glycerol. Since the total column volume is 24 mL, 500 ul of protein samples were injected, which
is less than 2% of the total volume.
2.2 ENZYME ASSAYS
2.2.1 UV absorption spectrum analysis
UV-visible absorption spectra for detecting flavin were recorded by Eppendorf
biospectrometer at room temperature. Purified protein samples in buffer containing 20 mM Tris
pH8.5, 200 mM sodium chloride, and 10% (v/v) glycerol were analyzed at OD450nm. After that,
sodium dithionite was added into the solution to reduce flavin. The spectra were recorded after 2
minutes and 90 minutes. After heated at 100 ℃ for 10 minutes and centrifugation, the flavin was
separated from the protein samples. The extracted flavin supernatant was also analyzed at OD450nm.
The FAD purchased from Sigma Aldrich used as standards. It was dissolved in the same buffer at
gradient concentrations of 5 µM, 10 µM, 50 µM, and 100 µM. To check if flavin reduction is
related to the substrate-binding and catalysis or nor, MonCI and Lsd18 protein samples were added
with 10x molar excess linalool and measured immediately by UV-visible absorbance. After
incubated at 4 ℃ overnight, the absorbance of the protein mixture was measured again for
comparison.
UV-visible spectra were also recorded by Eppendorf biospectrometer at room temperature
to detect NAD(P)H. All the samples were put in a 10 mm cuvette with 100 µl solution volume and
measured at 340 nm where the reduced NADH or NADPH has maximum absorption. For Fre
activity assay, 3 µM Fre, 16 µM FAD, and 400 µM NADH were mixed first in the buffer solution
of 20 mM Tris pH7.5 and 10% glycerol. The absorption of the mixture was measured at 340 nm
every 15 seconds for 5 minutes at the room temperature. For GDH activity assay, 0.05 mg ml-1
GDH protein sample, 0.5 mM NADP, and 180 mM glucose were mixed together in the buffer
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solution containing 50 mM HEPES pH7.5, 300 mM sodium chloride, and 10% glycerol. The
absorbance of the mixture was recorded at 340 nm continuously for 10 minutes at the room
temperature.
2.2.2 In-vitro enzyme assays
For the enzyme assays with linalool or the substrate analog 24, each of them contained a
final concentration of 80 µM of the substrate, 2 mM of NADH (or NADPH), 80 µM of FAD, and
15 µM enzyme in the buffer containing 50 mM Tris pH8.0, 300 mM sodium chloride, 5% glycerol.
After incubated at 30 ℃ for 48 hours, the reaction was quenched by adding equal volume of ethyl
acetate. Both the remaining substrate and the product will be extracted from the aqueous reaction
mixture by vortex and centrifugation. The concentrated extracted samples were then analyzed by
gas chromatography-mass spectrometry (GC-MS).
For the enzyme assay with the substrate analog 26, it included two reactions. The reaction
1 contained a final concentration of 80 µM substrate, 1 mM NADH, 1 mM NADPH, 80 µM FAD,
15 µM Lsd18, 15 µM Fre in the buffer of 50 mM Tris pH8.0, 300 mM sodium chloride, 5%
glycerol. After incubated at room temperature for 24 hours, the reaction was quenched by adding
equal volume of ethyl acetate. After vapor concentration, the reaction 1 product was analyzed by
liquid chromatography-mass spectrometry (LC-MS) and also used as the substrate for the second
reaction. The reaction 2 contained a final concentration of 80 µM substrate, 1 mM NADH, 1 mM
NADPH, 80 µM FAD, 15 µM Lsd18, 15 µM Fre and 15 µM Lsd19 in the buffer of 100 mM Bis
Tris pH6.5, and 10% glycerol. After incubated at room temperature for 12 hours, the reaction
mixture was extracted by the equal volume methanol. After vapor concentration, the final product
was analyzed by LC-MS.
2.2.3 GC-MS analysis
The extracted samples from the enzyme assays were analyzed by GC-MS (5973 Network,
Agilent) using a HP-5ms Ultra Inert GC column (30 m x 0.25 mm, 0.25 µm film thickness, J&W
Scientific Agilent). An oven temperature was programmed from 40 ℃ (3 minute) to 250 ℃ at 15
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℃ min-1 with helium (0.9 ml min-1) as the carrier gas. The selected ion monitoring mode was
applied, which was set to measure the specified mass with hundred-time higher sensitivity than
full scan mode. The specific fragment m/z for detecting linalool and linalool oxide are 59, 71, 93,
111, and 121, selected according to the GC-MS chemical database. For substrate analog 24 and its
epoxidation products, the specific m/z 55, 71, 82, 95, 112 and 135 were picked based on its
standard GC-MS results. The percent yield was estimated by calculating the percentage of product
peak area over the total area of both the substrate and product peaks.
2.2.4 LC-MS analysis
The extracted samples from the enzyme assay with the substrate 26 were analyzed by LCMS (Thermo Ultimate 3000 HPLC and Thermo TSQ Endura mass spectrometry). The product
mixture was separated first by HPLC and then analyzed with electrospray ionization mass
spectrometry. The HPLC column we used was Agilent Porshell 300-SB-C18 (5 µM), 2.1 mM ID
x 75 mM. The flow rate was 0.4 ml min-1. The column temperature was 40 ℃. The pump A buffer
was 100% H2O and 0.1% formic acid. The pump B buffer was 100% methanol and 0.1% formic
acid. The HPLC protocol was 0 min at 20% B; 1-6 min, linear gradient 20%-95% B; 6-10 min,
95% B; 10.2-13 min, 20% B. The detect mass range was 300-600 m/z (full scan). The base peaks
469.50-470.50+ m/z, 485.50-486.50+ m/z, and 501.50-502.50 m/z were selected specifically for
detecting the substrate analog 26 and its products.
2.3 X-RAY CRYSTALLOGRAPHY
2.3.1 Protein crystallization
For initial screening, Lsd18 and MonCI samples were set up in the 3-drop 96-well sittingdrop plates automatically by Formulatrix NT8 crystallization robot. The drop contained 0.2 µl
protein solution and 0.2 µl crystallization solution with 50 µl well condition. The initial screening
was carried out by using the commercial crystallization screens of MSCG 1-4 (Antrance),
Morpheus (Molecular Dimensions), JSCG (Molecular Dimensions), and SG1 (Molecular
Dimensions). The protein concentration, buffer, salt, crystallization temperature, and other
36

conditions were also explored during the initial screening. For crystal optimization, the additive
screen (Hampton research), silver bullets screen (Hampton research), reductive alkylation kit
(Hampton research), random microseeding were all tried.
For MonCI, the crystals were obtained directly from a 1:1 mixture of protein solution (6.2
mg ml-1 in 20 mM Tris pH7.5, 150 mM sodium chloride, 10% (v/v) glycerol) and a reservoir
solution (0.1 M Bis Tris pH6.5, 0.1 M MOPS pH6.8, 28% (w/v) PEG2000mme, 4% (v/v) glycerol)
by the sitting drop diffusion method. The crystallization trays were set up by Formulatrix NT8
crystallization robot. The crystallization drop contained 0.2 µl protein solution and 0.2 µl
crystallization solution with 50 µl well solution. The crystal grew up to the full size within one
week. Before flash freezing, MonCI crystals were transferred to a cryoprotectant solution
comprised of the crystallization buffer supplemented with 20% glycerol.
For Lsd18 crystallization, the protein sample needs to be alkylated to form crystals. After
anion exchange chromatography, protein fractions were exchanged into buffer containing 50 mM
HEPES pH7.5, 300 mM sodium chloride, and 10% (v/v) glycerol and then concentrated to 5 mg
ml-1. Each ml of samples was incubated with 20 µl 1 M dimethylamine borane complex and 40 µl
1 M acetaldehyde for 2 hours at 4 ℃. Same step was repeated again before adding 10 µl 1 M
dimethylamine borane complex. After overnight incubation, 125 µl 1 M glycine was added to the
mixture and incubated for 2 hours at 4 ℃. After that, the size exclusion chromatography was used
for further purification and change protein buffer into 20 mM Tris pH8.5 and 100 mM sodium
chloride. The hanging-drop evaporation method was applied for crystallization. The drop
contained 2 µl protein solution and 2 µl crystallization solution with 800 µl well condition. The
Lsd18 crystals were obtained from a 1:1 mixture of protein solution (5.5 mg ml-1 in 20 mM Tris
pH8.5 and 100 mM sodium chloride) and a reservoir solution (0.1 M Tris pH8.5, 1 M sodium
chloride, 32% (w/v) PEG8000) by the hanging-drop vapor diffusion method at 18 ℃. The crystals
were harvested into a cryoprotectant containing 0.1 M Tris pH8.5, 0.85 M sodium chloride, 32%
(w/v) PEG4000, and flash freezing in liquid nitrogen until X-ray data collection.
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For co-crystallization, Lsd18 protein also got ethylated first. After anion exchange
chromatography, protein fractions were exchanged into buffer containing 50 mM HEPES pH7.5,
300 mM sodium chloride, and 10% (v/v) glycerol and then concentrated to 5 mg ml-1. Each ml of
samples was incubated with 20 µl 1 M dimethylamine borane complex and 40 µl 1 M acetaldehyde
for 2 hours at 4 ℃. Same step was repeated again before adding 10 µl 1 M dimethylamine borane
complex. After overnight incubation, 125 µl 1 M glycine was added to the mixture and incubated
for 2 hours at 4 ℃. After that, the size exclusion chromatography was used for further purification.
To optimize Lsd18 co-crystals, three different protein buffers were explores. The protein buffer 1
was 20 mM Tris pH8.5 and 100 mM sodium chloride. The protein buffer 2 was 20 mM Bicine
pH8.5 and 100 mM sodium chloride. The protein buffer 3 was 20 mM HEPES pH8.0 and 100 mM
sodium chloride. The ethylated Lsd18 protein sample was first incubated with 100x molar excess
substrate 25 in ice for over 1 hour before setting up the crystallization trays. The Lsd18-ligand cocrystals were obtained from a 1:1 mixture of protein solution (5.6 mg ml-1 in 20 mM Bicine pH8.5
and 100 mM sodium chloride.) and a reservoir solution (0.1 M imidazole pH8.0, 0.8 M sodium
chloride, and 37% PEG4,000) by the sitting-drop vapor diffusion method at 18 ℃. The co-crystals
were harvested into a cryoprotectant containing of the 80% reservoir solution and 20% glycerol,
and flash freezing in liquid nitrogen until X-ray data collection.
2.3.2 X-ray diffraction, data collection and processing
For Lsd18 crystals, the diffraction data was collected at beamline 17-ID at the Advanced
Photon Source, Argonne National Laboratory (Argonne, Illinois, USA). A set of 360° data was
collected on a single flash-frozen crystal with a 199.990 mm distance between the crystal and the
detector Dectris Pilatus 6M Pixel Array. The wavelength at 17-ID was 1.00 Å at the time of data
collection. Each image was exposed for 0.248 seconds with an oscillation angle of 0.25°. Lsd18
co-crystals were diffracted by Mathews at SSRL.
MonCI crystals were diffracted at Stanford Synchrotron Radiation Lightsource (SSRL,
SLAC National Accelerator Laboratory). The sodium-bromide soaked crystals were collected at
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beamline BL9-2. To obtain phases by multi-wavelength anomalous diffraction (MAD) method,
the native crystal was first soaked in the cryoprotectant containing 0.5 M sodium bromide for 10
seconds before diffraction. Three sets of 720° data were collected on the same single crystal at
three different wavelengths in the vicinity of the absorption edge, including 0.9200 Å (peak),
0.9795 Å (high energy remote), and 0.9392 Å (inflection point). Each image was exposed for 0.2
seconds, with 15% transmission and 0.2° oscillation angle. For normal native crystals, they were
diffracted at SSRL beamline 12-2 for at the wavelength of 0.9795 Å.
2.3.3 Structural determination
The diffraction data of Lsd18 crystals were indexed, integrated and scaled automatically
with autoPROC (144). The initial phases were determined by molecular replacement (145) using
Molrep (146). The crystal structure of MonCI was used as a search model. Refinement was
performed with Phenix.refine (147) followed by manual examination and rebuilding of the refined
coordinates in the program Coot (148). The cofactor FAD coordinates were first adopted from the
4-OH benzoate hydroxylase (Protein Data Bank: 1DOD), and then adjusted manually by Coot
based on the electron density maps 2|Fo|-|Fc| and |Fo|-|Fc|.
The MonCI MAD diffraction data and native diffraction data were indexed, integrated, and
scaled by autoXDS (149). The program SHELXC (150) was used to generate a statistical analysis
of the diffraction data, determining the approximate resolution cutoff for the anomalous signal,
estimating the heavy-atom structure factor FA and phase shift a, and preparing the necessary files
for the following steps. 11 bromine atoms (10 atoms with occupancy >0.2) were located using the
program SHELXD (150), which helped solving the substructure. After that, the program SHELXE
(150) was used to improve initial phases and electron density by density modification, and also
auto-trace the poly-alanine backbone. Identification of the individual amino acids and matching
the structure with its protein sequence was done by the model building program Buccaneer (151).
Structural refinement was done by REFMAC (152) and Phenix_Refine (147), followed by manual
examination and rebuilding of the refined coordinates in the program Coot (148).
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2.4 PHYLOGENETIC ANALYSIS
The phylogenetic analysis was conducted by the online server Phylogeny.fr (153), which
includes four steps: alignment (MUSCLE), curation (Gblocks), phylogeny (PhyML + aLRT), and
tree rendering (TreeDyn). The gene sequential of five different epoxidases including monCI
(Streptomyces cinnamonensis, GenBank: AAO65803),

nanO (Streptomyces nanchangesis,

GenBank: AAP42870.1), tmnC (Streptomyces sp. NRRL 11266, GenBank: BAE93732.1), salC
(Streptomyces albus subsp. Albus, GenBank: CCD31908.1), and lsd18 (Streptomyces lasaliensis,
GenBank: CAQ64694.1) were aligned by MUSCLE (v3.8.31) configured for highest
accuracy.(154, 155) After the sequential alignment, the ambiguous regions including gaps and
poorly aligned were removed by Gblocks (v0.91b) by following parameters: minimum length of a
block after gap cleaning is 10; no gap were allowed in the final alignment; all segments with the
contiguous nonconserved positions bigger than 8 were rejected; minimum number of the
sequences for a flank position is 85%.(156) After sequential alignment, the phylogenetic tree was
reconstructed by using the maximum likelihood method implement in the PhyML program
(v3.1/3.0 aLRT).(157, 158) The WAG substitution model was selected assuming an estimated
proportion of invariant sites (of 0.162) and four gamma-distributed rate categories to account for
rate heterogeneity across sites. The gamma shape parameter was estimated directly from the data
(gamma is 97.543). Reliability of internal branch was assessed using aLRT test (SH-like). Then
graphical representation and edition of the phylogenetic tree were performed with TreeDyn
(v198.3).(159) The phylogenetic tree was generated in the online server iTOL (160, 161) with the
Niewick file of the Phylogenetic analysis.
2.5 HOMOLOG MODELING
The parameters and topologies for the natural substrates were prepared and modified by
several programs. The MDL Molfiles of the two-dimension chemical structures were first created
by ChemDraw. The online website sever PRODRG (152) then took the Mol files as the inputs and
generated a variety of topologies including the LIB files and PDB files. Alternatively, CCP4 Make
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ligand-Acedrg can also generate the CIF files and PDB files from the Mol files. The chemical
groups and the bonds were modified and adjusted by using Chimera (162). The substrates were
initially docked into the substrate-binding pocket of either Lsd18 or MonCI crystal structures
manually by Coot, Chimera, and Pymol. The resulting protein-substrate complex structures were
energy-minimized with Phenix Geometry Minimization (147).
Sequence alignment of acyl carrier proteins was performed by CLUSTALW (163) and
ESPript server (164), which identified the ACP domain from module 5 of MLSA1 (PDB ID: 6H0J)
as the best template structure to use in homology modeling of MonACPX. The homology structure
of MonCI was generated using the program MODELLER (165). Evaluation of structural models
was performed by calculation of z-DOPE score with MODELLER program and the best
MonACPX model was selected with comparing the score for all residues. Visualization and image
processing were performed by Pymol (166) and Maestro 12.2 (Shrödinger, LLC, Portland, OR)
programs.
2.6 MOLECULAR DOCKING
Structures of the MonACPX-MonCI complex were predicted using the HADDOCK2.2
webserver (167, 168). Docking was performed using the MonCl crystal structure and the homology
model of apo-MonACPX. The HADDOCK2.2 webserver’s default input settings were used, and
passive residues were assigned automatically around the active residues. Active residues for
MonCl were those located near the substrate-binding pocket entrance (side entrance): Asp377,
Asp378, Ile381, Thr398, Asp399, Pro400, Arg401, Leu402, Ile403, Gly404, Val405, Asp406,
Gln409, Arg412, Phe413, Pro440, Gln441, Ala442, Glu443, Gly445, Ser446, Asn447, Arg448,
and Leu450. Two docking runs were performed using different active residues for ACP. First run
was performed defining a narrower (Thr37, Gln38, Ser60, Leu61, Leu64, Glu65, Lys68, Thr69,
Met80) and second run a wider (Thr37, Gln38, Ala39, Gly40, Asn59, Ser60, Leu61, Thr62, Leu64,
Glu65, Thr67, Lys68, Thr69, Met80) selection of active residues surrounding Ser60 of MonACPX,
the attachment site for the 4´-phosphopantetheine group. Among the docked structures that were
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generated, we eliminated those in which Ser60 was not aligned with the side entrance and then
chose the solution that had the best HADDOCK score (-86.2±3.6) as the final model MonACPXMonCI.
2.7 MOLECULAR DYNAMICS SIMULATION
Each simulated system contained MonCI, FAD, and except for one system, premonensin
A. The MonCI and FAD coordinates were obtained from chain A of the experimental crystal
structure deposited in the PDB. 481 water molecules that are in the crystal structure and are
associated with chain A were also included in simulations. In all cases, hydrogen atoms were added
using the VMD psfgen plugin (169). For simulations which included premonensin A, the substrate
was manually positioned within the channel with the substrate orientation varying by system. The
initial substrate position was an approximate binding pose with the reactive double bond placed
~5 Å from and perpendicular to the O-H bond of the reactive -OOH group of FAD. The systems
were solvated and ionized using the VMD solvate and ionize plugins (169). Final systems
contained approximately 78,000 atoms, with a salt concentration of 150 mM sodium chloride to
mimic physiological conditions.
Interactions for simulated molecules were defined using the CHARMM36 force-field
parameters (170) and the TIP3P water model, with the CHARMM general force field (Cgenff)
(171-174) used to model the substrate. MD simulations were performed in the NpT ensemble using
the NAMD2.13 package (175). Temperature and pressure remained constant at 310 K and 1.01325
bar, respectively. The Langevin constant was γLang=1 ps-1. A simulation timestep of 2 fs was
used, with evaluation of van der Waals interactions at every timestep and evaluation of long-range
Coulomb interactions performed every 2 timesteps using the particle-mesh Ewald method (176).
All systems were initially minimized for 2,000 steps, after which water and ions were
equilibrated for 1 ns while the protein-FAD-substrate complex was restrained using harmonic
forces with a spring constant of 1 kcal/(mol Å2). A further 1 ns of equilibration was performed
with only the heavy atoms of the protein-FAD-substrate complex restrained, followed by 20 ns of
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equilibration in which disordered coil protein residues were not restrained. A final 20 ns
equilibration run was performed with harmonic restraints present only on the substrate atoms
constituting the double bond nearest FAD. Production runs, with all restraints released, were
performed for 200 ns. The analyses were performed during the last 100 ns of the production runs.
Images of simulated systems were prepared with VMD, with secondary structure
information obtained using STRIDE (177). RMSDs were calculated using the VMD RMSD
trajectory tool. The channel residues include MonCl residues 55, 56, 57, 58, 59, 60, 88, 92, 94, 95,
96, 97, 98, 99, 101, 112, 206, 208, 209, 210, 226, 227, 228, 229, 230, 232, 239, 240, 241, 242,
243, 244, 253, 254, 255, 256, 273, 277, 282, 329, 330, 331, 332, 333, 334, 336, 382, 385, 386,
387, 390, 414, 415, 417, 418, 421, 422, 431, 435.
2.8 CHEMICAL SYNTHESIS
2.8.1 Asymmetric epoxidation of substrate analog 24
The asymmetric epoxidation was done by using potassium peroxymonosulfate (Oxone)
and a fructose-derived organocatalyst, Shi’s catalyst. This reaction is believed to procced though
a dioxirane intermediate generated in situ by oxidation of a ketone with Oxone. The added sulfate
group, as a good leaving group, facilitates the ring closure of the dioxiranes. After epoxidation,
ring-opening occurred under the acidic condition.
The synthetic procedure mainly followed the one as reported.(103) A solution of 38 µM
Oxone in 9.1 ml Na2(EDTA) and 9.1 ml K2CO3 was added drop by drop into the chilled solution
containing 50 mg substrate analog 24, 42.4 mg D-fructose-derived Shi’s catalyst, 0.05 M Na2B4O7,
7.39 mg Bu4NHSO4, and 5.5 ml Na2(EDTA) during 2 hours. The mixture was then diluted with 1
N HCl solution and extracted by Et2O. The organic layer was washed with brine, dried over
anhydrous MgSO4 and concentrated by air. The reaction was monitored by thin layer
chromatography using phosphomolybdic acid as a developing agent.
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2.8.2 Symmetric epoxidation of substrate analog 24
The symmetric epoxidation was a Prilezhaev reaction with meta-Chloroperoxybenzoic
acid (m-CPBA) as a peroxy acid. This reaction proceeds by the ‘butterfly mechanism’, where the
peracid is intramolecularly hydrogen-bonded at the transition state. The high degree of polarization
induced an electrophilic oxygen atom added to the alkene.
200 mg Substrate 24 was added into the solution containing 4.2 ml methylene chloride and
101.6 mg sodium bicarbonate. The mixture was stirred and cooled in a 0 ℃ ice-water batch. A
solution of 0.3 g m-CPBA (70%, Sigma Aldrich) in 5.94 ml methylene chloride was added slowly
into the mixture over a period of 5 minutes. A heavy white precipitate formed immediately. After
that, the whole mixture was stirred at 0 ℃ for 30 minutes and then transferred to room temperature.
After 2 hours, equal volume of saturated sodium carbonate was added twice for washing. The
separated organic layer was dried over sodium sulfate.
2.8.3 Chemical synthesis of substrate analog 25
The substrate analog 25 was chemically synthesized by Dr. Chen Xi’s group in the
Northwest University in China. It included 15 steps, which started by preparation of tertbutyl(pent-4-yn-1-yloxy)diphenylsilane. The synthetic steps are shown in the illustration 2.1. After
the last synthetic step, the final product was purified by flash column chromatography (SiO2, 30%
ethyl acetate/hexane) and further purified by reverse phase high performance liquid
chromatography (HPLC, UniSil 10-120 C18 Ultra column, 10 µm particle size, 21.2 mm ID x 250
mm length). The final product was monitored at 215 nm ultraviolet wavelength. The HPLC
washing condition included a gradient of 20-95% methanol for 30 minutes, then 95% methanol
for 30 minutes at 15 ml min-1 flow rate. The final product structure was confirmed by 1H NMR
spectra.
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Illustration 2.1: Chemical synthesis of the substrate analog 25.
1

H NMR (600 MHz, CDCl3) δ 7.40 (d, J = 7.6 Hz, 2H), 7.36 (dd, J = 15.4, 8.0 Hz, 1H),

7.29 (d, J = 7.4 Hz, 2H), 5.63 (d, J = 7.3 Hz, 1H), 5.16 (q, 1H), 5.08 (q, 1H), 4.80 (t, 1H), 4.15 (d,
J = 3.7 Hz, 1H), 3.58 (s, 1H), 2.05-2.01 (m, J = 23.1 Hz, 8H), 1.90-1.85(m, 2H), 1.74-1.69(m, 3H)
1.62-1.55(t, J = 13.7 Hz, 5H), 0.96-0.90 (d, J = 30.9 Hz, 12H), 0.86-0.84(t, 3H).
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Chapter 3: Results
3.1 PROTEIN PURIFICATION AND CHARACTERIZATION
3.1.1 Expression and purification of the recombinant proteins
Both monCI and lsd18 genes were inserted into pCold I vector to facilitate protein
expression and folding. The Uniprot code for the MonCI is Q846W9; the Uniprot code for the
Lsd18 is B5M9L6. The GenBank code for the monCI gene is ANZ52466.1; the GenBank code for
the lsd18 (lasC) gene is BAG85033.1. The monCI and lsd18 genes were first inserted into the pET28a(+) vector. Even though the expression level of these two proteins were high, the yield of the
soluble protein was very low, which means that neither MonCI nor Lsd18 protein was able to be
folded very well during expression. So, we inserted both of the genes into the pCold I vector that
is low-cost and efficient to fold the recombinant proteins in E.coli. The pCold I vector was a DNA
cold-shock expression system purchased from TaKaRa. It uniquely contains the cold-shock protein
A (cspA) promoter. These vectors can specifically induce the target protein expression and
synthesis at a low temperature, at which condition the host protein expression is suppressed and
the activity of proteases is also decreased. It would protect the target protein and result in high
yield and purity of the target protein. Besides the cspA promoter, the pCold I vector also includes
other elements such as the lac operator for controlling the protein induction, ampicillin resistance
gene, his-tag sequence, and a Factor Xa cleavage site for removing the His tag from the target
protein.
The plasmid monCI-pCold I was introduced into the E. coli BL21-AI. Other bacterial
strains like Bl21(DE3) and Lemo21(DE3) were also tried but the expression level was lower
compared with BL21-AI due to the form of inclusion bodies. The chaperone plasmids were also
tried but they couldn’t prevent or recover MonCI precipitation sufficiently. E. coli BL21-AI strain
contains the gene of T7 RNA polymerase inserted into the araB locus of the araBAD operon. The
regulation of T7 RNA polymerase is under control of the arabinose-inducible araBAD promoter,
which makes this strain especially useful for tight regulation and expression of protein that may
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be toxic to other BL21 strains due to the leaky expression of T7 RNA polymerase. Due to the
relatively low yield of MonCI, four liters of cell culture were combined together for one-time
protein purification.
The recombinant 55.12-kDa MonCI protein was purified by the methods including IMAC,
IEX, and SEC. 10% (v/v) glycerol added in the buffer solution plays an essential role in stabilizing
MonCI proteins during purification. Without glycerol, MonCI proteins would form heavy
precipitation and cannot stay in homogenous state. Fractions were collected at each purification
step and analyzed by SDS PAGE. (Figure 3.1) The final purity of MonCI protein sample was
higher than 95%. Purification under native conditions gave a yellow solution which is due to the
presence of its flavin cofactor. The yield of MonCI was approximately 1.6 mg per liter of culture.
The final purified MonCI protein samples was concentrated into 6.2 mg ml-1 for storage (Figure
3.1A).
The plasmid lsd18-pCold I was introduced together with the chaperone plasmid pG-KJE8
in E. coli BL21(DE3) bacteria. Recombinant Lsd18 with a N-terminal His was expressed in soluble
form with the help of chaperons Dnak, DnaJ, GrpE, GroES and GroEL. These chaperones mediate
the correct folding of newly synthesized proteins. DnaK and DnaJ belong to the heat shock protein
70 system, binding with the exposed hydrophobic region and stabilizing the growing peptide chain
during translation. After translation, chaperone GrpE transport the unfolded polypeptides into the
chamber formed by chaperones GroEL and GroES. This closed environment facilitates the correct
folding of the peptide chains.
The recombinant 52.5-kDa Lsd18 was purified by several methods, including IMAC, IEX
and SEC. Due to the high pI value for Lsd18, which is about 7.26, the buffer pH value we applied
for anion exchange chromatography was also relatively higher. The IEX buffer we used was 20
mM Tris pH8.5. In this condition, Lsd18 was able to be purified and remained stable. We also
tried to change the Lsd18 buffer to pH value lower than 7.0. However, Lsd18 protein samples
would for aggregations very fast, which indicates that Lsd18 is not stable at the buffer with pH
lower than 7.5. Fractions were collected after each step and analyzed in SDS PAGE (Figure 3.1).
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Purification under native conditions gave a yellow solution which is due to the presence of its
flavin cofactor. After the final step SEC, Lsd18 protein samples was higher than 95%, and the
yield was approximately 5 mg per liter of culture. The sample was further concentrated to 5.5 mg
ml-1 for storage (Figure 3.1B).

Figure 3.1: SDS-PAGE analysis of purified proteins. Lanes: M, protein marker; 1, MonCI IMAC
eluate; 2, MonCI IEX eluate; 3, MonCI SEC fraction; 4, Lsd18 IMAC eluate; 5, Lsd18 IEX
eluate; 6, Lsd18 SEC fraction; 7, Fre SEC fraction; 8, GDH SEC fraction; 9, Lsd19 IEX eluate;
10, MonACPX IMAC eluate. The red arrowheads indicate the recombinant proteins accordingly.
To facilitate Lsd18 crystallization, the Lsd18 needs to get through the reductive alkylation
process during the protein purification. Reductive alkylation belongs to chemical modification that
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is able to alter protein surface properties and crystal behavior. Reductive alkylation of the protein
is a very simple method. It used the reducing agent dimethylamine-borane complex and
formaldehyde (reductive methylation), acetone (reductive isopropylation), or acetaldehyde
(reductive ethylation) to modify the %-amino group of lysine or the N-terminal amino group that
are exposed to the solvent. Reductive methylation and ethylation can prepare both mono- and dialkyl derivatives. In the case of Lsd18, we tried all formaldehyde, acetone, and acetaldehyde. At
the end, only acetaldehyde was effective to promote Lsd18 protein to form diffraction-quality
crystals. The reductive ethylation mechanism involves a nucleophilic addition of an unprotonated
lysine %-amino group to acetaldehyde and formation of an N-ethyl moiety. Then the intermediate
dehydrates and hydrogenate to produce monoethylated lysine. The equation of the reductive
ethylation is shown as below:
R-NH2 + CH3CHO à R-N=CHCH3 + H2O àR-N-CH2CH3
R-NH2 is a lysine or N-terminal amino acid of the protein backbone. Then the partially ethylated
lysine reacts with acetaldehyde to produce the final diethylated lysine due to the lower pKa of
monoethyllysine than that of the lysine. The equation is shown as below:
R-N-CH2CH3 + CH3CHO à R-N(CH3)-CH2CH3 à RN-(CH2CH3)2
After reductive ethylation, the Lsd18 crystal transformed from 2D into 3D. According to the solved
crystal structure of Lsd18, there are two lysine residues at the protein surface got ethylated.
The fre gene was synthesized by GenScript, then inserted into the pET-28a(+) vector and
transformed in E.coli BL21(DE3) for protein expression. The Uniprot code for the Fre protein is
P0AEN1. The GenBank code for the fre gene is BAE77459.1. The yield of Fre was about 6 mg
per liter of cell culture. After purification, the Fre solution displayed a tint of yellow color, which
was due to the bound flavin. According to the SDS PAGE, the Fre sample was higher than 90%
purity which is pure enough for conducting the enzyme assays (Figure 3.1C).
The GDH plasmid inserted in the pET28b vector was a gift from Professor Keatinge-Clay
from University of Texas at Austin. The Uniprot code for the GDH protein is P12310. The
GenBank code of the gdh gene is BAA09024.1. The purification of GDH only include two parts:
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IMAC and SEC. The whole purification protocol was relatively simple due to the high binding
specificity between his-tagged GDH and the nickel IMAC column. Based on the SDS PAGE
analysis, the final GDH protein sample had over than 95% purity, which is pure enough to be used
for the enzyme assays (Figure 3.1D).
The lsd19-pCold I plasmid was heritage from Dr. Xi Chen who worked on Lsd19 project
in out lab before. The Uniprot code for the Lsd19 protein is B6ZK72. The GenBank code for the
lsd19 (lasB) gene is BAG85034.1. The purification protocol of Lsd19 followed the method
mentioned previously.(113) Since Lsd19 encountered the misfolding issue when expressed in
E.coli, it was also inserted into the pCold I vector and expressed together with the chaperon
plasmid pG-KJE8. To get pure samples for the enzyme assay, the N-terminal his-tagged Lsd19
protein sample was purified by two steps IMAC and IEX. According to the SDS PAGE, the purity
of the final protein sample was higher than 90%. The final yield of Lsd19 was 2 mg per liter of the
cell culture (Figure 3.1E).
The gene of monACPX was synthesized by GenScript. The Uniprot code for MonACPX is
Q846Y3. The GenBank code for the monACPX gene is AAO65789.1. The MonACPX protein was
expressed in the E.coli BAP1 bacteria strain. This special bacterial strain was heritage from Dr.
Chaintan Khosla’s lab in the Stanford University.(178) The genotype of the BAP1 strain is
BL21(DE3) ΔprpRBCD::T7prom-sfp,T7prom-prpE. Through the homologous recombination, the
single copy of the sfp gene was integrated in the prp opern of BL21(DE3) strain, which is also
under the control of the T7 RNA polymerase promoter. The prpE gene which encodes the enzyme
responsible for converting propionate into pronyl-CoA was also placed under the control of T7
promoter. Therefore, the Sfp and PrpE enzymes were expressed together with MonACPX after
IPTG was added to the cell culture. The Sfp enzyme is a 4’-phosphopantetheinyl transferase from
Bacillus subtilis (strain 168). It transfers the 4’-phosphopantetheinyl moiety of CoA to a conserved
serine residue of MonACPX, which transforms MonACPX from the apo form to the holo form
through thioesterification reaction. Once MonACPX is activated, it is capable to bind with the
substrate, then interacts with and deliver the substrate to different unit enzymes involved in the
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polyketide synthases, such as acyltransferase, ketosynthase, and epoxidase. Since MonACPX does
not contain any aromatic amino acids, neither tyrosine nor tryptophan in its sequence, MonACPX
protein sample did not have the absorption at UV 280nm. There was no UV absorption peak
observed for MonACPX in the chromatography profile, which made it a little bit difficult to
monitor and purify the protein samples. At the beginning, all the factions collected through the
washing step were analyzed by running SDS PAGE to confirm where the MonACPX protein was
eluted out and how pure the protein sample was. After a series of method optimization, we included
the two steps, IMAC and SEC, for the MonACPX purification. After purification, the MonACPX
sample was concentrated and kept at -80 ℃ for storage. The standard curve of the Bradford
(Coomassie) protein assay is shown in the figure 3.2. According to the SDS PAGE, the final
sample was higher than 90% purity (Figure 3.1F). The linear standard curve of the Bradford protein
assay was generated by using a series of the BSA concentrations as the x-axis and the UV
absorbance at 595 nm as y-axis. The equation of the linear regression was y=4.5282x-0.011. The
R2 value is 0.9925 and all the dots are very close to the regression line, which means that this is a
good fit model and the result is highly accurate and reliable. Based on its UV absorbance at 595
nm, the MonACPX concentration was determined to 0.94 mg ml-1 after purification. The yield of
MonACPX protein was 0.282 g per liter of the cell culture.
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Figure 3.2: Bradford assay standard curve. The concentration of MonACPX was determined by
using the equation y=4.5282x-0.011 with an R2 value of 0.9925.
3.1.2 Column calibration
The gel filtration has been used as a way to determine the molecular weight or size by
Stokes radius of proteins, which assumes that there is a sigmoid relationship between the elution
volume values such as Kav and the logarithm of the protein molecular weight. The Kav value is the
proportion of pores available to the molecule. In our column calibration method, the Blue Dextran
2,000, which is a high-molecular-weight glucose polymer, was injected into the size-exclusion
chromatography column. Since Blue Dextran 2,000 has significantly high molecular weight, it did
not go through the pores of the gel filtration column, which means that the elution volume of Blue
Dextran 2,000 can be treated as the void volume of the column. Considering the theoretical
molecular weight of MonCI (55.1 kDa) and Lsd18 (52.5 kDa) monomers, four different protein
standards were chosen to make sure that experimental Kav values of the MonCI and Lsd18 can be
fit in the range of the calibration standard curve. Those four standards are conalbumin (75 kDa),
carbonic anhydrase (29 kDa), human intestinal trefoil factor dimer (13.7 kDa), and human
intestinal trefoil factor monomer (6.86 kDa)(Figure 3.3 A). To achieve a successful molecular
weight determination, the protein standards were prepared freshly in the buffer of 20 mM Tris
pH8.5 and 100 mM sodium chloride. Also, the injection volume was 500 ul which is less than 2%
of the total column volume. Based on the elution volume (Ve) of the protein molecules, the column
void volume (Vo, elution volume of Blue Dextran 2,000), the total bed volume (Vt), the Kav value
of each protein sample was able to be calculated as the equation shown below:
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Kav = (Ve - Vo) / (Vt - Vo)
The linear regression was derived by using the logarithm of the protein molecular weights, LogMr
values, as the x-axis, and their Kav values as the y-axis. The equation is calculated as y=-0.3267x
+ 1.665 with the 0.9984 R2 value indicating that this equation is significantly accurate and reliable.
Since MonCI and Lsd18 were injected into and eluted out from the size-exclusion column, their
Kav values were able to be calculated. The Kav value for MonCI was 0.1195, while the Kav value
for Lsd18 was 0.1482. Also, their experimental molecular weights were derived according to the
equation. For MonCI protein, its experimental molecular weight was 53.8 kDa; for Lsd18, its
experimental molecular weight was 43.9 kDa (Figure 3.3 B). Both of the Kav values were very
close to their theoretical molecular weights, which indicated that both MonCI and Lsd18 exist as
monomers in solution.
A.

B.

Figure 3.3: Size-exclusion chromatography analysis of MonCI and Lsd18. Standard proteins:
human intestinal trefoil factor monomer (6.86 kDa), human intestinal trefoil factor dimer (13.7
kDa), carbonic anhydrase (29 kDa), conalbumin (75 kDa). Superdex 200 10/300 GL column (GE
Healthcare) was used. (A) Size-exclusion chromatography profile of MonCI and standard
proteins. (B) The calibration curve with LogMr as the x-axis and Kav as the y-axis. Based on the
experimental Kav values, the positions of MonCI and Lsd18 are indicated by red and yellow
asterisk mark on the calibration curve.
3.2 ENZYME ASSAY RESULTS
3.2.1 UV absorption spectrum
In nature, FAD is the fully oxidized form (quinone form) of flavin adenine dinucleotide. It
can also exist in other redox states including flavin-N(5)-oxide, FADH• (semiquinone form), and
FADH2 (hydroquinone form). Switching among these states can happen by accepting or donating
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electrons. The fully oxidized FAD has an aromatic ring system, exhibiting yellow color; half
reduced FADH is either blue or red depending on the solution pH value; fully reduced FADH2 has
high polarizability and doesn’t own an aromatic ring system like FAD, so it is colorless. Catalytical
cycle including flavin reduction by NAD(P)H in monooxygenases is shown in illustration 1.2. To
observe the FAD reduction in MonCI, sodium dithionite was added into the MonCI solution in
order to force FAD reduced. Since FAD has a typical absorbance at 350 and 450 nm while FADH2
doesn’t have, a distinct decrease of the UV absorption spectrum was observed once sodium
dithionite was added. The absorption peak at 450 nm disappeared (Figure 3.4 A and B). Due to the
aerobic condition, FADH2 wasn’t remained too long before turned back to its oxidized form. UV
absorption increased back to the initial level (Figure 3.4 C). Color changing from yellow to clear,
and back to yellow was also observed during the incubation. All these experiments showed that
FAD is bound to MonCI in nature and is able to be reduced and oxidized during MonCI catalysis.
A.

B.

C.

Figure 3.4: UV absorption spectra for MonCI protein samples. (A) Spectrum of the purified
MonCI. (B) Spectrum after 2-minute incubation with sodium dithionite. (C) Spectrum after 90minute incubation with sodium dithionite.
To estimate the molar ratio of our FAD and the purified enzymes MonCI and Lsd18, similar
UV absorption spectrum analysis was carried out in our lab. Standard FAD compound was
dissolved in the buffer containing 20 mM Tris pH8.5, 200 mM sodium chloride, and 10% glycerol
with the gradient concentrations of 5 µM, 10 µM, 50 µM, and 100 µM. These FAD standard
samples were scanned from 300 to 600 nm UV spectrum. Characteristic absorption peaks were
observed at 362 and 451 nm. The purified protein solutions and their extracted FAD samples were
also scanned from 300 nm to 600 nm UV wavelength. The cofactor FAD has a typical maximum
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absorption at 450 nm. There is a proportional relation between the UV absorption and the FAD
concentration in solution. The absorbance at 450 nm for 5 µM FAD standard was 0.042; for 10
µM FAD standard was 0.088; for 50 µM FAD standard was 0.449; and for 100 µM FAD was
0.836 (Figure 3.5 A). Based on these measurements, the equation was derived as
y=0.0084x+0.008, where the absorbance at 450 nm was treated as the y-axis and the FAD
concentration (µM) was treated as the x-axis. The R2 value was 0.998, which indicated that this
standard model is considerably accurate and reliable (Figure 3.5 B).
Since there is very limited study about MonCI, which has actually never been heterologous
expressed and purified successfully, the MonCI cofactor still remains mysterious. Based on the
protein sequence analysis, MonCI also has two FAD-binding motifs: GD and GxGxxG (GGGSGG
in MonCI).(179, 180) UV absorption spectrum were used to analyze MonCI cofactor. All the
samples were scanned from 300 to 600 nm in the spectrophotometer. The purified MonCI solution
also exhibited characteristic UV absorption spectrum at 362 and 451 nm (Figure 3.5 C). The
extracted FAD from the denatured MonCI also had nearly the same spectrum with the FAD
standards, which indicates that MonCI naturally possesses FAD in a tightly bound form (Figure
3.5 D). The absorbance at 450 nm for the purified MonCI protein solution (4.66 mg ml-1, 84.04
µM) was 0.561, which means that there was about 65.83 µM FAD in the protein solution based on
the equation of FAD standards. Therefore, the molar ratio of FAD and MonCI was estimated as
0.78. Low MonCI protein stability may contribute to this result.
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A.

B.

C.

D.

E.

F.

Figure 3.5: UV absorption spectrum for FAD of different samples. (A) 100 µM FAD standard.
(B) Linear plot of FAD standards and their absorbance at 450 nm. (C) Purified MonCI solution.
(D) Extracted FAD sample from denatured MonCI solution. (E) Purified Lsd18 solution. (F)
Extracted FAD sample from denatured Lsd18 solution.
In 2012, Oikawa’s group studied the cofactor requirements of Lsd18. Based on the protein
sequence analysis, Lsd18 has conserved FAD-binding motifs GD and GxGxxG (GGGMAG in
Lsd18).(179, 180) The purified Lsd18 solution showed typical UV absorption spectrum of
flavoprotein at 362 and 451 nm (Figure 3.5 E).(103) Denatured Lsd18 samples by methanol was
also ran in reverse-phase HPLC. It gave a major peak identical to the standard FAD, which means
that FAD is tightly bound to Lsd18 in nature (Figure 3.5 F).(103) The absorbance at 450 nm for
the purified Lsd18 protein solution (7.55 mg ml-1, 143.81 µM) was 1.006, which means that there
was about 118.81 µM FAD in the protein solution. According to the FAD standards, the molar
ratio of FAD and Lsd18 was calculated as 0.83, consistent with Oikawa’s result. UV absorption
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of the extracted FAD sample was basically the same as the standards, further confirming that FAD
exist as a tightly bound cofactor in Lsd18 in nature.
To investigate how substrate-binding affects the cofactor FAD and the conformation of
MonCI, the UV spectra were recorded for the purified MonCI protein sample with and without
adding the substrate analog linalool. Two same MonCI protein samples were prepared as 21 mg
ml-1 in the buffer containing 20 mM Tris pH7.5, 15 mM sodium chloride, and 20% glycerol. The
3.9 µl 0.1 M linalool in methanol was added into one of the protein solution, while 3.9 µl methanol
was added into the other protein solution. The blank solution is 20 mm Tris pH7.5 and 20%
glycerol. As shown the figure 3.6, after adding linalool or methanol, the UV spectra were recorded
immediately from 300 nm to 600 nm. There was no obvious difference between the UV spectra of
these two MonCI protein samples, which either means that linalool did not interact with MonCI
or means that the entrance of the substrate linalool does not affect the FAD status or the MonCI
conformation. After incubating overnight at 4 ℃, there still no significant difference in the UV
spectra of the two samples. It indicates that linalool entering into the substrate-binding pocket does
not affect the MonCI conformation and FAD cofactor oxidation status significantly.
A.

B.

Figure 3.6: The UV absorption spectra for MonCI protein samples with and without adding the
substrate analog linalool. (A) The UV spectra measured immediately after adding linalool; (B)
The UV spectra measured after incubating the protein-substrate sample overnight.
To investigate how substrate-binding affects the cofactor FAD and the conformation of
Lsd18, the UV spectra were recorded for the enzyme Lsd18 with and without adding the substrate
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analog linalool based on time. Two same protein samples were prepared with 60 µM final Lsd18
concentration in the buffer containing 20 mM Tris pH7.5 and 100 mM sodium chloride. The 10 µl
10 mM linalool in dimethyl sulfoxide was added into one of the protein samples; the 10 µl dimethyl
sulfoxide was added into the other protein sample. The blank solution contained 20 mM Tris pH7.5
and 100 mM sodium chloride. As shown in the figure 3.7, the absorbance of the samples was
measured from UV 300 nm to 600 nm immediately after adding linalool or dimethyl sulfoxide.
The UV spectra of the Lsd18 sample with the addition of linalool displayed a little bit different
from the sample without linalool. However, the overall shape of both UV spectra still matches
with the flavoprotein UV spectra. It indicates that the interaction with linalool did not change the
cofactor FAD status. The differences between these two UV absorption spectra were probably
caused by the conformation change of the Lsd18 protein. After incubating at 4 ℃, the absorbance
at 362 nm and 451 nm of both protein samples decreased compared to the 0-minute UV spectra,
which means that the FAD cofactor shifted or moved partially. However, differences between the
two protein samples became less compared to the 0-minute UV spectra. It was probably because
that the linalool had already entered into the substrate-binding pocket and achieved to the
maximum occupancy after overnight incubation, therefore the Lsd18 conformation became more
stable and turned to be more similar to the initial conformation.
A.

B.

Figure 3.7: The UV absorption spectra for Lsd18 protein samples with and without adding the
substrate analog linalool. (A) The UV spectra measured immediately after adding linalool; (B)
The UV spectra measured after incubating the protein-substrate sample overnight.
Nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide
phosphate (NADP) can be reversibly reduced to NADH and NADPH by the addition of two
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hydrogen ions. They play an important role as coenzymes in many reversible reactions. Especially
for glycolysis, fatty acid oxidation, and tricarboxylic acid cycle, NAD is used as an acceptor of the
reducing equivalents. At the same time, NADH is reoxidized by dehydrogenases or the complex I
of the electron transport chain. NADP is involved in the reductive synthesis reactions like steroid
synthesis. Due to an additional pair of electrons drawing as a lone pair of electrons, both of the
reduced form NADH and NADPH have capability of absorbing the 340 nm-wavelength light.
They have the fluorescent emission at 450 nm and excitation at 340 nm. In opposite, the oxidized
form NAD and NADP do not have absorbance at 340 nm. Their physical properties allow us to
evaluate how active the enzymes are by monitoring the absorbance at 340 nm.
Fre protein is an NADH-dependent flavin reductase. It reduces flavin by transferring the
electrons from NADH. Therefore, as the cofactor, NADH gets oxidized into NAD. To check the
enzyme activity of Fre, the absorbance of the solution samples was measured at 340 nm. The
mixture included the Fre enzyme, its substrate FAD, and its cofactor NADH. The negative control
was the same solution without adding the Fre enzyme. The UV absorption spectra showed that the
negative control continuously had 340 nm absorbance around 2.0 during 5 minutes, while the
absorbance of the Fre solution kept decreasing to nearly 0, which means that amount of NADH
stayed the same in the negative control and kept decreasing in the Fre solution (Figure 3.8 A). This
UV spectra indicated that the NADH was consumed continuously by Fre enzyme. It verified that
the purified Fre enzyme was still active in vivo.
GDH protein is a glucose 1-dehydrogenase that reduce NADP to NADPH by transferring
the electrons from oxidizing glucose. To check if the purified GDH protein was active, the solution
of GDH, glucose, and NADP was measured for the absorbance at 340 nm. The negative control
was the same condition but did not contain the GDH enzyme. As shown in the UV spectra, the
negative control remained nearly 0 absorbance at 340 nm, while the GDH solution had an
increasing absorbance from 0.5 to 2.5 within 1 minute and kept at 2.5 absorbance for the remaining
4 minutes, which means that the negative solution did not form any NADPH and GDH solution
generated NADPH and remained at the highest amount in 5 minutes (Figure 3.8 B). This result
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implicated that the our purified GDH sample was active and was able to generate the reduced
NADPH.
A

B

Figure 3.8: The UV absorption spectra of the Fre and GDH activity assays. (A) The UV spectra
for Fre consuming NADH; (B) The UV spectra for GDH producing NADPH.
3.2.2 Epoxidation of substrate analogs
The in vitro enzyme activities of the purified Lsd18 and MonCI were investigated with the
natural substrate analogs linalool 22 and the synthesized compound 24. The reactions were carried
out in the optimized conditions to achieve the highest yield, and the ethyl acetate-extract after
incubation were analyzed by GC-MS. We also tried to run the linalool and the compound 24 by
LC-MS, but there are no clear peaks shown in the liquid chromatography profile. Since we had the
commercial chemical standards of linalool and linalool oxide, we were able to identify their GCMS peaks based on the m/z of their specific fragments. Linalool is the simplest substrate analog
that has been used for Lsd18 and MonCI. Both linalool 22 and linalool oxide 23 were purchased
from Sigma Aldrich. Commercial linalool oxide is a mixture of isomers cis- and trans-23. The
reactions involved in the in vitro enzyme assay are shown in illustration 3.1. The first step of
epoxidation is catalyzed by either Lsd18 or MonCI. The second step cyclization is a nonenzymatic
reaction, which can happen spontaneously after epoxidation. In GC-MS graph, linalool 22 showed
up at 9.16 minutes. Linalool oxide cis-23 showed up at 8.88 minute while trans-23 showed up at
9.06 minute.
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Illustration 3.1: Reactions involved in the enzyme assays. Linalool is used as the substrate
analog. Enzyme Lsd18 or MonCI catalyzes epoxidation, followed by nonenzymatic cyclization.
Compound 24 was synthesized by WuXi AppTec company. It has a terminal trisubstituted
olefin moiety that mimics the terminal C19-C24 part of prelasalocid 21. Standard products 25a
and 25b were synthesized by chemical reactions. Shi’s catalyst was involved in the asymmetric
epoxidation that prefers yielding (4R,5R)-epoxide instead of (4S,5S)-epoxide, while m-CPBA
catalyst was used for symmetric epoxidation which produce (4R,5R)- and (4S,5S)-epoxides in
nearly equal amounts. Same as linalool oxide, cyclization of epoxides take place spontaneously
without participation of neither enzymes nor catalysts. Enzymatic catalysis of compound 24 is
similar to the organic synthetic steps (illustration 3.2). In GC-MS graph, the substrate 24 showed
up at 12.35 minute. The products 25 showed up at both 12.26 and 12.30 minutes. Reactions with
Shi’s catalyst and m-CPBA both have 12.26- and 12.30-minute peaks with the similar peak ratio,
so whether the products 25a and 25b belong to these two peaks respectively hasn’t been confirmed.
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Illustration 3.2: Reactions involved in the organic synthesis and the enzyme assays. Compound
24 is used as the substrate analog. Enzyme Lsd18 or MonCI catalyzes asymmetric epoxidation,
while m-CPBA catalyst participates symmetric epoxidation. Both is followed by nonenzymatic
cyclization.
For MonCI, it is able to catalyze all three carbon double bonds of premonensin 20 with
stereoselectivity according to gene deletion experiments. It installs (R,R)- and (S,S)-epoxides
respectively on the internal and terminal olefins.(84, 85) So far, only in-vivo enzyme activity
assays have been tried.(84) MonCI was heterologously over-expressed in Streptomyces.
Coelicolor strain and fed with linalool. Compared with the non-transformed negative control
strain, MonCI-expressed S. coelicolor showed 10-20-fold greater conversion. After MonCI
purification, in-vitro enzyme activity assays were conducted with the substrates linalool and 24.
The buffer solution was optimized first to achieve the highest efficiency of MonCI. It turns out
that pH valued adjusted by sulfuric acid is better that hydrochloric acid. Gradient concentrations
of sodium chloride 0, 150, and 300 mM were also explored. MonCI shows the highest activity in
0 mM sodium chloride. These results indicates that the presence of chloride ions may have an
inhibiting effect on MonCI activity, which has actually been observed in other flavoproteins.(181,
182) Under the optimized buffer condition, MonCI gave a 35.66% yield of linalool, and a 12.71%
yield of compound 24 (Figure 3.9 and Table 3.1). Conversion of 24 was very low, which can be
explained by the distinct structural difference between 24 and the MonCI natural substrate 20. In
general, the purified MonCI sample showed a lower activity than Lsd18.
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A.

B.

Figure 3.9: GC-MS graphs of MonCI wildtype enzyme assays. (A) Ethyl-acetate mixture after
48-hour enzyme assay with linalool as the substrate. Peaks at 8.88 min and 9.06 min are linalool
oxide; peaks at 9.16 min and 9.21 min are linalool. (B) Ethyl-acetate mixture after 48-hour
enzyme assay with 24 as the substrate. Peaks at 12.26 min and 12.30 min are the products 25;
peaks at 12.35 min is the remaining substrate 24.

Table 3.1: Estimated percent yield of linalool oxide and 25 catalyzed by wildtype MonCI and
Lsd18.
Enzyme
Substrate
Estimated yield %

Linalool
35.66

MonCI
24
12.71

Linalool
62.92

Lsd18
24
89.70

For Lsd18, Oikawa et al. found that it catalyzes with its cofactor FAD and NAD(P)H. Both
NADH and NADPH is acceptable by Lsd18, but NADH is more preferred with a higher
transformation efficiency.(103) Reaction system consisting of Lsd18, FAD, NAD(P)H, and the
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substrate is actually sufficient enough, which means that Lsd18 is able to act as both epoxidase
and FAD reductase. However, incubating together with the Lsd19 or the flavin reductase like Fre
could also help increase its efficiency. In nature, Lsd18 is able to transform both carbon double
bonds of prelasalcoid into (R,R)-epoxides, starting from the terminal olefin. Compared with the
linalool and linalool oxide standards, GC-MS analysis showed that Lsd18 is able to catalyze
linalool without stereoselectivity, with linalool oxides in a 1/1 ratio of syn/anti (Figure 3.10 A).
Compared with standards 24 and 25, GC-MS analysis showed that Lsd18 is also able to catalyze
compound 24 (Figure 3.10 B). Based on Oikawa group’s investigation, Lsd18 can transform
compound 24 in a stereoselective manner by esterifying products 25 with (R)-2-methyoxy-2-(1naphthyl) propionate and HPLC analysis. By integrating the GC-MS peak area, the estimated
product yield of linalool and 24 was also calculated, shown in table 3.1. Conversion of compound
24 is 89.70% while conversion of linalool is 62.92%, which means that Lsd18 has a higher
transformation efficiency with 24 than linalool. It is reasonable because compound 24 has a higher
structural similarity with the Lsd18 natural substrate.
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A.

B.

Figure 3.10: GC-MS graphs of Lsd18 wildtype enzyme assays. (A) Ethyl-acetate mixture after
48-hour enzyme assay with linalool as the substrate. Peaks at 8.88 min and 9.06 min are linalool
oxide; peaks at 9.16 min and 9.21 min are linalool. (B) Ethyl-acetate mixture after 48-hour
enzyme assay with 24 as the substrate. Peaks at 12.26 min and 12.30 min are the products 25;
peaks at 12.35 min is the remaining substrate 24.
Besides the substrate analog linalool and 24, we also synthesize the compound 26 as the
substrate analog for Lsd18 enzyme. The compound 26 is more similar to the natural substrate
prelasalocid of Lsd18 in structure. It contains the C13-C24 part of the natural substrate and a phenyl
and a five-membered ring at the other terminal. Since this substrate analog is more similar to the
natural substrate, the binding affinity between the substrate and Lsd18 substrate-binding pocket is
higher. Therefore, using this substrate analog can increase the transformation efficiency of the
Lsd18 enzyme assays, and it is more promising to obtain the crystals of the Lsd18-substrate
complex. The reactions that take place during the enzyme assays are shown in the illustration 3.3.
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Illustration 3.3: Reactions involved in the enzyme assays. Compound 25 is used as the substrate
analog. Enzyme Lsd18 catalyzes stereoselective epoxidation, followed by cyclization catalyzed
either by Lsd19 with stereocontrol or by the nonenzymatic acid treatment.
The exact mass for the compound 26 is 469.32. After the terminal carbon double bond gets
transformed into an epoxide by Lsd18, the intermediate product 27 has the exact mass 485.31.
Furthermore, the internal carbon double bond also gets transformed into an epoxide by Lsd18. The
exact mass of this product 28 that contains two epoxides is 501.31. After cyclization catalyzed
either by Lsd19 or the acid treatment, the product 28 will be converted into the product 29, the
exact mass of which is also 501.31. The mass spectrometry peaks of the compounds 26, 27, 28 and
29 are shown in figure 3.11. The main mass spectrometry peak detected for compound 26 is 470.40
m/z; for compound 27 is 486.40 m/z; for compound 28 or 29 is 502.44 m/z. The extra mass was
probably contributed by the attached protons.
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Exact Mass: 469.32
Molecular Weight: 469.67
m/z: 469.32 (100.0%), 470.32 (31.4%), 471.33 (4.7%)
Elemental Analysis: C, 74.16; H, 9.23; N, 2.98; O, 13.63
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Figure 3.11: Mass spectrometry profiles of the compound 26, 27, 28 and 29 in the reaction 1
extract.
According to Oikawa’s protocol (103, 112), these two carbon double bonds get catalyzed
in two reactions in vitro. The terminal carbon double bond gets epoxidized first during reaction 1
which includes Lsd18, Fre, NADH/NADPH, and the substrate 26 in the buffer containing 50 mM
Tris pH8.0, 300 mM sodium chloride, and 5% glycerol. Then the intermediate product 27 gets
extracted by ethyl acetate and used as the substrate in the reaction 2 that includes Lsd18, Fre,
NADH/NADPH, and the substrate in the buffer containing 100 mM Bis Tris pH6.5 and 10% (v/v)
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glycerol. The in-vitro reaction 2 should only be applied in the epoxidation reaction with two carbon
double bonds, because the optimal pH condition in the epoxidation activity for the terminal and
the internal carbon double bonds is different. The terminal carbon double bond prefers to getting
epoxidized at basic pH like Tris pH8, while in the opposite, the internal carbon double bond prefers
to getting epoxidized at acidic pH like Bis Tris pH6.5. The extract samples of the reaction 1 and 2
were analyzed by LC-MS (Figure 3.12). As indicated by the m/z values, the HPLC peaks for each
compound were identified. The substrate analog 26 was eluted around 7.79 minute; the
intermediate product 27 was eluted at 7.16 minute; and the diepoxide product 28 or the final
product after cyclization 29 was eluted at 7.45 minute. After reaction 1, more than half of the
substrate 26 was transformed into the product either 27, 28 or 29. Since the peak of the product 28
or 29 got detected by LC-MS for the reaction 1 extract, it indicates that Lsd18 has already
proceeded to and catalyzed the internal carbon double bond. As shown in Figure 3.12(B), the
reaction did not catalyzed all the intermediate product into diepoxide, which was not consist with
the Oikawa’s results. The difference in the terminal moiety of the substrate 26 could be the reason.
28 or 29
26

A.

27
Reaction 1 extract
26
28 or 29

B.

27

Reaction 2 extract

Figure 3.12: HPLC profiles of the reaction 1 and 2 extract in the Lsd18 enzyme assays. (A) The
injected sample was the extract after reaction 1. (B) The injected sample was the extract after
reaction 2.
Different optimization methods were also employed in the enzyme assays in the purpose
of increasing the final product 29 yield. Firstly, Lsd19 was added into the protein solution. Because
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Lsd19 catalyzes the cyclization reaction of the compound 28, it can help increase Lsd18 efficiency
by consuming its products. As shown in the figure 3.13, the product peaks are actually lower in
the reaction with addition of Lsd19 than the reaction without Lsd19, which means that adding
Lsd19 did not help increase the Lsd18 efficiency in our case. Also, we incubated the reaction
mixture for a longer time to achieve the maximum yield. As shown in the figure 3.13, the product
peak is the highest in the reaction mixture with 24-hour incubation time. We also notice that both
the substrate and the products started degrading after 24 hours. The peaks of the 36-hour, 2-day,
and 3-day reaction mixtures were much lower compared to the peaks of 12-hour and 24-hour
reaction mixtures. Therefore, the optimal condition to achieve the maximum product yield is to
incubate the reaction mixture for 24 hours without addition of Lsd19.
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A.

B.

12 h, + Lsd19

12 h

C.

D.

36 h

24 h

E.

F.

3 days

2 days

Figure 3.13: The HPLC profiles of the reaction 1 extract from the Lsd18 enzyme assays with the
substrate 26. (A) The sample mixture was incubated for 12 hours before extraction by ethyl
acetate. (B) Lsd19 was added to the sample mixture. (C)-(F) Time-course HPLC analysis of the
reaction 1 mixture. The sample mixture was incubated for different time periods before extracted
by ethyl acetate. The peak for the substrate analog is marked by the orange circle; the peak of the
product 27 is marked by the red circle; the peak for the product 28 or 29 is marked by the blue
circle.
3.3 CRYSTAL STRUCTURES
To further study the mechanism of the epoxidases MonCI and Lsd18, we solved their
atomic resolution structures by X-ray crystallography. Based on the SDS PAGE, the purity of both
the MonCI and Lsd18 protein samples were higher than 95%, which is pure enough for
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crystallization. The homogeneity of the protein sample plays an important role in obtaining the
high-quality protein crystals. X-ray crystallography basically includes three steps: protein
crystallization, crystal diffraction by X-ray beam (diffraction data collection), and protein
structural determination (diffraction data process).
Protein crystallization is a process of the protein crystal forming.(183) During protein
crystallization, it proceeds in two steps: nucleation and growth. Critical nuclei is related to
supersaturation state and the surface free energy of the molecular addition.(184, 185) The crystal
growth follows mainly by the mechanism of growth by two-dimensional nucleation and
dislocation growth. It also follows by the mechanism of three-dimensional nucleation and normal
growth.(186, 187) Both of these two steps rely on the supersaturation of the mother liquor. This
supersaturated state is a non-equilibrium state when the molecular quantity is in excess of the
solubility limit. Formation and development of crystals, a solid state, is a way to re-establish the
equilibrium. Therefore, creating the supersaturation state is an essential step during protein
crystallization. To promote supersaturation, many different methods have been developed, such as
altering temperature, adding or removing salt, changing pH, and evaporation and so on. There are
several common techniques to grow protein crystals, combining the methods mentioned above.
These techniques include sitting-drop vapor-diffusion, hanging-drop vapor-diffusion, dialysis and
microdrops under oil.(188) So far, many of the chemicals have used as the precipitants to promote
protein crystallization, which includes salts, organic solvents, nonvolatile organic compounds,
low-molecular-weight polymers, and long-chain polymers.
After growing to the full size, protein crystals can be diffracted by high energy level X-ray
beam. The protein crystals are first soaked in the mixture of the crystallization solution and the
cryoprotectant solution, then can be mounted into a glass capillary or a nylon loop that is attached
to a solid rod. After that they get flash-frozen in liquid nitrogen and transferred onto a goniometer
that can rotate and adjust the position of the crystals very accurately. The most common
goniometer is the kappa goniometer which is able to rotate in three angles: & angle rotating in the
axis perpendicular to the beam, ' angle in an axis about 50° to the & axis, and ∅ angle in the
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capillary or loop axis. During diffraction, the protein crystals are maintained at very low
temperature in order to reduce the radiation damage and the noise in the Bragg peaks caused by
thermal motion. Once the crystal gets exposed to the high-energy-level X-ray beam, it scatters or
deflects the X-rays into different angles. The pattern of spots or reflections can be observed and
recorded on the screen behind the crystal. The spots at small angles correspond to low-resolution
data, while the spots at high angles correspond to high-resolution data. The diffraction quality can
be assessed such as crystal mosaicity and disorder by checking the peak width. Also, to be able to
construct the protein crystal structure, one image of the reflections is not enough because it only
provides the information of a small slice in the whole Fourier transform. A complete data set
including many images needs to be collected by rotating and diffracting the protein crystals stepby-step at different orientations. Sometimes, multiple diffraction data sets are required to solve the
phasing issues.
After collecting the sufficient diffraction images, these two-dimensional diffraction
patterns get transformed to a three-dimensional electron density model by Fourier transforms. The
diffraction data represents a reciprocal space of the actual crystal lattice. The diffraction spots are
decided by the size and shape of the unit cell, and also the crystal symmetry. The general data
processing consists of three steps: indexing, integration, scaling, and phasing. Indexing is to
identify the crystal space group, the unit cell dimensions, and the image peak positions in
reciprocal space. Integration is to determine the intensities by analyzing the same peak in multiple
images. Scaling is to scale all images together and make them at a consistent intensity scale.
Phasing is to combine all the variation and yield the whole electron density. To get the electron
density map, the structure factor that is related with the amplitude and phase of a wave needs to be
determined. The wave amplitude can be derived from its proportional relationship with the
intensity of the diffraction spots. However, the wave phase cannot be determined directly from the
experimental diffraction data, which is known as the phase issue. The phase can be determined by
several different ways. One is the ab initio phasing, or the direct method solve the phase by using
the relation between the phase of one reflection to two other phases considering the fact that
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scattering density is a positive real number. This direct method is only applicable for relatively
small molecules because the phase probability distribution has an inverse relation to the square
root of the number of atoms. Another method to solve phase is by anomalous X-ray scattering,
either multiple-wavelength anomalous diffraction (MAD) or single-wavelength anomalous
diffraction (SAD) phasing. The atomic scattering factor is decided by three parts: the normal
scattering factor ƒ0, ƒ’, and ƒ’’. The ƒ0 is dependent on the Bragg angle. The factor ƒ’ modifies the
ƒ0, while ƒ’’ is 90° advanced in phase. The other two factors ƒ’ and ƒ’’ are dependent on the
wavelength and represent the anomalous scattering showing up at the absorption edge. For MAD
experiment, the diffraction data is collected at several different wavelengths at the absorption peak
(ƒ’’), at the point of reflection on the absorption curve (ƒ’), and also at the remote where maximizes
the dispersive difference to the reflection wavelength. The MAD method normally needs to
prepare protein crystals with some heavy atoms inside the protein. Compared with the MAD
method, the SAD method only collects one diffraction data at a single wavelength. It provides the
measurements of the anomalous that can be used to estimate the contribution of the heavy atoms
to the scattering and derive the heavy-atom substructure. Thus, it solves the phase of the whole
protein crystal structure. The SAD method is normally used when there are intrinsic anomalous
scatters inside the protein, such as the bound ions or the sulfur atoms existing in the methionine
and cysteine amino acids. The advantage of using SAD method is that it is more efficient, it needs
less time in the X-ray beam, and it reduces the radiation damage to the protein crystals. Another
method to solve the phase problem is molecular replacement that uses a known protein homolog
structure as an initial search model to help determine the orientation and position of the protein
molecules in the unit cell. This method relies on the structural similarity between the search model
and the protein structure to be solved. The derived phase can help get the calculated intensities of
the protein model to the observed protein structures and it can also be used to generate the electron
density maps. The molecular replacement method includes two steps. The first step is to orient the
model generated from the protein homologs into the unit cell by a rotational search. The second
step is a translational placement of the new oriented protein model in the unit cell. The molecular
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replace method has been used more and more due to its conveniences and high efficiency. It does
not require extra experimental work like the MAD or SAD methods. It requires less time to
determine the protein structures. It is also very easy to be understood and the model building is
simplified without the needs of chain tracing.
After the generation of the electron density maps and construction of the initial protein
structural model, the protein structure can be finalized by multiple cycles of model re-building and
refinement. The refinement process is aimed to make the protein structure model fit better in the
electron density maps obtained from the experimental X-ray diffraction data. The various
refinement strategies are available in different programs such as Phenix refinement (147) and
CCP4 Rafmac (189). The refinement is composed by several steps such as correction for bulk
solvent, anisotropic scaling, twinning parameter refinement, ordered solvent, target weight
calculation, coordinate refinement, atomic displacement parameter refinement, and occupancy
refinement. After multiple cycles of refinement, the optimal protein crystal structure is obtained.
The final protein structure model can be evaluated by different parameters such as Rwork, Rfree, B
values, and root-mean-square deviations (bond lengths and angles).
3.3.1 The crystal structure of MonCI
The initial crystal hits of MonCI came from several different screening conditions, which
includes 0.1 M Bis Tris pH6.5, 30% PEG4000; 0.1 M Bis Tris pH6.5, 30% PEG2000mme; 0.1 M
MES pH6.5, 29% PEG3350; 0.1 M Imidazole pH6.5, 30% PEG4000; and 0.2 M sodium iodide,
20% PEG 3350. The commercial conditions that yielded the initial crystal hits were B12, C12,
D11, and F1 from Anatrace MCSG1 screen, F8 and H6 from Anatrace MCSG4 screen, and C11
from Molecular Dimensions ShotGun screen. The initial crystals displayed as needle clusters in
the solution, which was not large enough to be harvested or diffracted. Therefore, we applied
various crystal optimization methods to improve the MonCI crystals. It included the optimization
of buffer, pH, salt, precipitant, drop size, and temperature, addition of various additives, chemical
modification of the MonCI protein surface, and other methods. At the end, the best crystals grew
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in a combined buffer containing 0.1 M Bis Tris ph6.5, 0.1 M MOPS pH6.8, 28% PEG2000mme,
and 4% glycerol by the sitting-drop vapor-diffusion method, at 18 ℃. The MonCI crystals were in
rod shape and displayed in yellow color because of the tightly bound FAD in its oxidized form
(Figure 3.14 A).
A.

B.

C.

D.

Figure 3.14: Crystal pictures of MonCI and Lsd18. (A) MonCI crystals in color. (B) Initial
crystal hits of Lsd18. (C) Optimized crystals of Lsd18. (D) Single Lsd18 crystal in color.
Diffraction data collection and refinement statistics of MonCI crystal structure are shown
in table 3.2, which was determined from a single crystal. The unit cell of this triclinic crystal
contains two enzyme monomers. After final refinement, the Ramachandran favored is 918 (98%),
and the Ramachandran outliers is 2 (0%) based on the calculation by Molprobity (190). At the end,
the crystal structure of flavin-bound MonCI was determined at resolution up to 1.90 Å with the
Rwork/Rfree as 19.20%/23.40% (Figure 3.15). The phase of the MonCI crystal was solved by MAD
method using the bromide as the heavy atom inside the protein. Two molecules of MonCI are
present in the crystal asymmetric unit (chain A and B). We are able to trace the entire chain A
(residues 4-480) while some sections of chain B (residues 147-149 and 231) could not be modelled
due to the poor electron density. One FAD cofactor and one chloride ion is found in each chain.
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The final MonCI model has 7,180 protein atoms, 106 ligand atoms, 2 chloride ions, 673 water
molecules.
Table 3.2: Data collection and refinement statistics for MonCI crystal structure.
Data collection
Space group
Cell dimensions
a, b, c (Å)
a, b, g (°)
Wavelength (Å)
Resolution (Å)
Rsym (%)
I/s(I)
Completeness (%)
Redundancy
CC1/2
Refinement statistics
Resolution limit (Å)
No. of reflections
Rwork / Rfree
Number of atoms
Protein
Ligand
Ion
Water
B-factors (Å2)
Protein
Ligand
Ion
Water
R.m.s deviations
Bond lengths (Å)
Bond angles (°)

Native

Br derivative

Br derivative

Br derivative

P21

P21

P21

P21

Peak
0.9200
2.25 (2.31-2.25)
21.5 (161)
15.4 (1.31)
97.5 (98.3)
33.9 (16.4)

Inflection
0.9392
2.25 (2.31-2.25)
22.3 (166)
12.4 (1.44)
97.5 (98.4)
24.3 (24.6)

Remote
0.9795
2.1 (2.15-2.10)
18.5 (141)
13.5 (1.62)
97.6 (98.0)
24.3 (24.6)

61.2, 52.4, 141.6
90.0, 93.6, 90.0
Native
0.9795
1.90 (1.95-1.90)
12.3 (131)
13.6 (1.63)
96.4 (95.8)
8.0 (8.1)
0.999 (0.658)
39.7-1.9 (1.97-1.90)
73,491 (3,632)
0.192/0.234
7,180
106
2
673
35.2
27.8
46.3
36.8
0.0086
1.596

*

This structure was determined from one single crystal.
Values in parentheses are for the highest resolution shell.
Rsym = Σ | Iavg – Ii | / Σ Ii, where Ii is the observed intensity and Iavg is the average intensity of observations of symmetry-related
reflections.
Rwork = Σ | Fp – Fp(calc.) | / Σ Fp, where Fp and Fp(calc.) are observed and calculated structure factors; Rfree is calculated with
5% of the data.
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Figure 3.15: 1.9 Å resolution X-ray crystal structure of MonCI. Chloride ion and water are
shown as green and red spheres, respectively. The FAD cofactor is drawn as a stick model. The
fused FAD- and substrate-binding pocket is shown as a grey surface. For clarity, only those
water molecules located inside the pocket are shown.
MonCI has two different entrances through which the substrate and solvent molecules can
enter, a side entrance and a top entrance. The two entrances are orthogonally positioned and they
both have an opening with diameter of about 6.5 Å. The top entrance is more hydrophilic while
the side entrance is more hydrophobic. The side entrance is positive-charged, full of the positive
residues (Figure 3.16 A). While the side entrance is connected to active site cavity by a narrow,
8.5 Å-long tunnel, the top entrance immediately leads directly to the active cavity (Figure 3.16 B).
We speculate that the top entrance in MonCI functions as a solvent channel. In the MonCI crystal
structure, the substrate-binding pocket is occupied by 44 water molecules. As premonensin A
enters the pocket, about 24 water molecules are expected to be displaced, and the top entrance
provides an exit passage for these water molecules. A similar two-entrance system was previously
reported for 3-hydroxybenzoate hydroxylase from Comamonas testosterone. But both entrances
in 3-hydroxybenzoate hydroxylase connect to the active site cavity via a short tunnel, and they lie
parallel to one another (Figure 3.16 C). In agreement with our hypothesis that the side entrance of
MonCI serves the substrate and the top entrance serves the water molecules, the protein surface
near the side entrance is lined with hydrophobic residues, presumably enhancing with interaction
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with the greasy premonensin A, while the surface near the top entrance is lined with hydrophilic
residues, promoting interaction with water.
A.

B.

C.

Figure 3.16: The fused FAD- and substrate-binding pocket of MonCI. (A) The top and side
entrance that provide access to MonCI’s active site cavity. Hydrophobic surfaces are colored in
red and hydrophilic surfaces are colored in white. (B) Cross-section of MonCI showing the
dimensions of the substrate-binding pocket. The indicated pocket length (~40 Å) is that of the
pocket trajectory leading to the side entrance. (C) Substrate-binding pocket alignment of MonCI
and human squalene epoxidase (SQLE; PDB ID: 6C6N). The pocket surface of MonCI is shown
in white and the pocket surface of SQLE is shown in pink. The SQLE bound Cmpd-4 inhibitor is
shown as a stick model and the binding pocket is marked with the red broken line. The two
entrances in MonCI and the respective trajectory leading to the active site are marked with black
broken lines.
MonCI consists of a substrate-binding domain which is located near the C-terminus, and a
FAD-binding domain which is located near the N-terminus. These two domains are extensively
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integrated, where each domain is composed of multiple noncontiguous segment of the protein
sequence. The FAD- and the substrate-binding pocket are fused together, resulting in a long,
continuous tunnel. The cofactor FAD is located at the bottom of the fused pocket and it is partially
exposed to the solvent. The isoalloxazine ring of FAD adopts the so-called “in” position, which is
the expected conformation of FAD during epoxidation. The substrate-binding pocket, which lies
immediately on top of FAD, is about 40 Å long and about 25 Å wide (Figure 3.16 B). Interestingly,
the size of the substrate-binding pocket in MonCI is significantly larger than that of the substrate
molecule, premonensin A, which is approximately 30 Å long and 5 Å wide when fully extended.
The significance of this size discrepancy is discussed in a later section.
The FAD cofactor makes numerous direct and water-mediated interactions with MonCI
residues (Figure 3.17 A). The isoalloxazine ring of FAD makes a π-π stacking interaction with the
imidazole group of His57, and its N1, N3, O2, and O4 atoms from hydrogen bonds with backbone
atoms of Ala56, Leu58, Gly333, and Met336, respectively. The pyrophosphate group of FAD form
hydrogen bonds with Ser15 side chain and Ala17 main chain atoms, and the adenine base of FAD
forms a π-cation interaction with the guanidine group of Arg37 and hydrogen bond interaction
with Ala140. The FAD-binding domain of MonCI is characteristic of flavin-dependent
monooxygenase family that carries a conserved motif GxGxxG and a Rossmann dinucleotidebinding fold with central five stranded parallel b-sheet. This central b-sheet locates between a
three-stranded antiparallel b-sheet and a four-helix bundle, forming a three-layer bba substructure.
The flavin phosphate makes hydrogen-binding contacts with the conserved motif GxGxxG
(GGGSGG in MonCI) (Table 3.3).
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A.

B.

Figure 3.17: Zoomed view of cofactor FAD and chloride in MonCI. (A) Protein environment of
the FAD cofactor in MonCI. Interaction distances are given in Å. (B) Protein environment of the
chloride ion in MonCI. Interaction distances are given in Å.
One chloride ion was modelled next to the isoalloxazine ring of FAD. The chloride
coordinates with five hydrogen bond donors (Gln52 main chain nitrogen, Ser298 side chain
hydroxyl group, and three water molecules) in a distorted trigonal bipyramidal stereochemistry
(Figure 3.17 B). Structural alignment of the MonCI crystal structure and the NADPH-bound 4hydroxybenzoate hydroxylase (PDB ID: 1K0J) shows that the chloride in MonCI is located where
the adenine based of NADPH is expected to bind.(108) Therefore, chloride is expected to act as a
competitive inhibitor of MonCI. In agreement with this theory, chloride was previously shown to
competitively inhibit the flavoenzyme p-hydroxybenzoate hydroxylase, a structural homolog of
MonCI, although the inhibition mechanism was not determined.(181)
Three-dimensional structure alignment using the DALI server (191) identified the
following proteins as the closest MonCI structural homologs: bacterial halogenase Bmp2 (PDB:
5BVA; RMSD = 2.9 Å) (192), human squalene epoxidase (PDB: 6C6N; RMSD=3.0 Å) (193), and
bacterial p-hydroxybenzoate hydroxylase (PDB: 1PBE; RMSD=3.4 Å) (194) (Figure 3.18). These
enzyme share 13 to 18% sequence identity with MonCI (Table 3.3). In general, the protein fold of
the FAD-binding domains is highly conserved while that of the substrate-binding domain is more
variable. The volume of the fused FAD- and the substrate-binding pocket correlates well with the
size of the respective substrate molecule. MonCI has the largest pocket volume (995 Å3), followed
80

by squalene epoxidase (629 Å3), p-hydroxybenzoate (552 Å3), and Bmp2 (294 Å3), as calculated
using CASTp 3.0.(194) The manner in which these enzymes interact with their substrate is
different. MonCI and Bmp2 act on a substrate that is covalently tethered to the 4’phosphopantetheine prosthetic group of an acyl carrier protein whereas squalene epoxidase and phydroxybenzoate hydroxylases act on the free substrate. However, there are no obvious
distinguishing structural features that would explain this mechanistic difference.
A.

B.

Lsd18
(epoxidase)

MonCI
(epoxidase)
O

O

OH

O

OH

O

OH

S

C.

D.

Bmp2
(halogenase)

E.

Squalene
epoxidase

p-Hydroxybenzoate
hydroxylase

Figure 3.18: X-ray crystal structure of MonCI, Lsd18 and their structural homologs and the
chemical structure of the respective substrates. The FAD-binding domain of each protein is
colored in blue and the substrate-binding domain is colored in pink. The fused FAD- and
substrate-binding pocket is shown in grey. Site(s) of chemical transformation in each substrate
molecule is highlighted in red. ACP: Acyl carrier protein. (A) MonCI from Streptomyces
cinnamonensis. (B) Lsd18 from Streptomyces lasaliesis. (C) Bmp2 from Marinomonas
mediterranea (PDB ID: 5BVA). (D) Human squalene epoxidase (PDB ID: 6C6N). (E) pHydroxybenzoate hydroxylase from Pseudomonas fluorescens (PDB ID: 1PBE).
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Table 3.3: Sequence alignment of epoxidases involved in the polyether biosynthesis. MonCI
(Streptomyces cinnamonensis), NaO (Streptomyces nanchangesis), TmnC (Streptomyces sp.
NRRL 11266), SalC (Streptomyces albus subsp. albus), Lsd18 (Streptomyces lasaliensis), Bmp2
(Pseudoalteromonas sp. PS5), PHBH (Pseudomonas fluorescens), and SQLE (Homo sapiens).
The proteins are listed in decreasing order of sequence identity to MonCI: NanO 59.8%, SalC
52.6%, TmnC 49.5%, Lsd18 47.8%, Bmp2 14.8%, PHBH 14.8%, SQLE 14.1%. The two
conserved sequences (Residues 47-64 and 327-340 in MonCI), which are found only in polyether
producing monooxygenases, are highlighted in red and yellow. The conserved GXGXXG FADbinding region is highlighted in green and indicated by the green asterisk marks.
MonCI
NanO
SalC
TmnC
Lsd18
Bmp2
PHBH
SQLE

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------MWTFLGIATFTYFYKKFGDFITLANREVLLCVLVFLSLGLVLSYRCRHRNGGLLGRQQSG

0
0
0
0
0
0
0
60

MonCI
NanO
SalC
TmnC
Lsd18
Bmp2
PHBH
SQLE

---------------------------------------------------------MTT
-----------------------------------------------------------M
------------------------------------------------MPAADGRVTHLM
----------------------------------------------------MAEATRGP
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-----------------------------------------------------------SQFALFSDILSGLPFIGFFWAKSPPESENKEQLEARRRRKGTNISETSLIGTAACTSTSS
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1
12
8
1
6
0
120

MonCI
NanO
SalC
TmnC
Lsd18
Bmp2
PHBH
SQLE

TRPAHAVVLGASMAGTLAAHVLARHVDAVTVVERDA-LPEEP--QHRKGVPQARHAHLLW
TTPTRAVVLGGGWAGMLTAHVLARHLESVTVVERDI-LPDGP--HHRKGQPQARHVHVLW
TGETHAVVLGGGLTGMLTSAVLARHLDKVTVIERDV-LPEGP--ELRKGVPQARHAHLLW
NTRVHGVVLGGGLAGVLAARALRDHVDHVTVVERDT-YPDLT--EPRKGVPQGRHAHILW
TNTRSAVVLGGGMAGMLVSSMLARHVGSVTVIDRDA-FPAGP--DLRKGVPQARHAHILW
FTHYDVVIIGSGPAGSLCGIECRKKGLSVLCIEKE-QFPRFHIGESLTG----NAGQIIR
-MKTQVAIIGAGPSGLLLGQLLHKAGIDNVILERQ--TPDYVLGRIRAGVLEQGMVDLLR
QNDPEVIIVGAGVLGSALAAVLSRDGRKVTVIERDLKEPDRIVGEFLQP----GGYHVLK
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60
58
69
65
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MonCI
NanO
SalC
TmnC
Lsd18
Bmp2
PHBH
SQLE

SNGARLIEEMLPGTTDRLLAAGARRL-G--------FPEDLVTLTGQGWQHRFPATQFAL
SSGAGIVENLLPGTAERLLAAGARRI-G--------FQSDLVTLTAWGWQYRFPATAYAM
SGGARAIDSVLPGTVKQLIAEGAHRL-Y--------LPRDVVWLTPHGWQHRFSGSQFMV
SGGAEAIEELLPGTLDRLRAAGAHRI-G--------VKEDMVLYSAYGWQHRFPGSHYAL
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Lsd18
Bmp2
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SQLE

VASRPLLDLTVRQQALGADNITVRQRTEAVELTGSGGGSGGRVTG--VVVRDLDS--GRQ
MCTRPLLDWVVRDAILAGGRIEVEHGTEAVELAGD----RSRVTG--VRVRDAGG--GEP
TCSRALLDWVVRRQALAEPKITVRQETEVLGLLGG----AGQVTG--VRLRDR-S--GES
TCSRPLLDRTVREAALDHPDTEVLTRTEAHGLLGD----RTSVTG--VRVRTS-D--GAT
ACSRALLDWTVREETLREERIALVEKTEVLALLGD----AGRVTG--VRVRDQES--GEE
---RSDFDD-MIKRKAVEHGVEYKLGMV-TDVIKD----GEKVVG--ALYKADGV--EHQ
T------------------VTVYGQTEVTRDLMEA----R-EACGATTVYQAAEVRLHDL
AFHHGRFIMSLRKAAMAEPNAKFIEGVV-LQLLEE----DDVVMG--VQYKDKET--GDI
:
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132
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MonCI
NanO
SalC
TmnC
Lsd18
Bmp2
PHBH
SQLE

EQLEADLVIDATGRGSRL---------------KQWLAALGVPALEEDVVDAGVAYATRL
RLLEADLVVDATGRASRL---------------GHWLAALGLPAVEQDVVDAGIGYATRM
TELAADLVVDAGGRASAL---------------RRWLPELGLDQVEEDVVDSGIAYATRV
RELPADIVVDATGRGSRL---------------RHWLTDLGLPPAAEESVDTGLTYATRV
REVPADLVVDTTGRGSPS---------------KRLLAELGLPAPEEEFVDSGMVYATRL
--VRSKVLVDASGQNTFLS------RKGVAGKRQIEFFSQQIASFAH--------YKGVE
QGERPYVTFERDGERLRLDCDYIAGCDGFHGISRQSIPAERLKVFERVY---PFGWLGLL
KELHAPLTVVADG---------------LFSKFRKSLVSNKVSVSSH--------FVGFL
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MonCI
NanO
SalC
TmnC
Lsd18
Bmp2
PHBH
SQLE

FKAPPGATTHFPAVNIAADDRVREPGRFGVVYPIE-----------GGRWLATLSCTRGA
FKAPEGADGNFPAVQVAADPLTRQPGRFGVVYPQE-----------GGRWLVTLTSTRGA
FKAPAPVAQGFPMVNIAAAPGLGKPGQNGALVPIE-----------DGKWLVTLAGTRGG
FRAPAGAPGAFPVVSVYADHRSGEPGRNGLLLPIE-----------DGRWIITLSGTRGG
FRAPEAAATNFPLVSVHADHRAGRPGCNAVLMPIE-----------DGRWIVTVSGTRGG
-RDLPPFSTN------TTILYSKQYHWS-WIIPISPDTDSLGVVIPKDLYYKECKNPDDA
-ADTPPVS--------HELIYANHPRGFALCSQRS---------ATRSRYYVQVPLTEKV
MKNAPQFKAN------HAELILANPSPV-LIYQISSSETRVLVDI-------RGEMPRNL
.
.

261
255
265
261
255
246
231
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MonCI
NanO
SalC
TmnC
Lsd18
Bmp2
PHBH
SQLE

QLPTHEDEFIPFAE-NLNHPILADLLRDAEPLTPVFGSRSGANRRLYPERLEQWPDGLLV
PLPTDEDEFTGYAK-VLRHSIVSELMSVAEPISPIFQSHSGANRRMYPERMPQWPEGLLI
EPPTDDDSFLDFAR-GLRHPVLADLLERAEPLGPVKGSRSTVNRRLYYDRVANWPDGLLV
EPTADEERFATFAR-SLRDPIIADLIEAAEPLTPVRTTRSTLNRRMHLDRLADRPEGLVA
EPPADDEGFARFARDGVRHPLVGELIAKAQPLTSVERSRSTVNRRLHYDRLATWPEGLVV
IAWGM-DHISPEL----KRRF-----KNAERQGD---SQSMADFSYRIEP--FVGDGWMC
EDWSD-ERFWTELKARLPAEV-----AEKLVTGPSLEKSIAPLRSFVVEP--MQHGRLFL
REYMV-EKIYPQIPDHLKEPF-----LEATDNSH---LRSMPASFLPPSS--VKKRGVLL
: :
.
.
.

320
314
324
320
315
291
283
405

MonCI
NanO
SalC
TmnC
Lsd18
Bmp2
PHBH
SQLE

IGDSLTAFNPIYGHGMSSAARCATTIDREFER------------SVQEGT--GSARAGTR
LGDSLAAFNPVYGHGMSSAARAAEALDKELAR------------D-------GFGEGGTR
LGDALAAFNPVYGHGMSCSALSAKALDAELGR-----------------S--GLAPGMVQ
LGDCVVSLNPIHGHGMSVAARSARALEACLSR------------A----G--GLKPGLAR
LGDAVAAFNPVYGHGMSAAAHSVLALRSQLGQ-----------------R--AFQPGLAR
IGDAHRFLDPIFSYGVSFAMKEGIRAAEAIAQVVAGQDWKAPFYAYRDWSNGG------AGDAAHIVPPTGAKGLNLAASDVS------------TLYRLLLKAYREGRGELLERY-SA
LGDAYNMRHPLTGGGMTVAFKDI-------------KLWRKLLKGIPDLYDDA------**.
* . *:. :

366
355
365
362
356
344
330
445

MonCI
NanO
SalC
TmnC
Lsd18
Bmp2
PHBH
SQLE

ALQKAIGAAVD-DPWILAATKDIDYVNC---------RVSATDPRLIGVDTEQRLRFAEA
QVQRALSEVVD-DPWIMAGLNDIQYVNC---------RNLSSDPRLTGPDVAERLKFSDF
AVLQKVAKVVD-DPWLLATTQDICYPGT---------KVTAQDPRIAP-RGDQEQQFADL
TAQQAIAAAAD-APWLLSASQDLCYPDN---------KAAVSDPRLTT-QAAQRQGFADM
AAQRAIAVAVD-DAWVLATSHDIGYPGC---------RTQTRDPRLTR-HAGERQRVTDL
---QQIAADLIRYFWIYP----------------IFFGYQMQNPDLRDE---V----IRL
ICLRRIWKAERFSWWMTSVLHRFPD-------------TDAFSQRIQQT---E---LEYY
----AIFEAKKSFYWARKTSHSFVVNILAQALYELFSATDDSLHQLRKA---C--FLYFK
:
*
:

416
405
414
411
405
378
371
496

MonCI
NanO
SalC
TmnC
Lsd18
Bmp2
PHBH
SQLE

ITAASIRSPKASEIVTDVMSLNAPQAELGSNRFLMAMRADERLPELTAPPFLPEELAVVG
LSGKSIRSPKVCEVTTSVLSLNAPQKALGDSRFLSLLRTDTSHPKLVEPPFHPEELEMVG
LSTAALHDPVVSAAAMQVTALAAPVSSLESPHLVAALRKGKAHEPLTAPPFKDAELAVLD
VTSASLVNERVCDALTAVTTLTAPLGSLETPEFLAAMRQ-PARPPLTAAPLKDAEAAVLR
VGLTATRNQVVNRAAVALNTLSAGMASMQDPAVMAAVRRGPEVPAPTEPPLRPDEVARLV
LG----------------------------------------GCCFDCEGWKAPAI--FR
LGSEAGLAT------IAENYV--GLPYEEIE----------------------------LGGECVAGP------VGLLSVLSPNPLVLIGHFFAVAIYAV-YFCFKSEPWITKPRALLS
:

476
465
474
470
465
396
394
549

MonCI
NanO
SalC
TmnC
Lsd18
Bmp2
PHBH
SQLE

LDAATISPTPTPTPTAAVRS----LKPSGIAAKGALG-----------GDAAGAAASA--------------AAK---------------------SGAGVTA-----------------NAIEEYDRKQ------------MAS
------------------------SGAVLYKACSVIFPLIYSEMKYMVH

496
478
484
473
472
409
394
574

3.3.2 The crystal structure of Lsd18
Initial crystal hits of Lsd18 came from several conditions like 0.1 M Tris pH8.5, 0.7 M
sodium citrate (MCSG4_B6); 0.2 magnesium chloride, 0.1 M Tris pH8.5, 30% (w/v) PEG4000
(MCSG4_F12); 0.2 M sodium chloride, 0.1 M Tris pH8.5, 25% (w/v) PEG3350 (MCSG1_D9).
These initial crystals were in small needle clusters or thin plate clusters, which were not good
enough to be harvested or diffracted (Figure 3.14 B). Optimizing the crystallization conditions
included varying salts, precipitants, buffers, temperature, and protein concentrations. Untagged or
no-alkylated Lsd18 proteins were also tried, but none of promising hits was obtained. It turned out
that salt (sodium chloride) concentration plays an important role in the crystal shape. When the
concentration of sodium chloride increased from 0.1 M to 0.85 M, Lsd18 crystals switched from
two-dimension plate crystals to three-dimension rhombic large crystals (Figure 3.14 C and D). It
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took around 5 days for Lsd18 crystals to grow up to the full size by hanging-drop evaporation
method at 18 ℃. Crystals also exhibit yellow color due to the tightly bound FAD cofactors.

Table 3.4: Data collection and refinement statistics for Lsd18 and it complex crystal structures.
Data collection
Space group
Cell dimensions
a, b, c (Å)
a, b, g (°)
Resolution (Å)
Rsym(%)
I / sI
CC1/2
Completeness (%)
Redundancy
Refinement
Resolution (Å)
No. reflections
Rwork / Rfree
No. atoms
Protein
Ligand/ion
Water
B-factors
Protein
Ligand/ion
Water
R.m.s. deviations
Bond lengths (Å)
Bond angles (°)

Lsd18

Lsd18-ligand complex

P1

P1

46.37, 61.81, 75.37
74.63, 81.71, 77.11
34.75 – 1.54
6.005 (61.49)
10.7 (2.0)
0.997 (0.781)
95.6 (94.35)
3.5 (3.6)

47.04, 61.97, 76.29
74.80, 81.87, 76.80
32.94 -1.85
11.8 (109.6)
10.18 (1.79)
0.998 (0.704)
97.6 (96.3)

34.75 – 1.54
112052
0.163/0.200

32.94-1.85
67199
0.180/0.230

7200
108
995

7083
177
491

22.34
15.92
33.05

30.13
45.82
36.48

0.020
2.02

0.020
1.89

*

This structure was determined from one single crystal.
Values in parentheses are for the highest resolution shell.
Rsym = Σ | Iavg – Ii | / Σ Ii, where Ii is the observed intensity and Iavg is the average intensity of observations of symmetry-related
reflections.
Rwork = Σ | Fp – Fp(calc.) | / Σ Fp, where Fp and Fp(calc.) are observed and calculated structure factors; Rfree is calculated with
5% of the data.

Diffraction data collection and refinement statistics of Lsd18 crystal structure are shown
in table 3.4, which was determined from a single crystal. The unit cell of this triclinic crystal
contains two enzyme monomers. After final refinement, the Ramachandran favored is 98.49%,
and the Ramachandran outliers is 0% based on the calculation by Molprobity (190). At the end,
the crystal structure of flavin-bound Lsd18 was determined at resolution up to 1.54 Å (Figure
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3.19). The phase of the Lsd18 crystal diffraction is solved by molecular replacement, using the
MonCI crystal structure as the structural model. After refinement, the crystal structure of flavinbound Lsd18 was determined at resolution up to 1.54 Å with the Rwork/Rfree as 0.163/0.200. The
crystal structure includes 7200 protein atoms, 106 ligand atoms, 2 chloride ions, and 995 water
molecules. We are able to trace the entire chain A (residues 20-487) and chain B (residues 20487). There are several residues exhibiting alternative conformations for their sidechains, which
include Arg21, Arg91, Ile102, Ser108, Asn232, Arg315, Arg376, Thr401, Val437, and Met455 in
chain A. Also based on the electron density, the residues Lys299 in both chain A and B have been
ethylated. This lysine is at the surface of the Lsd18 protein, where is easier to get ethylated
compared to the lysine residues inside the protein.
C

C

90°

N

Figure 3.19: 1.46 Å resolution X-ray crystal structure of Lsd18. Chloride ion and water are
shown as green and red spheres, respectively. The FAD cofactor is drawn as a stick model. The
fused FAD- and substrate-binding pocket is shown as a grey surface. For clarity, only those
water molecules located inside the pocket are shown.
Similar to MonCI structure, Lsd18 also has two difference entrances where its substrate
and solvent molecules can enter and exist. Both of these two entrance locate at the side of the
Lsd18 surface (Figure 3.20). The side entrance I is about 9.1 Å in width. The other entrance, the
side entrance II is about 6.7 Å, locating at the other side of the Lsd18 surface. The side entrance II
has more hydrophilic and positively charged residues, while the side entrance I is more
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hydrophobic (Figure 3.20 B). Considering their hydrophobicity, we assume that the side entrance
II of Lsd18 functions as a solvent channel while the side entrance I functions as a substrate-binding
channel. This hypothesis agrees well with the water distribution in the substrate-binding pocket
(Figure 3.20 A).
Side entrance I

Side entrance I

A.
Side
entrance II

Side
entrance II

B.

~35 Å
90°
~23 Å

Figure 3.20: The fused FAD- and substrate-binding pocket of Lsd18. (A, B) The two side
entrances that provide access to Lsd18’s active site cavity. The water molecules are show in the
red spheres. Hydrophobic surfaces are colored in red and hydrophilic surfaces are colored in
white. (C, D) Cross-section of Lsd18 showing the dimensions of the substrate-binding pocket.
The indicated pocket length (~35 Å) is that of the pocket trajectory leading to the side entrance.
The substrate-binding pocket of Lsd18 locates above the flavin isoalloxazine ring,
consisting of an eight-stranded b-sheet and two separate three-helix bundles (Figure 3.18 B). It is
much longer than the substrate pockets of (PDB: 1BKW) and Bmp2 halogenase (PDB: 5BVA),
providing enough space for the substrate prelasalocid. Near the entrance of the substrate-binding
pocket, few positive-charged residues like arginine form a surface-exposed basic path. This patch
is complementary to the negative-charged surface of the acyl carrier proteins (ACPs), which
indicates that the ACP-bound native substrate is presented to Lsd18 by protein-protein interactions.
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According to the enzyme assays, Lsd18 was shown to function as both epoxidase and flavin
reductase. Its crystal structure also reveals that Lsd18 consists of a fused pocket for both the
cofactor FAD and the substrate.
The FAD-binding domain is characteristic of flavin-dependent monooxygenase family that
carries a conserved motif GxGxxG and a Rossman dinucleotide-binding fold with central five
stranded parallel b-sheet. This central b-sheet locates between a three-stranded antiparallel b-sheet
and a three-helix bundle, forming a three-layer bba substructure. The flavin phosphate makes
hydrogen-bonding contacts with the conserved motif GxGxxG (GGGMAG in Lsd18) (Table 3.3).
The adenosine diphosphate ribosyl binds at the C termini of the central sheet by hydrogen bonds.
The adenine base is stacked with the guanidine group of residue Arg51 by p-cation interaction. As
previously observed on PHBH (107, 108, 195, 196), the isoalloxazine ring of FAD moves between
the “in” and “out” positions during its catalysis for FAD oxidation/reduction and the substrate
translocation. In the Lsd18 crystal structure, FAD isoalloxazine ring is p-p stacked with the
imidazole rings of His71 (Figure 3.21 A).

A.

B.

Figure 3.21: Zoomed view of cofactor FAD and chloride in Lsd18. (A) Protein environment of
the FAD cofactor in Lsd18. Interaction distances are given in Å. (B) Protein environment of the
chloride ion in Lsd18. Interaction distances are given in Å.

87

Similar to MonCI, one chloride ion was modelled next to the isoalloxazine ring of FAD in
the Lsd18 crystal structure (Figure 3.21 B). The chloride coordinates with five hydrogen bond
donors (Gln66 main chain nitrogen, Ser309 side chain hydroxyl group, and three water molecules)
in a distorted trigonal bipyramidal stereochemistry (Figure 3.21 B). Structural alignment of the
Lsd18 crystal structure and the NADPH-bound 4-hydroxybenzoate hydroxylase (PDB ID: 1K0J)
shows that the chloride in Lsd18 is located where the adenine based of NADPH is expected to
bind.(108) Therefore, chloride could be a competitive inhibitor for Lsd18. In agreement with this
theory, chloride was previously shown to competitively inhibit the flavoenzyme phydroxybenzoate hydroxylase, a structural homolog of Lsd18, but the inhibition mechanism was
not determined.(181)
In structure, the most similar structures to Lsd18 in PDB are flavin-dependent Bmp2
halogenase (PDB: 5BVA; 2.9 Å RMSD for Ca atoms; Z-score = 29.3) and p-hydroxybenzoate
hydroxylase (PHBH; PDB: 1PBE; 3.7 Å RMSD for Ca atoms; Z-score = 29.1) (Table 3.3 and
Figure 3.18). They exhibit main similarity in the FAD-binding region while the substrate-binding
regions are more distinct. Among all the epoxidases available in the Protein Data Bank (PDB),
nearly all of them is cation- (Zn+/Fe2+-) dependent.(197-200) Only styrene monooxygenase and
human squalene monooxygenases are flavin-dependent. According to their functions and
structures, Lsd18 and human squalene monooxygenase belong to the family of group A flavindependent monooxygenases that are encoded by one single gene. The oxygenase StyA and StyB
are group E flavin-dependent monooxygenases that consist of a two-enzyme system. Unlike
Lsd18, styrene monooxygenase has two separate components: oxygenase StyA and flavin
reductase StyB, which are encoded by two individual genes.(138, 201) Structural alignment
showed distinct difference between Lsd18 and styrene monooxygenases including the StyA
structure (PDB: 3IHM) and StyB structures (PDB: 1USC, 1USF, 4F07). The Lsd18 and human
squalene monooxygenase (PDB: 6C6N; 3.7 Å RMSD for Ca atoms; Z-score = 29.1). Both of these
two enzymes are flavin-dependent epoxidases with the single-component enzyme system. They
show a high structural similarity in the FAD-binding domain. However, their substrate-binding
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domains are more different in structure due to the difference in their natural substrates (Figure
3.18).
B.
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I331
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Figure 3.22: Structural comparison between MonCI and Lsd18. (A) Overall structural
comparison. (B) Zoomed-view of the MonCI Tyr208 and Lsd18 Tyr218. The hydrogen-bond
length of Tyr208 to Asn329 and Ile331 in MonCI is labeled. (C) The comparison of the
conserved residues and the regions in MonCI and Lsd18. MonCI is colored in wheat; Lsd18 is
colored in pink; the MonCI FAD is colored in cyan; the Lsd18 FAD is colored in pale cyan.
Lsd18 and MonCI share high similarity in both sequence and structure. The sequence
identity is 47.8%; the structural RMSD is 1.63 (Table 3.3 and Figure 3.22 A). Their secondary
structures are basically the same. Both of them have a fused pocket for FAD- and substratebinding. The FAD-binding domain is very similar in Lsd18 and MonCI structures. Their cofactor
FAD locates at the same position inside the Lsd18 and MonCI, staying in the same oxidation
conformation. Both have a chloride ion near the FAD isoalloxazine ring, which could play an
inhibition role during catalysis. The pocket volume of Lsd18 is 889.441 Å3, a little bite smaller
than the pocket volume of MonCI, 995 Å3. This pocket volume difference could be related to the
different sizes of their native substrates prelasalocid and premonensin. The prelasalocid is
approximately 24 Å long and 4.5 Å when fully extended, while the premonensin is about 30 Å
long and 5 Å wide. Their pocket entrances are also slightly different. In Lsd18, there are two side
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entrances. The side entrance II (the solvent entrance) leads to the side entrance I (the substrate
entrance). The side entrance I is connected directly with the active cavity. In MonCI, there are two
entrances, one is at the top (solvent entrance), the other is at the side (substrate entrance).
Compared to the Lsd18 pocket entrance, the top entrance of MonCI is separated further away from
its side entrance, and it is connected to active site cavity by a narrow, 8.5 Å-long tunnel, while its
top entrance immediately leads to the active cavity. The active cavity of Lsd18 is relatively
narrower than the active cavity of MonCI. Even though their secondary structures are very similar,
but the residue components are different. We have noticed that the residues at their active sites are
very conservative. Both of their active sites are restrained by a tyrosine residue, a short helix
region, and a loop region. The active site in Lsd18 contains Tyr218, a helix region Ala338-Ser348
(AFNPVYGHGMS)

at

the

re

face

of

FAD,

and

a

loop

region

Arg61-Ser75

(RKGVPQARHAHILWS) at the si face of FAD. The active site in MonCI contains Tyr208, a
helix region Ala327-Ser337 (AFNPIYGHGMS) at the re face of FAD, and a loop region Arg47Ser61 (RKGVPQARHAHLLWS) at the si face of FAD (Figure 3.22 C). Even though the residues
Ile72 and Val342 in Lsd18 are not exactly the same as the residues Leu58, Ile331 in MonCI, they
are all non-polar residues with the side chain in the same orientations. For the tyrosine residue, the
side chain of Tyr218 in Lsd18 stays closer to the FAD, making the active site relatively smaller,
while the side chain of Tyr208 in MonCI is further from the FAD and forms the hydrogen bonds
with the Ile331 backbone and Asn329 side-chain carbonyl group, making the active site more
spacious for its native substrate with a bulky terminus (Figure 3.22 B). Generally, the active sites
of Lsd18 and MonCI are significantly similar to each other. The residues surrounding the active
site are also very conservative among other epoxidases involved in the polyether biosynthesis such
as NanO (Streptomyces nanchangesis), TmnC (Streptomyces sp. NRRL 11266), and SalC
(Streptomyces albus subsp. albus), which means that their epoxidation mechanism could be
uniformed (Table 3.3).
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3.3.3 The co-crystal structure of Lsd18-ligand complex
To achieve the Lsd18-ligand structure, various conditions and methods have been tried.
We tried both soaking and co-crystallization methods for the Lsd18-ligand complex
crystallization. The soaking method is to crystallize the ligand-free Lsd18 crystal first, then
followed by addition of the ligands in the crystallization solution. During the soaking process, the
ligand will enter inside the protein crystal and interact with the proteins. The co-crystallization
method is to incubate the Lsd18 protein with the ligand first in solution, then continued by setting
the crystallization trays with the Lsd18-ligand mixture. In this method, the ligand first interacts
and bind with the protein in solution, then the protein-ligand complex forms crystals together. We
tried both of these methods in various conditions. For soaking method, time of adding the ligand,
ligand concentration, soaking time, and soaking temperature were explored. The crystal crosslinking by using glutarahyde was also carried out to stabilize and strength the Lsd18 crystals. For
co-crystallization method, the protein-to-ligand molar ratio, incubation temperature, incubation
time, and addition of cofactors FAD and NADH/NADPH were explored in the past. We tried all
three different substrate analogs, linalool, compound 24, and compound 26 as the ligands in both
soaking and co-crystallization method. Same as the ligand-free Lsd18 crystallization, the Lsd18
protein sample needs to get reductive alkylation to achieve diffraction-quality crystals. We
screened many crystals from different conditions. We got the best ligand density from a cocrystallization condition. The 5.1 mg ml-1 Lsd18 protein sample in the buffer containing 20 mM
Bicine pH8.5 and 100 mM sodium chloride was incubated with 75x molar excess substrate analog
26 (the stock solution is 0.1 M dissolved in methanol) at 4 ℃ for one hour before setting up the
crystallization trays. The crystallization solution is 0.1 M imidazole pH8.0, 0.8 M sodium chloride,
and 37% PEG4000. The 0.2 µl mixture of the Lsd18 and the substrate analog 26 was mixed with
the 0.2 µl crystallization solution in the sitting-drop plate with 50 µl well solution. The co-crystals
were harvested around 3 months after the crystallization plate setting up. 20% (v/v) glycerol was
used as the cryoprotectant. The co-crystals were diffracted at SSRL with the help of the beamline
scientist Irimpan I. Mathews.
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Figure 3.23: 1.80 Å resolution X-ray crystal structure of Lsd18-ligand complex structure. (A, B)
The chain A structure with the substrate 26 in the pocket. The chain A is colored in pale green.
The substrate 26 is shown in purple sticks. (C, D) The chain B structure with the product 27 in
the pocket. The chain B is shown in smudge color. The product 27 is shown in marine color.
Chloride ion is shown as the green sphere. The FAD cofactor is drawn as a stick model. The
fused FAD- and substrate-binding pocket is shown as a grey surface.
Diffraction data collection and refinement statistics of Lsd18-ligand complex crystal
structure are shown in table 3.4, which was determined from a single crystal. The unit cell of this
triclinic crystal contains two enzyme monomers. After final refinement, the Ramachandran
favored is 97.95%, the Ramachandra allowed is 1.48%, and the Ramachandran outliers is 0.22%
based on the calculation by Phenix table_one program (147). At the end, the crystal structure of
the Lsd18-ligand complex was determined at resolution up to 1.85 Å (Figure 3.23). The phase of
the Lsd18 crystal diffraction is solved by molecular replacement, using the ligand-free Lsd18
crystal structure as the structural model. After refinement, the crystal structure of the Lsd18-ligand
complex was determined at resolution up to 1.85 Å with the Rwork/Rfree as 0.176/0.226. The
difference between Rwork and Rfree values seem very distinct, which means that there could be overfitting issues with the protein refined structure. Further modeling and refinement are still in process
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to achieve a better and more reliable Lsd18-ligand complex structure. The current co-crystal
structure includes 7083 protein atoms, 175 ligand atoms, 2 chloride ions, and 491 water molecules.
We are able to trace the entire chain A (residues 20-487) (Figure 3.23 A and B) and chain B
(residues 20-487) (Figure 3.23 C and D). Based on the electron density, we also fit the substrate
analog 26 in the substrate-binding pocket of chain A, and the intermediate product 27 in the
substrate-binding pocket of chain B. There are several residues exhibiting alternative
conformations for their sidechains, which include Tyr218 in chain A and Arg224 in chain B. The
extra electron density on the terminus of the side chain also indicated that Lys299 residues in both
chain A and B have been ethylated. This lysine is at the surface of the Lsd18 protein, where is
easier to get ethylated compared to the lysine residues inside the protein. The overall structure of
the Lsd18-ligand complex is very similar to the ligand-free Lsd18 structure. All the structures were
aligned by the online server TM-align.(202)
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Figure 3.24: Structural comparison of the chain A structure of the native Lsd18 and the Lsd18ligand complex crystal structures. (A) Overall structure comparison of Lsd18 chain A. (B, C)
Zoomed view of the substrate-binding pocket residues that exhibit different conformations in the
chain A of Lsd18 and Lsd18-ligand complex structures.
For Lsd18 chain A, the ligand-free and the ligand-bound complex structures were aligned
with 467 residues (RMSD= 0.38) (Figure 3.24). The oxidized FAD cofactors are basically at the
same position. Same as the chloride ion near the FAD. Their backbones are mainly the same, but
some loop regions, especially the loops at the substrate-binding region, do not match very well.
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For example, loop regions at the entrance of the substrate-binding pocket, residues 241-249 and
residues 405-412, moved outside a little bit in the complex structure. The loop of the residues 241249 is at the top entrance while the loop of the residues 405-411 is at the side entrance or the
substrate-binding entrance. The helix region, residues 411-423 that is a part of the substrateentrance and the substrate-binding pocket, also moved its position in the Lsd18-ligand complex
structure. The backbone movement in the Lsd18-ligand complex structure expanded the space of
the substrate-binding pocket, which made it easier for the substrate and enter and interact with the
protein. The N-terminal loop in the Lsd18-ligand complex structure also moved a little bit
compared to the one in the ligand-free Lsd18 structure, which is probably due to the loop flexibility
at the terminus. Besides the movement of the backbone, the side chains of several residues also
moved. Some of the movement was probably due to the flexibility on the protein surface, including
Arg21, Lys62, Arg68, Glu139, Arg142, Arg163, Arg168, Glu173, Glu201, Arg246, Asp258,
Glu278, Glu295, Ser305, Arg321, Gln367, Arg376, Arg404, Arg410, and Arg473. Unlike the
residues inside the protein, the side chains on the protein surface is not restrained by any
interactions, therefore they are more flexible and exhibit multiple conformations. Interestingly,
some side chains of the residues along the substrate-binding pocket also moved their conformation.
First is the residues near the substrate entrance changed their conformation in the Lsd18-ligand
complex structure, which includes Glu414, Arg417, Leu421, Met446, Gln450, and Met455. These
residues tend to change their conformations to make the substrate entrance wider in the Lsd18ligand complex structure. Secondly, there are some residues in the substrate-binding pocket that
moved their side chains. The residues Met124 and Asn440 moved their side chains from facing
inside to facing outside of the substrate-binding pocket. When there is no ligand in the substratebinding pocket, the side chains of Met124 and Asn440 are facing towards the active site, which
would help guide the substrate slide into the pocket and move forward to the active site. Once the
substrate enters, the side chains of Met124 and Asn440 change their conformation and face
towards the entrance of the pocket, in which way it would hold the substrate inside the pocket and
prevent the substrate slide out before the reaction (Figure 3.24 B and C). There is also another
94

residue, Ser108 in the pocket changing its conformation due to the formation of a weak hydrogen
bond with the substrate hydroxy bond (Figure 3.24 B and C). This hydrogen bond also helps hold
the substrate inside the pocket.
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Figure 3.25: Structural comparison of the chain B structure of the native Lsd18 and the Lsd18ligand complex crystal structures. (A) Overall structure comparison of Lsd18 chain B. (B, C)
Zoomed view of the substrate-binding pocket residues that exhibit different conformations in the
chain B of Lsd18 and Lsd18-ligand complex structures.
For Lsd18 chain B, the ligand-free and the ligand-bound complex structures were aligned
with 467 residues (RMSD= 0.41) (Figure 3.25) The oxidized FAD cofactors are nearly at the same
position. Same as the chloride ion near the FAD. The chain B backbone of the Lsd18-ligand
complex structure is very similar to the one of the ligand-free Lsd18 structure. The main difference
of the backbone shows at the pocket entrances. The top entrance or the solvent entrance region,
including the residues 240-249 and 391-421, became smaller in the Lsd18-ligand complex
structure, while the side entrance or the substrate entrance, including the residues 406-425 and
447-455, expanded wider in the Lsd18-ligand complex structure. This backbone movement is
likely due to the interaction with the ligand inside the pocket. Also, there are some side chains of
the residues changing their conformation in the Lsd18-ligand complex structure. Same as chain A,
some residues on the protein surface changed their conformations due to their flexibility in
solution. These residues include Arg21, Cys62, Trp134, Arg142, Glu150, Lys151, Glu173,
Glu201, Arg285, Gln301, Ser305, Arg310, Tyr343, Gln367, Arg376, Arg400, Arg404, Arg434,
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Arg460, and Glu469. There are also some residues at the substrate entrance changing their
conformations, which includes Arg417, Met446, and Met455. Their side chains moved out and
made the substrate entrance wider. Same for the residues Met124 and Asn440, their side chains
moved towards the substrate entrance in the Lsd18-ligand complex structure in the purpose of
holding the substrate in the pocket. The side chain of Ser108 also change its conformation like the
one in chain A, but there are no more interactions between Ser108 and the hydroxyl group of the
ligand because the ligand moved away after the reaction. However, two more residues Tyr218 and
His392 in chain B attracted our attention. Tyr218 displayed in two alternative conformations in
the crystal structure. One conformation is the same as the one in chain A which is more parallel to
the FAD isoalloxazine ring, pointing towards the ligand. The other conformation is the side chain
moving further away from the FAD and the active site. Considering that the Tyr218 is very close
to the ligand we fit at the active site, it is likely that the Tyr218 plays an important role for Lsd18
functions. It forms a hydrogen bond with the epoxide we fit at the active site in chain B, in which
case, the epoxide product may be leaded out of the active site by the conformation change of
Tyr218 (Figure 3.25 B and C). Also, this tyrosine residue is very conservative in all other
epoxidases involved in the polyether biosynthesis. To further explore its role in catalysis, we have
mutated Lsd18 Tyr218 into a phenylalanine or an alanine. The Lsd18 mutant Y218A was not able
to be expressed and folded very well, which means that changing Tyr218 into an alanine may
affect the protein folding process. The Lsd18 mutant Y218F was expressed and purified
successfully. According to the enzyme assay, the yield of the product 25 was nearly the same as
the wildtype, which means that the Lsd18 catalytic efficiency was not affect by mutation. It is
likely that Tyr218 may not be essential for epoxidation, but it could still play a role in the
stereoselectivity of the epoxide product since the hydroxy group of the Tyr218 side chain is able
to form the hydrogen bond with the epoxide group. Further studies of this tyrosine’s role on the
stereoselectivity of epoxidation need to be done in the future. The other residue that changed its
conformation in chain B is His392 that located near the pocket entrance. When there is no ligand
in the pocket, the side chain of His392 faces towards the side entrance. At this conformation, it
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narrows the top entrance and promote the substrate to enter from the side entrance. When there is
the ligand in the pocket, the side chain of His392 flips it conformation and widens the substratebinding pocket (Figure 3.25 B and C). Considering that the epoxide product is the pocket of chain
B, the conformation change of His392 could help the ligand exist out of the pocket after
epoxidation.
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Chapter 4: Discussion
4.1 PROTEIN PROPERTIES
4.1.1 FAD reductase, Fre
Fre is the NADH-dependent flavin reductase from E.coli (strain K12). It is a monomer of
26.2 kDa molecular weight that catalyzes the reduction of flavins by using NADH or NADPH. Its
gene sequence was identified by Reichard et al in 1992.(203) Its crystal structure was solved by
Eklund et al in 1999 (204), which shares a high structural similarity to the structure of the
ferredoxin reductases of flavoproteins even though their sequence similarity is very low.
Interestingly, Fre does not contain a binding site for the AMP moiety of FAD, therefore it only
interacts with the FAD substrate by a hydrophobic isoalloxazine binding site. This binding site is
consist of a serine and a threonine, and it forms hydrogen bonds with the riboflavin isoalloxazine
in a substrate-binding complex. It means that the recognition of the flavin substrate mainly takes
place on the isoalloxazine ring. The contribution from the binding of the flavin ribityl side chain
is very limited. Fre is able to use both NADH and NADPH as the electron donor and receives
various flavin analogues as the electron acceptors. According to Oikawa’s results, it showed that
the existence of Fre can help increase the Lsd18 efficiency. Even though Lsd18 is capable to reduce
FAD by itself, the general efficiency is low. So, in our enzyme assays, Fre was included as a coenzyme for Lsd18. We have successfully expressed and purified the Fre protein sample. The UV
spectra indicated that the purified Fre sample was active and was able to keep oxidizing NADH
and reducing FAD. The GC-MS analysis showed that the efficiency of Lsd18 was higher and the
yield of epoxide product was also higher by addition of Fre, which was probably due to the higher
FAD reduction process catalyzed by Fre.
4.1.2 Glucose 1-hydorgenase, GDH
GDH is the glucose 1-dehydrogenase from Bacillus subtilis (strain 168), which belongs to
the family of the short-chain dehydrogenases/reductases. Its gene was first discovered by Rudikoff
et al in 1986.(205) It functions as a developmentally regulated enzyme of Bacillus subtilis. It is
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responsible for the oxidation of glucose to gluconolactone together with the concomitant reduction
of NADP to NADPH. GDH is involved in the sporulation biological process and gets induced at
the stage III of sporulation in Bacillus subtilis. It exists as a homotetramer with 28 kDa molecular
weight of the monomer. The inspiration of adding GDH in the enzyme assay of Lsd18 was from
the study of modular polyketide synthases ketoreductases by Komsoukaniants.(206) In their work,
they employed GDH in the enzyme assays as a way to regenerate NADPH, which enabled the
polyketide synthase enzymologists to perform in vitro reactions in a more affordable way. The
reaction was also under the control and generated significant amount of the polyketide products.
Since for the enzyme assays carried out by flavin-dependent epoxidases, it also requires NAD(P)H
as the electron donor for the FAD reduction. NAD(P)H itself is not very stable in solution. It can
get oxidized very fast. Therefore, GDH was purified and added into the enzyme assays in order to
regenerate NADPH continuously for the epoxidases. We have successfully expressed and purified
the active GDH enzymes. The UV spectra showed that the purified GDH protein sample was active
and was able to produce NADPH for at least about 10 minutes. However, the GC-MS analysis
showed that addition of GDH did not increase the product yield of the Lsd18 enzyme assays. It
could due to the fact that Lsd18 has already reached to its highest efficiency and occupancy, and
the amount of the cofactor NADPH was already enough with the help of GDH. So, for the
following enzyme assays, GDH was not included in the enzyme assays since it did not help
increase the product yield.
4.1.3 Lsd19
Lsd19 (or LasB) is the epoxide hydrolase involved in the biosynthesis of polyether
lasalocid in the Streptomyces lasaliensis bacterial strain. It was identified by both Leadlay’s groups
in 2008 (96) and Oikawa’s group in 2009 (97). It catalyzes two consecutive epoxide-opening
cyclization reactions after the epoxidation reaction catalyzed by Lsd18. The crystal structures of
Lsd19 contain an amino- and a carbonyl-terminal domains, Lsd19A and Lsd19B connected
together by a short loop.(113) These two domains have identical backbone conformations. The
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Lsd19A domain is responsible for the 5-exo cyclization reaction while Lsd19B is responsible for
the 6-endo cyclization. To form the ether rings in lasalocid, Lsd18 first transforms the linear
polyene intermediate, prelasalocid into a diepoxide by two rounds of epoxidation reactions. Then
Lsd19 catalyzes the diepoxide into a tetrahydrofuran-tetrahydropyran (THF-THP) product which
is lasalocid A. According to the enzyme assays carried out by Oikawa’s group (103), the addition
of Lsd19 helped increase Lsd18 efficiency. We also tried to add Lsd19 in the enzyme assays of
Lsd18. Based on the GC-MS analysis, the product yield did not increase significantly by addition
of Lsd19. So, in the following enzyme assays, Lsd19 was not included in the mixture. However,
Lsd19 could be used to differentiate the stereochemistry of the epoxide product in the future
research due to its highly regioselective manner. When the Lsd19 substrate is (22R,23R)diepoxide, the cyclization product was THF-THP. When the Lsd19 substrate is (22S,23S)diepoxide, the cyclization product was THF-THF (Illustration 4.1).(112) Therefore, we could use
Lsd19 to different the stereochemistry of the diepoxide. It has been revealed that Lsd18 catalyzes
the stereoselective epoxidation, transforming the compound into a (22R,23R)-diepoxide. So, the
final product is THF-THP by adding Lsd19 in the enzyme assays. If the Lsd18 mutants exhibit the
reverted stereoselectivity and product the (22S,23S)-diepoxide, the final product catalyzed by
Lsd19 will be THF-THF. Therefore, once the THF-THP and THF-THF peaks are identified by
LC-MS, we will be able to tell the stereoselectivity of the Lsd18 and its mutants. Furthermore, we
will be able to determine which residues play an essential role in the stereoselectivity of Lsd18.
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Illustration 4.1: Reactions catalyzed by Lsd18 and Lsd19 by using the compound 26 as the
substrate.
4.1.4 MonACPX
MonACPX is a discrete acryl carrier protein that is involved in the biosynthesis of
monensin in the Streptomyces cinnamonensis bacterial strain.(85) It is a relatively small protein
that is about 11.26 kDa. They normally carry negative charges and contain helix-bundles with
high-degree sequence and structural similarities among themselves. The previous study has
revealed its role in binding the full-length linear polyketide chain and transferring it from the
polyketide synthases to other individual enzymes such as MonCI, MonBI/MonBII, and MonE for
oxidation cyclization and other modification reactions.(141) All the acryl carrier proteins are
expressed in the inactive apo form first, then transformed into the active holo form by attaching a
4’-phosphopantetheine moiety to their conservative serine residue. For MonACPX, the
conservative serine is Ser60 (Table 4.1). The attached 4’-phosphopantetheine moiety can be
covalently linked with the polyether intermediates and deliver the intermediates to the active sites
of different enzymes involved in the polyether biosynthesis. In our experiments, the MonACPX
was expressed in the E.coli BAP1 bacterial strain that is genetically modified with the gene of 4’phosphopantetheinyl transferase Sfp. Therefore, MonACPX was expressed and got immediately
transformed into its holo form by Sfp inside bacteria. Due to the lack of aromatic amino acids, it
is more difficult to purify the MonACPX samples. Also due to the aggregation issue, the final
MonACPX yield was relatively low. We tried to include the MonACPX in the MonCI enzyme
assays, but it did not help improve the MonCI activity. We also tried to study the binding affinity
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between MonACPX and MonCI by surface plasmon resonance method, but there was no clear
binding detected. We also incubated MonACPX and MonCI protein samples together and set up
the crystallization trays with different commercial screens. However, none of co-crystals appeared.
To study the protein-protein interactions between MonACPX and MonCI and investigate how the
polyene substrate is delivered to MonCI active site by MonACPX, we conducted the modeling and
docking experiments. Since all the acryl carrier proteins share significantly high similarity in their
sequences and structures, we first generated the MonACPX model by using its homolog ACP
domain from MLSA1 module 5 as the template. The 4-phosphopantetheine moiety was also built
on Ser60 in the MonACPX model by Coot. According to the previous studies and co-crystal
structures (207-212), the acryl carrier proteins interact with other enzymes primarily through the
electrostatic attraction. The negative charged surface of the acryl carrier proteins can bind with the
positively charged patch of other enzymes in different binding orientations. The same principles
are also applied to the interactions between MonACPX and MonCI. More details are discussed in
the MonCI section 4.1.5.
Table 4.1: Sequence alignment of the acyl carrier proteins. It includes the acyl carrier proteins
from Streptomyces cinnamonensis (MonACPX, Uniprot ID: Q846Y3), Streptomyces erythraeus
(Uniprot ID: Q03131), Escherichia coli (strain K12, Uniprot ID: P0A6A8), Bacillus subtilis
(strain 168, Uniprot ID: P80643), Aquifex aeolicus (strain VF5, Uniprot: O67611), and
Azospirillum brasilense (Uniprot: P94123). The conserved serine was highlighted in red.
S.cinnamonesis
S.erythraeus
E.coli
B.subtilis
A.acelicus
A.brasilense

EEREKLLTDTIRTQA----GTLLNTTLSDDSNFLENGLNSLTALELTKTLMTLTGMEIAM
----EALFELVRSHAAAVLGHASAERVPADQAFAELGVDSLSALELRNRLGAATGVRLPT
----STIEERVKKIIGEQLGVKQEEVTNNASFVEDLGADSLDTVELVMALEEEFDTEIPD
----ADTLERVTKIIVDRLGVDEADVKLEASFKEDLGADSLDVVELVMELEDEFDMEISD
----MSLEERVKEIIAEQLGVEKEKITPEAKFVEDLGADSLDVVELIMAFEEEFGIEIPD
----SDVAERVKKIVVDHLGVEESKVTENASFIDDLGADSLDTVELVMAFEEEFGCEIPD
: :
*
.
: * :** .:**
:
. .:

S.cinnamonesis
S.erythraeus
E.coli
B.subtilis
A.acelicus
A.brasilense

VAIVENPTPAQLAHHLGQEL
TTVFDHPDVRTLAAHLAAEL
EEAEKITTVQAAIDYINGHQ
EDAEKIATVGDAVNYIQNQQ
EDAEKIQTVGDVINYLKEKV
DAAEKILTVKDAIDFIKANA
.
.: .

76
76
76
76
76
76
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56
56
56
56
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4.1.5 MonCI
MonCI is an epoxidase that is involved in the biosynthesis of monensin from Streptomyces
cinnamonensis. It is able to transform a terminal and two internal olefin moieties in the linear
polyene, premonensin into a (S, S)- and two (R, R)-epoxides, respectively. According to the column
calibration result, the MonCI protein exists as monomers in solution, which is about 55.1 kDa.
MonCI is a flavin-dependent monooxygenase that relies on the cofactor FAD and NAD(P)H to
catalyze the carbon double bonds. The characteristic and unique UV absorbance spectra for FAD
have revealed that MonCI naturally carries the FAD cofactor in its oxidized form. The cofactor
FAD can be reduced by either NAD(P)H or other reducing agents such as sodium dithionite. The
oxidized FAD exhibits yellow color while the reduced FAD exhibits transparent. This is why the
purified MonCI protein sample also was yellow color. The UV spectra also showed that addition
of the substrate did not change the FAD status or the overall conformation of MonCI.
To study how active the MonCI sample was after purification, we also conducted the invitro enzyme assays that contained MonCI, cofactor FAD, NADH/NADPH, and the substrate
linalool or the compound 24. After incubation at the room temperature, the reaction mixture was
extracted by ethyl acetate and analyzed by GC-MS. Based on their specific ionized fragments, the
remining substrate and the products after reaction were able to be identified. It turned out that the
product yield, either the products of linalool or the compound 24, was not very high. It also took
a very long time, at least 12 hours to reach to its maximum yield. This could possibly be caused
by the low binding-affinity between the substrate and MonCI enzyme. Even though both linalool
and the compound 24 contain one or more carbon double bonds, they are still not very similar to
the MonCI native substrate in structure. Firstly, the native substrate of MonCI, premonensin 20,
contains a bulky carbonyl terminal before the olefin moieties. Secondly, there are different
substitutions on the olefin groups among premonensin and the substrate analogs linalool and the
compound 24. Therefore, these two substrate analogs do not enter into and fit with the MonCI
substrate-binding pocket very well. Thus, the product yield was relatively lower. The other
possibility is that the purified MonCI sample was not very active or stable. In the process of
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purification, we encountered the protein stability issue for MonCI. Firstly, MonCI was not able to
be expressed and folded well inside the bacteria. We solved this problem by inserting the monCI
gene into the pCold I vector and transforming the plasmid into the E.coli BL21-AI strain. Secondly,
the MonCI protein tended to aggregate during purification. The MonCI proteins was eluted out in
different peaks in ion exchange chromatography, which means that MonCI protein was not stable
and may stay in different conformations due to misfolding. In this case, addition of 10% (v/v)
glycerol did help stabilize the protein. After adding 10% (v/v) glycerol in all the buffers, the MonCI
protein was more stable. However, it still precipitated and formed aggregation after overnight at
room temperature. Besides, the chloride ions may play an important role in inhibiting the MonCI
activity. We have compared the product yields of the MonCI enzyme assays in the different buffer
systems with the chloride ion in gradient concentrations. The linalool was used as the substrate
analog due to its relatively high transformation rate. For the buffer system without any chloride
ion, the estimated linalool oxide yield was 57.6%; for the buffer system with 1.2 mM chloride ion,
the estimated linalool oxide yield was 49.3%; for the buffer system with 150 mM chloride ion, the
estimated linalool oxide yield was 47.7%; for the buffer system with 300 mM chloride ion, the
estimated linalool oxide yield was 45.1%. It showed that the product yield decreased when the
concentration of the chloride ion was higher. The product yield was the highest one when there
was no chloride ion. This result indicates that chloride ion inhibits the MonCI enzyme activity.
Based on the crystal structure analysis, the chloride ion locates near the isoalloxazine ring of FAD
and at the NAD(P)H-binding site. It prevents the FAD from moving out and prevents the NAD(P)H
from binding to MonCI. So, the chloride ion inhibits the MonCI enzyme activity possibly through
affecting the FAD reduction. Due to all the possible reasons, the purified MonCI sample did not
show a high activity on catalyzing neither linalool nor the compound 24.
To further investigate the mechanism of the stereoselective epoxidation, we also solved the
crystal structure of MonCI. The diffraction data was solved up to 1.90 Å by the MAD method.
There are two identical MonCI monomers in a single unit cell. Its crystal structure reveals the
FAD-binding and the substrate-binding domains are fused together as one pocket. The cofactor
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FAD is tightly bound inside the protein by forming the hydrogen bonds with the residues and the
water molecules. The substrate-pocket is relatively large compared to the MonCI homologs due to
the larger size of the substrate. There are two entrances for its substrate-binding pocket: one is the
top entrance for solvent; the other is the side entrance for the substrate. The two entrances are
orthogonally positioned and they both have an opening with a diameter of about 6.5 Å. The side
entrance is more hydrophobic and contains more positively charged residues for interacting with
and the acryl carrier protein during the substrate delivery. We predict that premonensin A enters
MonCI via the side entrance based on two observations. First, it was previously shown that
premonensin A is tethered to a discrete acyl carrier protein, MonACPX, prior to oxidation by
MonCI (213). Therefore, MonACPX must first dock with MonCI in order for premonensin A to
enter MonCI’s active site cavity. Acyl carrier proteins are known to interact with their partner
proteins primarily by electrostatic interaction (207-209, 212). Our MonCI crystal structure shows
that the surface surrounding the side entrance is electrostatically positive whereas the surface
surrounding the top entrance is largely negative (Figure 4.1). Our homology model of MonACPX
shows that Ser60, the probable attachment site of the 4´-phosphopantetheine prosthetic group, is
surrounded by several acidic residues (Thr45, Thr46, Leu47, Asp49, Asp50, and Glu55) resulting
in an electrostatically negatively surface (Figure 4.1). Therefore, the side entrance of MonCI is
electrostatically more compatible for interaction with MonACPX than the top entrance. Second,
the location of the substrate entrance in other flavin-containing monooxygenases aligns better with
MonCI’s side entrance than its top entrance. For example, the cavity leading to the side entrance
in MonCI aligns very well with the way squalene is thought to bind to the human squalene
monooxygenase (193), a close structural homolog of MonCI. These observations strongly suggest
that premonensin A enters MonCI via the side entrance.
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Figure 4.1: Electrostatic surface potential map of MonCI and MonACPX calculated using the
VMD and APBS programs. Color scale is from -4 kbTec-1 (red) to 4 kbTec-1 (blue). Colors
range from blue (positive, +0.12) to white (neutral, 0) to red (negative, -0.12). The yellow circles
indicate the shared contact surface area between MonCI and MonACPX predicted by molecular
docking. Asterix denotes the location of Ser60 in MonACPX.
4.1.6 Lsd18
Lsd18 is a flavin-dependent epoxidase that is involved in the biosynthesis of lasalocid A
from Streptomyces lasaliesis bacterial strain. It is responsible to transform two olefins in the
prelasalocid A into two (R,R)-epoxides. The time-course analysis showed that the initial
epoxidation takes place at the terminal olefin of the prelasalocid 21. According to the column
calibration, Lsd18 exists as monomers in solution with the size of 52.5 kDa. Oikawa’s group has
conducted a series of in-vitro enzyme assays to investigate the epoxidation mechanism of Lsd18.
Their results have shown that Lsd18 protein sample carried the oxidized form FAD which was
able to get reduced by the reducing agent, sodium dithionite. Our UV absorption spectra also
displayed the characteristic flavoprotein absorbance curve for the purified Lsd18 sample. We tried
both NADH and NADPH as the reducing agents, there was no significant difference in the product
yield. Therefore, an equal amount of NADH and NADPH was used in the Lsd18 enzyme assays.
Based on the UV absorption spectra, addition of the Fre reductase increased the Lsd18 efficiency
remarkably. Addition of GDH did not help improve the product yield. Also, addition of the
substrate linalool did not change the FAD oxidation status or the protein overall conformation in
a significant level.
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In the enzyme assays, Lsd18, Fre reductase, cofactor FAD, cofactor NADH/NADPH, and
the substrate were incubated together. After overnight incubation at the room temperature, Lsd18
was able to achieve the highest product yield. After that, more Lsd18 tended to precipitate and
starting to lose the activity. The substrate and product also tended to be degraded more. There were
three different substrate analogs we used for the enzyme assays. The compound linalool is the
simplest one. It is commercially available, and its chemical properties has been studied very well.
The compound 24 mimics the terminal olefin in the native substrate prelasalocid A. The compound
26 is the most similar substrate analog that contains both the internal and terminal olefin moieties
in prelasalocid. As indicated in the GC-MS results, the transformation rate of the compound 24 is
higher than the linalool transformation rate. It was possibly caused by the higher structural
similarity to the Lsd18’s native substrate. The LC-MS results also showed that Lsd18 was able to
catalyze both of the olefins. Oikawa’s group showed that the epoxidation of the internal and the
terminal olefins can be catalyzed in vitro in a controlled manner by adjusting the pH value of the
buffer systems. The terminal olefin should be catalyzed first in a Tris buffer at pH 8.0 (reaction 1).
The internal olefin should only be catalyzed later in a Bis-Tris buffer with pH at 6.5 (reaction 2).
However, in our experiments, the diepoxide product has already been generated after the reaction
1. It could be caused by the long incubation time, or the addition of Fre reductase. Therefore,
method optimization needs to be done in the future to control the speed of epoxidation for the
substrate 26. Besides studying how active the purified Lsd18 protein is, we also want to explore
the epoxidation stereoselectivity of Lsd18. The tricky part of this study is to differentiate the
stereochemistry of the products. Oikawa’s group differentiated the stereochemistry of the epoxide
products through chemical modification. An external chemical group was attached to the epoxide
products, then the stereoisomers could be separated and identified by LC-MS. We also tried the
same method; however, our efforts were unsuccessful due to the lack of purification step, low
transformation rate, and the limited chemicals. Therefore, the chemical modification method was
not applicable in our lab. Then we came up with an alternative method that applies the
regioselective property of Lsd19. As mentioned before, Lsd19 is highly regioselective. It
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transforms the (22R,23R)-epoxide substrate into a THF-THP product, and transforms the
(22S,23S)-epoxide substrate into a THF-THF product. Therefore, we can applied Lsd19 in the
Lsd18 enzyme assays. Once the olefin is epoxidized by Lsd18, Lsd19 can continue and catalyze
the cyclization reaction. Based on the final products either THF-THF or THF-THP by LC-MS
analysis, the stereochemistry of the epoxide product would be deduced. This method would help
us explore the key residues in Lsd18 that play an important role in the stereoselectivity.
To explore the epoxidation mechanism, we solved the crystal structures of the Lsd18 with
and without ligand. The Lsd18 ligand-free crystal structure was solved with the resolution up to
1.54 Å, and the Lsd18-ligand complex crystal structure was solved up to 1.85 Å. The Lsd18
structure is very similar to the MonCI structure (RMSD= 1.63) that contains a fused FAD- and
substrate-binding pocket. Each Lsd18 monomer has a tightly bound FAD. Similar to MonCI, there
are also two entrances to the substrate-binding pocket. However, these two entrances both locate
at the side of the protein surface. The side entrance I aligns more closely with the MonCI side
entrance. It is likely to be the substrate entrance that is more hydrophobic and contains more
positively charged residues. The side entrance II locates near the top entrance of MonCI. It is likely
to be the solvent entrance since it is more hydrophilic. The side entrance is for water molecules to
enter and exit from the pocket during the catalysis. The crystal structure of the Lsd18-ligand
complex is highly similar to the ligand-free Lsd18 structure (chain A RMSD= 0.38; chain B
RMSD= 0.41), except that several residues exhibit different conformations such as Ser108,
,Met124, and Asn440. The conformation changes of the residue side chains may be related to the
substrate entrance and product exit. These residues could also play an important role during the
catalysis. Therefore, in the future, mutation analysis could be conducted on these residues and
confirm how these residues affect the Lsd18 function.
4.1.7 Epoxidases involved in the polyether biosynthesis
All ionophore polyether biosynthetic gene clusters contain a gene that encodes for an
epoxidase. For example, nanchangmycin gene cluster contains nanO (142), salinomycin gene
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cluster contains salC (139), tetronomycin gene cluster contains tmnC (214). All these genes encode
for a flavin-dependent monooxygenase that, similar to MonCI and Lsd18, has the capacity to
perform multiple epoxidations on the same substrate molecule, setting them apart from all other
flavoenzymes. The phylogenetic tree was generated to show the similarity among all these
epoxidases involved in the polyether biosynthesis (Illustration 4.2). Polyether-producing
epoxidases share a high sequence identity (49 to 60%). Sequence alignment analysis of MonCI,
NanO,

SalC,

TmnC,

and

Lsd18

has

revealed

two

highly

conserved

regions;

RKGX1PQX2RHX3HX4LWS (residues 47-64 in MonCI; X1 = V/Q, X2 = A/G, X3 = A/V, X4 =
L/V/I) and AFNPX1X2GHGMS (residues 327-340 in MonCI; X1 = I/V, X2 = Y/H). The former
sequence is part of an extended loop located on the si side of the FAD isoalloxazine ring, while
the latter sequence is part of an α-helix located on the re side. Interestingly, the active site and the
NAD(P)H-binding site we have identified in MonCI and Lsd18 are located in these conserved
regions. Therefore, it appears that polyether producing epoxidases in general utilize a similar
steric-driven stereocontrol mechanism. It should be noted that the two conserved sequences we
have identified are present only in flavin-dependent monooxygenases involved in polyether natural
product biosynthesis.

Illustration 4.2 Sequence-based phylogeny of the epoxidases involved in the polyether
biosynthesis.
4.2 FAD REDUCTION MECHANISM OF MONCI AND LSD18
With the crystal structures of both MonCI and Lsd18, we are able to explore the mechanism
of the stereoselective epoxidation involved in the biosynthesis of natural polyether products. Both
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MonCI and Lsd18 belong to the group A flavin-dependent monooxygenases since they are both
the two-enzyme system and use the NAD(P)H as the electron donor. The catalytic mechanism of
the flavin-dependent monooxygenases includes an oxidative and a reductive half reactions. The
FAD exists in the oxidized form in nature. The catalytic cycle starts from the NAD(P)H-mediated
FAD reduction. Then the reduced FAD interacts with the molecule oxygen and form a reliable
C4a-(hydro)peroxyflavin intermediate that acts as the actual oxygen transferring agent. After C4a(hydro)peroxyflavin eliminates water and oxygen transferring to the substrate, the FAD returns to
its oxidized form.
Based on the structural comparison, both MonCI and Lsd18 share relatively high structural
similarity to the typical group A flavin-dependent monooxygenase, p-hydroxybenzoate
hydroxylase (PHBH) (MonCI-to-PHBH RMSD= 3.4; Lsd18-to-PHBH RMSD= 3.7). The PHBH
enzyme is also called as 4-hydroxybenzoate 3-monooxygenase that catalyzes the regioselective
hydroxylation of 4-hydroxybenzoate and yield a 3,4-dihydroxybenzoate product. Like other
flavin-dependent monooxygenase, PHBH functions in several steps: flavin reduction, formation
of the C4a-(hydro)peroxyflavin intermediate; binding and activation of the substrate; product
formation and release; also the flavin oxidation.(107) As previously observed on PHBH (222-224),
the isoalloxazine ring of FAD is able to move between the “in” and “out” positions during its
catalysis for FAD oxidation/reduction and the substrate translocation. Structural alignment of the
MonCI and Lsd18 with PHBH “in” and “out” conformations (PDB: 1DOB) indicates that the
cofactor FAD currently sits at the “in” position in the crystal structures of MonCI and Lsd18. Both
of their flavin isoalloxazine rings are stabilized by the p-p stacking interaction with the imidazole
ring of a conserved histidine. To force FAD move to the “out” conformation, we prepared two
Lsd18 His71 mutants, His71A and His71S. The enzyme assays did show a slightly lower
transformation rate of the substrate 24 for these two mutants. The estimated product yield for H71S
mutant was 53.28%. The estimated product yield for H71A was 55.33%. It indicates that the His71
does play role in stabilize FAD, but it is not the key residue during catalysis. We also tried to
crystallize the Lsd18 mutants, but it was unsuccessful due to the poor diffraction. In the PHBH
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crystal structure (PDB: 1DOB), FAD stayed in the “out” conformation. After structural alignment
(RMSD between PHBH and MonCI structures is 3.67) and fitting the PHBH “out”-position FAD
into MonCI, there is only one residue, Gln52, causing steric clash (Figure 4.2 A and B). In crystal
structure, Gln52 forms a hydrophobic pocket for FAD isoalloxazine ring together with Pro330 and
His57. It also forms hydrogen bonds with the FAD pyrophosphate group and ribityl chain. It has
the same case for Lsd18. After the structural alignment (RMSD between PHBH and Lsd18
structures is 3.68) and fitting the PHBH “out”-conformation FAD into Lsd18, only one residue,
Gln66, causes steric clash (Figure 4.2 C and D). This residue Gln66 interacts with the
pyrophosphate and ribityl of the “in”-position FAD. Thus, Gln52 in MonCI and Gln66 in Lsd18
could act as a gate for the FAD-binding pocket. When the FAD moves to the “out” position, this
glutamine breaks the hydrogen bond with FAD and moves away from the FAD. When the reduced
FAD moved back to the “in” conformation, the glutamine moves closer to FAD and isolates the
FAD from the solvent, which helps stabilize the intermediate C4a-(hydro)peroxyflavin. Therefore,
rupture of these interactions and conformational change of the residue glutamine could be
necessary for FAD to move to the “out” position. To confirm its role in FAD reduction, we
prepared two Lsd18 mutants Q66G and Q66N that have shorter side chains than the glutamine. As
what was expected, the estimated product yield for Q66N was 18.05%. The estimated product
yield for Q66G was 9.6%. Both of these mutants displayed much lower conversion of substrate
24. It indicated that Gln66 does play an essential role during Lsd18 catalysis. Without the
regulation and protection of the glutamine, the cofactor FAD may not be able to move smoothly
between “in” and “out” conformations. The intermediate C4a-(hydro)peroxyflavin might not be
stable neither.
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Figure 4.2: Modeling of “out”-conformation FAD in MonCI and Lsd18. (A) Modeled “out’conformation FAD of PHBH (PDB: 1DOB) in the MonCI pocket. The MonCI FAD is shown in
wheat color while the PHBH FAD is shown in light blue color. (B) Side view of the modeled
FAD in MonCI. The distance between Gln52 and “in”- and “out”-conformation FAD is labeled
in Angstrom. (C) ) Modeled “out’-conformation FAD of PHBH (PDB: 1DOB) in the Lsd18
pocket. The Lsd18 FAD is shown in pink color while the PHBH FAD is shown in light blue
color. (B) Side view of the modeled FAD in Lsd18. The distance between Gln66 and “in”- and
“out”-conformation FAD is labeled in Angstrom.
Besides the FAD conformation changes, we also explored how NAD(P)H interacts with
the epoxidases and transfers the electrons to FAD. Since NAD(P)H was not observed in Lsd18
crystal structure, it may indicate that NAD(P)H doesn’t remain bound to the protein before and/or
after FAD reduction. Based on the sequence analysis, a loop region that consists of the sequence
GDSLTA in MonCI and the sequence GDAVAA in Lsd18 is likely to interact with NAD(P)H.
Amine and hydroxyl groups in this loop may interact with the diphosphate group of NAD(P)H.
Compared with NADPH-bound PHBH structure (PDB: 1K0J), MonCI Arg54 and Lsd18 Arg68
could also bind to the adenosyl moiety of NAD(P)H. A salt bridge may form between the
guanidinium group of arginine and the ribose phosphate of NAD(P)H.
Overall, FAD reduction mechanism of the epoxidases represented by MonCI and Lsd18
could be very similar to PHBH. NAD(P)H binds to the conserved motif and some residues like
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arginine in the groove in the neighbor of the FAD-binding pocket. Once FAD switches to its “out”
position, the hydride transfer occurs from the pro-R side of NAD(P)H (at C4) to the re side of the
flavin (at N5). (108, 215, 216) Once transferring is completed, FAD swings back to its “in”
position, and NAD(P)+ would be released from the enzyme.
4.3 STEREOSELECTIVE MECHANISM OF MONCI AND LSD18
Since the crystal structures of MonCI and Lsd18 are highly similar, the MonCI crystal
structure was used as the model to investigate the stereoselective mechanism by docking and
dynamic simulation. Previous feeding studies and gene deletion experiments have established
premonensin A, an (E,E,E)-triene, as the intermediate which MonCI acts on during monensin
biosynthesis (217, 218). Sequential epoxidation of all three C=C groups in premonensin A can
theoretically produce eight distinct triepoxide enantiomers (Figure 4.3). Remarkably, MonCI
produces only the (12R,13R,16R,17R,20S,21S)-triepoxypremonensin A product. To elucidate the
molecular basis for this exquisite stereocontrol, we first conducted a modeling study based on the
crystal structures of MonCI.

Figure 4.3: Eight possible triepoxypremonensin A enantiomers.
We analyzed the structure of other flavin-dependent monooxygenases for which both the
unliganded and the substrate bound crystal structures are available. We found 18 such pairs in the
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Protein Data Bank, and they all showed minimal structural differences (RMSD = 0.16 to 0.60 Å)
(Table 4.2). The structural changes between the ligand-free and the ligand-bound Lsd18 crystal
structures are also very minimal. This indicates that flavin-dependent monooxygenases in general
do not undergo significant conformational change upon substrate binding. Therefore, we used the
MonCI crystal structure coordinates directly in our modeling study.

Table 4.2: Flavin-dependent monooxygenases for which both the ligand-free and substratebound protein crystal structures are available.
Protein name
EncM
Rifampicin monooxygenase
Rifampicin monooxygenase
TetX
TetX
2-hydroxybiphenyl 3-monooxygenase
p-Hydroxybenzoate hydroxylase
(PHBH)
3-hydroxybenzoate
6-hydroxylase
Geranylgeranyl reductase
Tetracycline destructase Tet (50)
Halogenase PltM
3-hydroxybenzoate hydroxylase
MTMOIV baeyer-villiger
monooxygenase
TropB
PyrH Tryptophan 5-halogenase
Thio glycine oxidase
Cmis2 glycine oxidase homologue
Human squalene epoxidase

Unliganded protein
structure
(PDB accession code)
4XLO
5KOW
5VQB
2XYO
4GUV
4Z2U
1KOL
4BK2
4OPL
5TUE
6BZI
2DKI
4K5R
6NEV
2WES
1NG4
6J38
6C6R

Ligand-bound protein
structure
(PDB accession code)
3W8W
5KOX
6BRD
2Y6R
4A99
5BRT
1KOI
4BK1
4OPT
5TUF
6BZA
2DKH
4K5S
6NET
2WET
1NG3
6J39
6C6N

RMSD
(Å)
0.44
0.54
0.51
0.41
0.38
0.25
0.33
0.22
0.17
0.15
0.60
0.18
0.45
0.21
0.43
0.16
0.33
0.30

First, we modified the FAD in the crystal structure to the reactive C4a-(hydro)peroxyflavin
intermediate. Because the si face of the isoalloxazine ring is closely packed against the protein
loop (residues His55 to Leu58), it is highly unlikely for oxygen to approach the isoalloxazine ring
from this side. In contrast, the re face is fully exposed to the water-filled cavity, indicating that
molecular oxygen will approach the flavin’s C4a atom from the re side and produce the reactive
C4a-(hydro)peroxyflavin intermediate in which the peroxide group protrudes out from the re side.
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Next, we constructed six different models of premonensin A bound to MonCI, where each model
was created by placing each of the three C=C groups of the substrate next to C4a(hydro)peroxyflavin in two alternative conformations, one which is conducive to (R,R)-epoxide
formation and the other which is conducive to (S,S)-epoxide formation (Figure 4.4). The two
remaining double bonds that do not participate in the epoxidation reaction were left unmodified.
Therefore, these models reflect the substrate conformation immediately prior to the first
epoxidation event.
A.

B.

Figure 4.4: Premonensin A docking in MonCI crystal structure. (A) The fused substrate- and
FAD-binding pocket of MonCI and the predicted structure of the bound C4a(hydro)peroxyflavin adenine dinucleotide. (B) Models of the MonCI-premonensin A complex.
Premonensin A was built inside the MonCI substrate-binding pocket in the conformation
required to produce the six different enantiomeric products. The broken red circle indicates
regions of steric clash between the protein and the substrate.
First, we generated a model of the holo-MonACPX-MonCI complex (Figure 4.5) by
creating a homology model of apo-MonACPX using the program MODELLER (219) and then
docking this model to the MonCI crystal structure using the program HADDOCK (220). Next, we
attached the 4´-phosphopantetheine prosthetic group to the conserved Ser60 of MonACPX in the
docked structure. Because polyketide substrates are tethered to the 4´-phosphopantetheine group
of acyl carrier proteins via a thioester linkage, our model of the holo-MonACPX-MonCI complex
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provides a good approximation of the location of the premonensin A C1 atom in the actual enzymesubstrate complex. Then we placed premonensin A inside the MonCI active site cavity in three
different conformations, each representing epoxidation of a different double bond in premonensin
A and in the orientation that would yield the correct stereoisomer. We imposed three constraints
while modeling the different premonensin A conformations: 1) MonCI is completely static, 2) C1
atom of premonensin A is attached to the thiol group of the 4´-phosphopantetheine group, and 3)
the C=C bond in premonensin A that is undergoing epoxidation must lie within 6 Å of the
hydroperoxyl group of the FAD. Our results show that the active site cavity of MonCI can
accommodate premonensin A in all three conformations necessary for epoxidation of C12=C13,
C16=C17, and C20=C21 (Figure 4.5 B) The extra-large active site cavity of MonCI allows
premonensin A to transition from one required conformation to another even though its C1 atom
is fixed in position due to its attachment to the 4´-phosphopantetheine group of MonACPX.
For C12=C13, the substrate conformation that is conducive to (12R,13R)-epoxide
formation could be modelled without any conflict. In contrast, the substrate conformation that is
expected to form the (12S,13S)-epoxide creates a steric clash with the main chain atom of Ile331.
For C16=C17, the substrate conformation conducive to (16R,17R)-epoxide formation could be
constructed inside the pocket but not the (16S,17S)-epoxide conducive conformation, again due to
a steric clash with the main chain atom of Ile331. For C20=C21, the (20S,21S)-epoxide conducive
conformation could be modelled but not the (20R,21R)-epoxide conducive conformation, this time
due to a steric clash with the side chain of Leu58. Taken together, our models predict that MonCI
exclusively produces the (12R,13R,16R,17R,20S,21S)-triepoxypremonensin A. It is important to
recognize that the stereochemical outcome is not determined by the MonCI structure alone but that
it is also directed by the structure of the substrate molecule. The steric clashes that we have
identified above involve the methyl group attached to C12, the ethyl group attached to C16, and
the methyl group attached to C18 of premonensin A. Therefore, modification of the substrate
structure at these positions can potentially alter the stereochemical outcome of the epoxidation
reaction. Since premonensin A structure is determined by the nature of the modular polyketide
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synthases that appear earlier in the monensin biosynthesis pathway, MonCI appears to have
coevolved with the polyether producing polyketide synthases.
A.

B.

Figure 4.5: MonACPX docking and substrate delivery to MonCI. (A) Predicted structure of the
holo-MonACPX- MonCI complex. MonACPX and MonCI are colored in green and gold,
respectively. (B) Three models of the MonCI-premonensin A-MonACPX complex. Premonensin
A was modelled inside the MonCI substrate-binding pocket by positioning each of the three
double bonds next to the C4a atom of the isoalloxazine ring. The carbon atoms of 4´phosphopantetheine, premonensin A, and FAD are colored in green, yellow, and light blue,
respectively.
MonCI converts each of the three C=C groups present in premonensin A into an epoxide
(86). Since MonCI contains only one FAD, it can only catalyze one epoxidation reaction at a time.
Therefore, in order to transform all three C=C groups, either MonCI or the substrate molecule must
undergo substantial structural reorganization during the reaction cycle. As previously discussed,
flavin-dependent monooxygenases are, in general, rigid enzymes and therefore we predict that
premonensin A, rather than MonCI, undergoes conformation change in order to successively
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position each of the three C=C groups next to the reactive C4a-(hydro)peroxyflavin moiety.
However, premonensin A has limited freedom of movement because it is covalently tethered to an
acyl carrier protein which is fixed in position (213). To understand how premonensin A may
reorganize itself inside the MonCI active site cavity under such a restrictive condition, we
conducted a modeling study based on the MonCI crystal structure.
Atomistic molecular dynamics simulations were performed to investigate the dynamics of
the ligand-free MonCI and premonensin A bound MonCI. Premonensin A within MonCI can be
short and wide as it folds into a U-shape or a longer and narrower J-shape, depending on which
C=C group is positioned at the active site. To examine if premonensin A in different shapes and
orientations can fit stably within MonCI’s active site cavity, RMSDs of substrate-binding channel
residues were evaluated (Figure 4.6 A). In all of the systems in which premonensin A was present,
RMSDs of channel residues are smaller than 1.5 Å, and similar to the RMSD for the ligand-free
MonCI system. Therefore, the MonCI cavity design is such that it remains stable and robust while
accommodating the substrate in all different shapes and orientations examined. Interestingly,
average RMSDs of channel residues for native systems, with substrate in (12R,13R), (16R,17R)
and (20S,21S) configurations, are always lower than RMSDs of non-native systems, although the
differences are within standard deviations.
Epoxidation reactions of premonensin A in MonCI could occur in a predetermined order.
The probability of a reaction taking place has been shown to depend on the stability of the substrate
within the enzyme’s active site pocket (221-224). The stability of premonensin A in different initial
conformations within the MonCI active site cavity was tracked during 200 ns of MD simulations
(Figure 4.6 B). In the case of the systems where C12=C13 is initially near FAD (both the R,R and
S,S configurations), the substrate as a whole remains very close to its initial conformation and the
binding pose. Furthermore, the C12=C13 group remains in a pose in which a chemical reaction is
favored. In the systems where C16=C17 and C20=C21 are initially near FAD, substrates change
shapes, and the C=C moves away from the flavin group. Our results suggest that C12=C13 of
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premonensin A may be the first C=C group that is epoxidated by MonCI, since only that double
bond remains stably positioned at the immediate reaction site.
A.

B.

Figure 4.6: Molecular dynamic simulation of the MonCI-premonensin A complex. (A) RMSD of
channel residues for each simulated system. Backbone atoms of channel residues are shown as
blue surface, the substrate is shown as black surface, and FAD is shown in stick representation.
(B) Conformation of premonensin A at the start (red) and after 200 ns (blue) of simulation.
Carbon atoms of the double bond nearest to the flavin group are shown as transparent spheres. In
the (12R,13R) and (12S,13S) systems, these carbon atoms are not displaced after 200 ns. In all
other systems, these carbon atoms become displaced from their initial positions.
For Lsd18, it acts on the prelasalocid A, an (E,E)-diene, as the intermediate during the
biosynthesis of lasalocid A. It transforms the diene intermediate stereoselectively into the
(18R,19R,22R,23R)-disepoxylasalocid A product (Figure 4.7 C). The internal and terminal carbon
double bonds were also modeled at the Lsd18 active site, which showed the same results as we
observed in the MonCI modeling (Figure 4.7 B). The alkene groups were only be able to enter the
active site in a certain conformation due to the space restrain. When the substrate was modeled in
the unfavored conformation at the active site, the space clash between the ethyl group attached to
the alkenes and the protein residues could not be avoided. The backbone of residue Val342 and
the side chain of residue Ile72 play an essential role in restrain the active site space. As shown in
the Lsd18-ligand complex structure, the substrate 26 stayed at the active site at the conformation
to product an (R,R)-epoxide. The stereoselectivity of Lsd18 is determined by the group
modification on the alkene substrate and the space restrain by residues Ile72 and Val342 (Figure
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4.7 A and B). To further test our hypothesis, we mutated the residue Ile72 into an alanine or a
glycine. These two mutants I72A and I72G provide more space at the Lsd18 active site due to the
shorter side chains of alanine and glycine compared to isoleucine. Based on the GC-MS analysis,
both of these mutants gave slightly lower product yield for the substrate 24. However, due to the
limitation on differentiating the product stereochemistry, we were not able to determine how the
stereoselectivity of the mutants was. As mentioned before, the compound 26 and Lsd19 could be
applied in the Lsd18 enzyme assays to identify the stereochemistry of the epoxide products.
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Figure 4.7: Prelasalocid A docking in Lsd18. (A) The fused substrate- and FAD-binding pocket
of Lsd18 and the predicted structure of the bound C4a-(hydro)peroxyflavin adenine dinucleotide.
(B) Models of the Lsd18-prelasalocid A complex. Prelasalocid A was built inside the Lsd18
substrate-binding pocket in the conformation required to produce the four different enantiomeric
products. The broken red circle indicates regions of steric clash between the protein and the
substrate. (C) Four possible disepoxyprelasalocid A enantiomers.
Overall, our crystallographic and computational studies of MonCI and Lsd18 have
provided important molecular insights into how the epoxidases involved in the polyether
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biosynthesis achieve the stereoselective epoxidation during the biosynthesis of the natural
polyether products. We proposed that the epoxidases that are involved in the polyether
biosynthesis exert the stereoselectivity by dictating, via pre-formed pocket shape, which face of
the substrate alkene is directed at C4a-(hydro)peroxyflavin. Residues such as Leu58 and Ile331 in
MonCI, Ile72 and Val342 in Lsd18, are the key residues that restrain the space of the active site;
thus they may play an important role in the stereoselectivity of epoxidation.
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Chapter 5: Conclusions and Future directions
5.1 MAJOR CONCLUSIONS
A combination of X-ray crystallographic and computational methods has been applied to
reveal the structural basis for the stereoselective epoxidation involved in the biosynthesis of
polyether natural products. The flavin-dependent monooxygenases MonCI and Lsd18 are the
epoxidases responsible for the biosynthesis of monensin and lasalocid, respectively. Both of their
crystal structures contain a fused FAD- and substrate-binding pocket where FAD reduction and
epoxidation can be related together. Since their structures are all similar to the ones of phydroxybenzoate hydroxylases, the mechanism of FAD reduction could be very similar, which
involved the conformation change of the FAD before and after the reduction. By comparing the
structures of Lsd18 ligand-free and ligand-bound complex structures, we notice that the side chains
of some residues shifted when the substrate or product exist in the pocket. The conformational
change of these residues may play an important role in promoting the substrate entrance and the
product exit. Through docking and molecular dynamic simulation work, we propose that the
MonCI and Lsd18 control the epoxide stereochemistry by the unique shape at their active sites,
which allows only one certain face of the substrate alkene to be directed at the reactive C4a(hydro)peroxyflavin. More interestingly, MonCI and Lsd18 share high structural and sequence
similarity at their active sites, where those residues are significantly conserved among all the
epoxidases involved in the polyether biosynthesis. It is likely that the mechanism of epoxidation
is uniformed during the polyether biosynthesis. Besides, MonCI’s and Lsd18’s capacity to epoxide
multiple alkenes on their native substrates is made possible by their relatively large pocket volume.
It enables the substantial movement and refolding of the substrate molecule when it remains bound
to the enzyme.
5.2 FUTURE DIRECTION
Even though the hypothesis of the stereoselective epoxidation mechanism has been
proposed, it has not been fully proved yet. We solved the complex structure of Lsd18 with its
122

substrate/product, the Rwork/Rfree ratio was not good enough. Further modeling and refinement are
required to be done to achieve a more reliable Lsd18 complex structure. In this way, we would be
able to study interactions between the ligand (substrate/product) and the protein residues more
accurately. Based on the structural information of MonCI and Lsd18, there are several residues
found to play an essential role in restraining the shape and space at the active site. Gene
mutagenesis has been conducted on these residues in order to alter or remove the stereoselectivity
for Lsd18. All of these Lsd18 mutants have already been constructed and successfully purified.
However, more enzyme assays need to be performed with the substrate analog 26 to confirm the
stereoselectivity of the mutants. Due to its regioselectivity towards the epoxides, Lsd19 enzyme
will be included in the enzyme assays to help differentiate the stereochemistry of the Lsd18
epoxidation products.
Regarding to the long-term future plans, our studies could be applied to drug research by
bioengineering the epoxidases to produce various polyether analogs. In recent years, much
progress has been made in engineering polyketide biosynthesis pathways. For example,
researchers have successfully produced modified polyketides using engineered polyketide
synthases. Although there are many successful cases, it is widely known that polyketide
engineering frequently results in drastically reduced product yields, generation of side products,
and random failures. These issues are likely due to disrupted protein-protein interactions in the
engineered enzymes and incompatibility of the modified intermediate with downstream enzymes.
Access to high-resolution structural information of the biosynthetic enzymes will help avoid these
problems. For example, identification of key residues involved in protein-protein recognition will
allow construction of engineered enzymes that preserve this essential function rather than
disrupting it. And knowledge of the enzyme active site architecture will allow structure-based
remodeling of the active site pocket to accommodate nonnative substrates. Different polyether
analogs could be synthesized by reshaping the active site of the epoxidases. And this reshaping
can be achieved by mutating the key residues at the active site. For example, if the Lsd18 active
site is modified, the (22S,23S)-epoxide could be generated instead of its native (22R, 23R)-epoxide.
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After Lsd19 cyclization, a final THF-THF product will be produced instead of the native THFTHP lasalocid. However, our investigation of MonCI and Lsd18 has also uncovered an additional
issue for polyketide engineering, which is that the stereochemical outcome of epoxidation may be
unintentionally altered if the polyketide backbone is modified. If we wish to modify the ethyl group
attached to C16 in monensin to a methyl group, we can achieve this by engineering the upstream
polyketide synthase protein by substituting its ethylmalonyl-CoA specific acyltransferase domain
with a methylmalonyl-CoA specific counterpart. However, based on our MonCI crystal structure
and our modeling analysis, epoxidation at C16=C17 on the resulting modified polyketide chain is
likely to produce an alternate stereoisomer, or a mixture of enantiomers, because there will be no
steric clash with the key residue Ile331. Therefore, to preserve the stereochemistry of the natural
product, it may be necessary to engineer MonCI alongside the polyketide synthase. This example
illustrates that we must take into consideration all of downstream biosynthetic enzymes, and not
just the polyketide synthase proteins, when engineering a polyketide biosynthesis pathway.
Although this greatly complicates polyketide engineering efforts, access to high-resolution
structures of biosynthetic enzyme should help navigate through this challenge.
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Abbreviation and Notations
PKS

polyketide synthase

ACP

acyl carrier protein

AT

acyltransferase

KS

ketosynthase

KR

ketoreductase

DH

dehydratase

ER

enoylreductase

TE

thioesterase

CoA

coenzyme A

A-1,3

allylic 1,3 strain

CCW model

biosynthetic model proposed by Cane, Celmer, and Westly in 1983

APPA

acetate, propionate, propionate, acetate

PABA

propionate, acetate, butyrate, acetate

BABA

butyrate, acetate, butyrate, acetate

PAPA

propionate, acetate, propionate, acetate

FAD

flavin adenine dinucleotide

NADH

nicotinamide adenine dinucleotide

NADPH

nicotinamide adenine dinucleotide phosphate

NMR

nuclear magnetic resonance

FMN

flavin mononucleotide

m-CPBA

meta-chloroperoxybenzoic

E.coli

Escherichia coli

PCR

polymerase chain reaction

dNTP

deoxynucleoside triphosphate

DNA

deoxyribonucleic acid
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DMSO

dimethylsulfoxide

IPTG

isopropyl-b-D-galactoside

LB medium

lysogeny broth medium

OD

optical density

IMAC

immobilized metal affinity chromatography

IEX

ion exchange chromatography

SEC

size exclusion chromatography

SDS PAG

sodium dodecyl sulfate polyacrylamide gel electrophoresis

PMSF

phenylmethylsulfonyl fluoride

Tris

2-amino-2-(hydroxymethyl)propane-1,3-diol

DTT

(2S,3S)-1,4-bis(sulfanyl)butane-2,3-diol

GC-MS

gas chromatography mass spectrometry

LC-MS

liquid chromatography-mass spectrometry

Bis Tris

2[bis(2-hydroxyethyl)amino]2-2(hydroxymethyl)propane-1,3-diol

m/z

mass-to-charge ratio

HPLC

high performance liquid chromatography

MOPS

3-morpholinopropane-1-sulfonic acid

PEG

polyethylene glycol

HEPES

2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid

Bicine

2-(bis(2-hydroxyethyl)acetic acid

MAD

multi-wavelength anomalous diffraction

SAD

single-wavelength anomalous diffraction

PDB

protein data bank

EDTA

2,2’,2’’,2’’’-(ethane-1,2-diyldinitrilo)tetraacetic acid

pI value

isoelectric point

pKa value

negative log of the acid dissociation constant

2D

two dimension
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3D

three dimension

Vo

column void volume

Ve

elution volume of the protein molecules

Vt

total bed volume of columns

Rwork

the measure of the quality of the atomic model obtained from the
crystallographic data.

Rfree

calculated with 5% of the data

RMSD

root-mean-square deviation of atomic positions
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Appendix
Appendix 1. Codon-optimized gene sequence of monCI
5’ATGACCACCACCCGTCCGGCGCACGCGGTTGTTCTGGGCGCGAGCATGGCGGGCAC
CCTGGCGGCGCACGTTCTGGCGCGTCACGTTGACGCGGTTACCGTGGTTGAGCGTGA
TGCGCTGCCGGAGGAACCGCAGCACCGTAAGGGTGTGCCGCAAGCGCGTCATGCGC
ACCTGCTGTGGAGCAACGGTGCGCGTCTGATCGAGGAAATGCTGCCGGGTACCACC
GACCGTCTGCTGGCGGCGGGTGCGCGTCGTCTGGGTTTCCCGGAAGATCTGGTTACC
CTGACCGGCCAGGGTTGGCAACACCGTTTCCCGGCGACCCAGTTTGCGCTGGTTGCG
AGCCGTCCGCTGCTGGATCTGACCGTGCGTCAGCAAGCGCTGGGTGCGGATAACAT
CACCGTTCGTCAACGTACCGAAGCGGTGGAACTGACCGGTAGCGGTGGCGGTAGCG
GCGGTCGTGTTACCGGCGTGGTTGTGCGTGACCTGGATAGCGGTCGTCAGGAGCAAC
TGGAAGCGGACCTGGTGATTGATGCGACCGGCCGTGGTAGCCGTCTGAAGCAGTGG
CTGGCGGCGCTGGGCGTTCCGGCGCTGGAGGAAGACGTTGTGGATGCGGGTGTGGC
GTACGCGACCCGTCTGTTCAAAGCTCCGCCGGGTGCGACCACCCACTTTCCGGCGGT
TAACATTGCGGCGGATGATCGTGTGCGTGAGCCGGGCCGTTTCGGTGTTGTGTATCC
GATTGAAGGCGGTCGTTGGCTGGCGACCCTGAGCTGCACCCGTGGTGCGCAGCTGC
CGACCCATGAGGATGAGTTCATCCCGTTTGCGGAGAACCTGAACCACCCGATTCTGG
CGGACCTGCTGCGTGATGCGGAACCGCTGACCCCGGTTTTTGGCAGCCGTAGCGGTG
CGAACCGTCGTCTGTACCCGGAGCGTCTGGAACAATGGCCGGACGGCCTGCTGGTG
ATCGGTGATAGCCTGACCGCGTTCAACCCGATTTATGGTCATGGTATGAGCAGCGCG
GCGCGTTGCGCGACCACCATCGACCGTGAGTTTGAACGTAGCGTTCAGGAAGGTAC
CGGTAGCGCGCGTGCGGGTACCCGTGCGCTGCAAAAGGCGATTGGTGCGGCGGTGG
ATGATCCGTGGATCCTGGCGGCGACCAAAGACATTGATTACGTTAACTGCCGTGTGA
GCGCGACCGACCCGCGTCTGATTGGTGTGGATACCGAGCAGCGTCTGCGTTTTGCGG
AAGCGATCACCGCGGCGAGCATTCGTAGCCCGAAAGCGAGCGAGATTGTTACCGAC
GTGATGAGCCTGAACGCGCCGCAAGCGGAACTGGGTAGCAACCGTTTCCTGATGGC
GATGCGTGCGGATGAACGTCTGCCGGAACTGACCGCGCCGCCGTTTCTGCCGGAGG
AACTGGCGGTTGTGGGTCTGGATGCGGCGACCATCAGCCCGACCCCGACCCCGACC
CCGACCGCGGCGGTGCGTAGCTAAGAATTC-3’
Appendix 2. Codon-optimized gene sequence of lsd18
5’CATATGACGAACACGCGCTCGGCGGTTGTCCTGGGTGGTGGTATGGCTGGTATGCTG
GTCTCATCAATGCTGGCTCGTCACGTTGGCTCAGTGACCGTTATTGATCGTGACGCA
TTTCCGGCAGGTCCGGATCTGCGCAAAGGTGTCCCGCAAGCTCGTCATGCGCACATT
CTGTGGTCTGGCGGTGCGCGTATCGTTGAAGAACTGCTGCCGGGTACCA
CGGATCGTCTGCTGGGTGCAGGTGCTCATCGTATTGGCATCCCGGACGGTCAGGTGT
CTTATACCGCTTACGGTTGGCAGCACCGCTTTCCGGAAGCACAATTCATGATTGCCT
GCTCCCGCGCACTGCTGGATTGGACCGTTCGTGAAGAAACGCTGCGTGAAGAACGC
ATCGCCCTGGTCGAAAAAACCGAAGTGCTGGCTCTGCTGGGTGATGCAGGTCGTGTG
ACGGGCGTCCGTGTGCGTGACCAGGAAAGCGGTGAAGAACGTGAAGTTCCGGCGGA
TCTGGTGGTTGACACCACGGGTCGCGGTAGCCCGTCTAAACGTCTGCTGGCAGAACT
GGGTCTGCCGGCACCGGAAGAAGAATTTGTTGATAGCGGTATGGTCTATGCTACCCG
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TCTGTTTCGTGCACCGGAAGCAGCAGCAACGAACTTCCCGCTGGTTTCGGTCCATGC
TGATCACCGTGCAGGTCGTCCGGGTTGTAATGCAGTGCTGATGCCGATTGAAGACGG
CCGCTGGATCGTGACCGTTAGTGGTACGCGTGGCGGTGAACCGCCGGCAGATGACG
AAGGTTTTGCCCGTTTCGCACGTGATGGTGTGCGTCATCCGCTGGTTGGTGAACTGA
TCGCGAAAGCCCAGCCGCTGACCAGCGTTGAACGTAGTCGCTCCACGGTCAACCGT
CGCCTGCACTATGATCGTCTGGCAACCTGGCCGGAAGGCCTGGTCGTGCTGGGTGAC
GCAGTCGCTGCGTTTAATCCGGTGTACGGCCATGGCATGTCAGCAGCAGCTCACTCG
GTGCTGGCACTGCGTAGCCAGCTGGGTCAACGTGCATTCCAGCCGGGTCTGGCACGT
GCAGCACAACGTGCAATTGCTGTCGCGGTGGATGACGCCTGGGTGCTGGCAACCTCT
CATGATATCGGTTACCCGGGTTGCCGTACCCAGACGCGTGACCCGCGCCTGACCCGT
CACGCAGGCGAACGTCAACGCGTTACGGATCTGGTCGGTCTGACCGCAACGCGCAA
CCAGGTTGTCAATC
GTGCAGCTGTGGCGCTGAACACCCTGAGCGCTGGCATGGCGTCTATGCAGGATCCG
GCAGTGATGGCAGCAGTTCGTCGCGGTCCGGAAGTTCCGGCACCGACCGAACCGCC
GCTGCGCCCGGATGAAGTCGCTCGTCTGGTCTCTGGTGCTGGTGTTACCGCTTAAGA
ATTC-3’
Appendix 3. Codon-optimized gene sequence of fre
5’CATATGACAACCTTAAGCTGTAAAGTGACCTCGGTAGAAGCTATCACGGATACCGTA
TATCGTGTCCGCATCGTGCCAGACGCGGCCTTTTCTTTTCGTGCTGGTCAGTATTTGA
TGGTAGTGATGGATGAGCGCGACAAACGTCCGTTCTCAATGGCTTCGACGCCGGATG
AAAAAGGGTTTATCGAGCTGCATATTGGCGCTTCTGAAATCAACCTTTACGCGAAAG
CAGTCATGGACCGCATCCTCAAAGATCATCAAATCGTGGTCGACATTCCCCACGGAG
AAGCGTGGCTGCGCGATGATGAAGAGCGTCCGATGATTTTGATTGCGGGCGGCACC
GGGTTCTCTTATGCCCGCTCGATTTTGCTGACAGCGTTGGCGCGTAACCCAAACCGT
GATATCACCATTTACTGGGGCGGGCGTGAAGAGCAGCATCTGTATGATCTCTGCGAG
CTTGAGGCGCTTTCGTTGAAGCATCCTGGTCTGCAAGTGGTGCCGGTGGTTGAACAA
CCGGAAGCGGGCTGGCGTGGGCGTACTGGCACCGTGTTAACGGCGGTATTGCAGGA
TCACGGTACGCTGGCAGAGCATGATATCTATATTGCCGGACGTTTTGAGATGGCGAA
AATTGCCCGCGATCTGTTTTGCAGTGAGCGTAATGCGCGGGAAGATCGCCTGTTTGG
CGATGCGTTTGCATTTATCTGAGAATTC-3’
Appendix 3. Codon-optimized gene sequence of monACPX.
5’CATATGACCAGCACCGACCACACCAGCGGTCAGGATGCGACCGAGCTGGAAAAACA
GCTGGCGGCGGCGACCCCGGAGGAACGTGAGAAACTGCTGACCGACACCATCCGTA
CCCAGGCGGGTACCCTGCTGAACACCACCCTGAGCGACGATAGCAACTTCCTGGAG
AACGGCCTGAACAGCCTGACCGCGCTGGAACTGACCAAGACCCTGATGACCCTGAC
CGGTATGGAGATCGCGATGGTGGCGATTGTTGAAAACCCGACCCCGGCGCAGCTGG
CGCACCACCTGGGTCAAGAACTGGCGCACACCACCGCGTAAGAATTCGATATC-3’
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Appendix 5. The vector map of pET28a(+). The genes of fre and monACPX were inserted into
the cleavage sites NdeI and EcoRI in the pET28(+).
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Appendix 6. SDS PAGE analysis of Lsd18 mutants. From lane 1 to lane 9: Lsd18 wildtype,
Lsd18 mutants Q66N, Q66G, I72A, I72G, H71A, H71S, Y218F, and protein ladder. The lsd18
and its mutants are marked by the red arrow.
Mutant
Y218F
H71A
H71S
Q66N
Q66G
Estimated yield % 89.53
53.28
55.33
18.05
9.6
Appendix 7: Estimated percent yield of 25 catalyzed by Lsd18 mutants
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